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Metastatic melanoma, a prevalent and deadly form of skin cancer, remains an 
aggressive clinical outcome that lacks effective preventative and/or curative therapeutics. 
Patients diagnosed with advanced metastatic melanoma face a dreaded 10-year survival rate 
of less than 10%. By performing in vivo selection for highly metastatic melanoma cells, we 
systematically identified three microRNAs (miRNAs) that promoted metastasis across 
multiple mutationally diverse human melanoma subtypes. These miRNAs were found to 
promote metastasis by enhancing the invasive capacity of melanoma cells and also by 
allowing melanoma cells to recruit endothelial cells into the metastatic niche, leading to 
enhanced metastatic angiogenesis. Importantly, the expression levels of these miRNAs 
served as prognostic biomarkers in stratifying melanoma patients at high risk from those at 
low risk for metastatic relapse. Notably, therapeutic delivery of specific locked nucleic acids 
(LNAs) antisense to the three miRNAs synergistically suppressed metastasis in pre-clinical 
models, attesting to the therapeutic potential of combinatorial miRNA silencing for the 
prevention of melanoma metastasis.  
Through systematic transcriptomic analyses and mutagenesis studies, I found that the 
three miRNAs silenced a common set of target genes: the heat-shock factor DNAJA4 and the 
metabolic protein apolipoprotein E (ApoE). Interestingly, this work also revealed that 
DNAJA4 positively regulated ApoE expression, establishing ApoE as the central molecule in 
this convergent network. Consistent with these findings, treatment of multiple melanoma 
lines with ApoE blocked their metastatic capacity, while ApoE expression in patients’ tumors 
was significantly prognostic of melanoma progression outcomes. Systematic loss-of-function 
experiments revealed that melanoma-derived extracellular ApoE exerted dual cell-intrinsic/ 
cell-extrinsic effects on metastasis: ApoE acting on melanoma cell LRP1 receptors inhibited 
melanoma invasiveness, while ApoE acting on endothelial cell LRP8 receptors suppressed 
metastatic endothelial recruitment (MER). 
In light of ApoE’s key metastasis-suppressive role, we next investigated therapeutic 
approaches to chronically activate ApoE in metastatic melanoma. We identified the nuclear 
hormone liver-X receptor (LXRβ), a known transcriptional trans-activator of ApoE, as an 
ideal target given its ubiquitous expression across all normal tissues as well as melanoma 
subtypes. Oral delivery of LXR agonists strongly suppressed melanoma tumor progression 
and metastasis across multiple mutationally diverse and genetically initiated pre-clinical 
melanoma models, consistent with broad-spectrum in vivo efficacy of LXRβ activation 
therapy in melanoma. Importantly, combining LXR agonist treatment with approved 
melanoma drugs elicited additive melanoma-suppressive responses, revealing therapeutic 
cooperativty between LXR activation and modern frontline agents. Complementary 
molecular and genetic approaches revealed that LXRβ agonism mediated melanoma 
suppression through the coordinate transcriptional induction of ApoE in both melanoma cells 
as well as stromal tissues. Collectively, this thesis provides molecular, genetic, and 
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CHAPTER I: INTRODUCTION 
 
Molecular Determinants of Malignant Melanoma 
Malignant melanoma, the most aggressive form of skin cancer, incurs ~48,000 deaths 
each year globally (Lucas et al., 2006). Recently, melanoma has exhibited a steep incidence 
rate progression with a greater than 60% increase over the past 20 years, making it the fifth 
most common cancer in men and the sixth most common one in women (Garbe and Leiter, 
2009; Jemal et al., 2010). Even though localized primary “stage I” melanomas are completely 
curable in nearly all cases, multiple distant organ spread of disseminated melanoma cells 
incurs a 10-year survival rate of less than 10% for advanced “stage IV” melanoma patients 
and a feared median survival time in the range of 8 to 18 months (Chin et al., 2006; Bhatia et 
al., 2009).  Presently, the sole path to providing lasting cure for metastatic melanoma patients 
remains prevention of metastatic relapse in the adjuvant setting. However, interferon alpha, 
the only Food and Drug Administration (FDA)-approved melanoma adjuvant therapy, offers 
a meager 5-year survival benefit of ~1-3% (Garbe et al., 2011), underscoring the clinical 
need for the development and implementation of effective metastasis prevention therapies in 
melanoma. Systematic experimental approaches aimed at identifying molecules with 
functional and clinical relevance to melanoma metastatic progression will likely have 
important implications for decreasing mortality rates from this dreaded disease. 
Cutaneous melanomas typically originate following the malignant transformation of 
skin epidermal melanocytes. The strongest risk factor for melanoma is environmental 
ultraviolet (UV) light exposure, which leads to accumulation of DNA damage and UV light-
induced mutational inactivation of tumor suppressor genes and/or activation of oncogenes 
(Gilchrest et al., 1999; Pleasance et al., 2009). Interestingly, people with fair/white skin 
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complexion are nearly 70 times more likely to develop melanoma than those with dark/black 
pigmentation (Halder and Bang, 1988). Based on this observation, it was proposed that 
eumelanin, the type of melanin that gives rise to black/brown pigment, could serve as a 
physical shield against UV light by scattering UV radiation and reducing its penetration 
through the epidermis, thereby protecting melanocytes from UV-induced DNA damage and 
generation of mutations linked to melanoma initiation (Kobayashi et l., 1995; Cao et al., 
2013). 
In addition to UV light exposure, familial history of melanoma can also increase 
one’s likelihood to develop melanoma by more than two-fold (Ford et al., 1995; Gandini et 
al., 2005), suggesting a genetic contribution to the disease’s onset. To that end, genetic 
studies have identified inactivating germline mutations in the CDKN2A gene on chromosome 
9p21 in 25-40% of familial melanoma tumors (Hussussian et al., 1994; Kamb et al., 1994). 
CDKN2A encodes two alternative splice variants: p16INK4A (also known as MTS-1) and p14ARF.  
Both of the CDKN2A gene products exert a common tumor-suppressive function by halting 
cell cycle progression. Whereas p16INK4A acts by inhibiting the cyclin-dependent kinase 4 
(CDK4) and thus suppressing G1 phase progression, p14ARF interacts with MDM2 and 
sequesters it away from degrading its target protein, the tumor suppressor p53 (Hollstein et 
al., 1991).  Interestingly, somatic inactivating mutations in CDKN2A have also been found in 
a small subset (~4-20%) of sporadic melanoma tumors (Chin et al., 2006; Hodis et al., 2012) 
While familial melanomas only account for about 8-12% of melanoma cases (Chin et 
al., 2006), the majority of melanoma tumors develop sporadically and are driven by a wide 
range of somatically acquired mutations following exposure to UV light and/or other 
environmental factors. The most frequently occurring somatic mutations found in melanoma 
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tumors are activating mutations in the MAP kinase signaling effectors N-Ras and B-Raf, with 
mutational frequencies ranging between 15-33% (Demunter et al., 2001; Goel et al., 2006) 
and 40-60% (Davies et al., 2002; Hodis et al., 2012), respectively. Strikingly, a single amino 
acid substitution (V600E) in the B-Raf kinase activation domain, which causes kinase 
hyperactivation, accounts for more than 90% of all B-Raf mutations found in melanoma 
tumors (Davies et al., 2002). The abundance of activating mutations in the B-Raf oncogene 
harbored by roughly half of melanoma patients inspired pre-clinical and clinical efforts to 
pharmacologically inhibit the hyperactive B-Raf mutant protein in melanoma (Yang et al., 
2010; Bollag et al., 2010). This led to the FDA approval in 2011 of vemurafenib, a small 
molecule inhibitor of the hyperactive mutant B-Raf kinase variant, for the treatment of 
metastatic melanoma (Chapman et al., 2011). Despite the unprecedented success of 
vemurafenib in eliciting tumor-suppressive responses in over 80% of all treated advanced B-
Raf-mutated melanoma patients and extending their respective median survival times by 6-10 
months (Sosman et al., 2012), vemurafenib responses are short-lived, with nearly all patients 
eventually succumbing to therapeutic resistance and subsequently experiencing lethal 
progression of their melanoma tumors (Nazarian et al., 2010).  
In addition to B-Raf inhibitors, small molecules targeting MAP kinase signaling 
effectors downstream of B-Raf have also been developed. Accordingly, in 2013 the FDA 
approved trametinib, a small molecule inhibitor of the MEK1 and MEK2 kinases, for the 
treatment of metastatic melanoma based on its demonstrated activity in extending 
progression-free survival in B-Raf-mutated melanoma patients (Kim et al., 2013). While the 
overall survival benefits of trametinib are still unclear, this targeted therapy, which acts on 
the same pathway as vemurafenib, is similarly undermined by emergence of clinical 
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resistance. Moreover, trametinib shows limited activity in patients with melanomas that have 
progressed on vemurafenib, rendering it ineffective in melanoma tumors with previously 
acquired resistance to B-Raf inhibition (Kim et al., 2013).  
Besides activating mutations in B-Raf and N-Ras, a number of additional molecular 
alterations have been implicated in melanoma progression including hyperactivation of 
certain cyclin-dependent kinases such as CDK2, abnormal activation of receptor tyrosine 
kinase signaling (EGFR, PDGFR, c-MET, and c-KIT), mutational inactivation of PTEN 
and/or hyperactivation of PI3 kinase-AKT signaling, aberrant transcriptional regulation by 
the major melanocyte transcription factor MITF, as well as increased activation of global 
regulators of protein homeostasis such as HSP90 (as reviewed in Chin et al., 2006). 
However, the majority of these genetic and molecular deregulations have been functionally 
linked to melanoma progression by studies mainly looking at in vitro cell proliferation and/or 
in vivo primary tumor growth. Future studies should provide important insights into the 
contribution of these factors to the more advanced stages of melanoma progression involving 
melanoma metastatic dissemination, which is the primary cause of melanoma-related deaths. 
 
Immunomodulatory Therapy in Melanoma 
Immunotherapy, which harnesses a patient’s own immune system to combat the 
tumor, has shown great therapeutic promise for the management of metastatic melanoma. In 
2011, alongside the approval of the B-Raf inhibitor vemurafenib, the FDA also approved the 
immunomodulatory antibody ipilimumab for the treatment of advanced metastatic melanoma 
(van Elsas et al., 1999; Hodi et al., 2010). Ipilimumab acts by antagonizing cytotoxic T 
lymphocyte antigen 4 (CTLA-4), a T cell-expressed receptor that competes with the T cell 
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stimulatory CD28 receptor to inhibit ligand activation and T cell function. Thus, by blocking 
CTLA-4 function, ipilimumab activates the body’s endogenous T cell response, leading to 
the immune-based suppression of melanoma tumor progression. Even though ipilimumab 
elicits responses in a small subset of advanced melanoma patients (10-20%), the majority of 
these responses, unlike for vemurafenib, are remarkably durable and can last more than two 
years in many cases (Page et al., 2013).   
The therapeutic success of the anti-CTLA-4 antibody was followed by continuous 
clinical efforts to target additional regulators of T cell function. This led to the development 
of immunomodulatory antibodies blocking the programmed cell death (PD-1) receptor and 
its ligand PDL-1, whose roles are to inhibit the immune response by activating a pro-
apoptotic cell program (Freeman et al., 2000; Dong et al., 2002). Therapeutic strategies 
targeting PD-1 signaling have shown promising results in early clinical trials (Topalian et al., 
2012).  Interestingly, whereas CTLA-4 serves to inhibit early T cell function and is acutely 
expressed during the onset of T cell activation, PD-1 shows sustained expression during 
chronic T cell activation and broadly inhibits T cell responses in peripheral tissues (Page et 
al., 2013). The distinct regulatory roles played by CTLA-4 and PD-1 in modulating T cell 
function have been exploited clinically in yielding additive tumor-suppressive effects upon 
combination regimens targeting both CTLA-4 and PD-1. Early phase I clinical testing with 
advanced stage melanoma patients demonstrated that combined anti-CTLA-4 and anti-PD-1 
antibody treatment elicited improved response rates (up to 53% in the first trial done) 
compared to what was previously observed with each single agent (Wolchok et al., 2013). 
These findings suggest that melanoma patients may experience greater therapeutic benefit 
from drug combinations targeting multiple molecular determinants of immune cell function.   
	   6 
The development and clinical implementation of vemurafenib and ipilimumab have 
been deemed by physicians to be revolutionary for the clinical management of metastatic 
melanoma, as all other approved agents had previously failed in extending the overall 
survival of advanced melanoma patients in large randomized clinical trials. Nevertheless, the 
current median survival time of melanoma patients, even with approved therapeutics, 
remains less than two years and there is a large number of patients that do not respond to 
approved therapeutics and/or their melanomas develop resistance to targeted agents, 
underscoring the clinical need for the development of novel effective approaches.  
 
The Metastatic Cascade 
Nearly 100% of all deaths incurred by melanoma tumors are the consequence of 
melanoma metastases, which arise through the dissemination of melanoma cells from a 
primary lesion to multiple distal organ sites. The spread of cancer cells to distant organs is 
assisted by vascular flow that by necessity reaches all cell types in the body.  Upon 
extravasating, or leaving the vasculature, cancer cells initiate colonies that expand and 
destroy the anatomic and functional architecture of host organs—giving rise to organ 
dysfunction, organ failure, and ultimately death of the organism (Gupta and Massagué, 2006; 
Hanahan and Weinberg, 2011; Talmadge and Fidler, 2010).  
From a molecular standpoint, metastasis constitutes a fascinating process, consisting 
of multiple sequential and molecularly complex steps, each of which could prove rate-
limiting to the ability of a cancer cell to reach and colonize distant target organs. The 
metastatic cascade begins with the formation of a primary tumor at an orthotopic site, such as 
the skin for melanoma tumors. The growth of the primary tumor is fueled by the proliferation 
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of cancer cells and vascularization of the tumor. The phenotypic and molecular heterogeneity 
present at the primary tumor stage allows for a few selected cells to eventually acquire 
phenotypic traits that favor their tumor detachment, stromal invasion, and ultimate entry into 
the blood stream. Once in the circulation, cancer cells are faced with the challenge to survive 
in the absence of anchorage as they migrate to peripheral sites. Eventually, the disseminated 
cells reach and arrest at a distant target organ, extravasate from the circulation, invade 
through the surrounding stroma, give rise to micrometastatic colonies, recruit endothelial 
cells, and initiate metastatic angiogenesis, which ultimately fuels macrometastatic formation 
and progressive organ colonization (Fidler, 2013; Figure 1.1).  
The rate-limiting nature of each sequential step in the metastatic cascade renders this 
process highly inefficient, with less than 0.01% of all disseminated cells ultimately being 
successful in initiating metastatic colonies (Talmadge and Fidler, 2010). Additionally, 
disseminated cells can enter into a dormant state upon reaching their target organ site, 
allowing a patient to remain in remission for years (Giancotti, 2013). Unfortunately, this 
seemingly cancer-free state is often interrupted by an unexpected metastatic relapse as the 
cancer cells exit dormancy and resume colonization. Recent investigations into metastatic 
dormancy and re-activation mechanisms have shed light into some of the cell-intrinsic 
signals and cell-extrinsic cues within the metastatic niche that govern these clinically 





















Figure 1.1. The Multiple Steps of the Metastatic Cascade. Metastatic dissemination occurs 
through a series of sequential events. First, the formation and growth of a primary tumor 
leads to the emergence of a few selected cancer cells that detach from the tumor and are able 
to invade through the surrounding stroma. A few of these cells eventually intravasate into the 
blood stream where their migration and dissemination are assisted by vascular flow. 
Eventually, the disseminated cancer cells arrive at a distal organ site where they arrest and 
extravaste into the organ stroma. Guided by both cell-intrinsic and cell-extrinsic cues, the 
cancer cells then initiate micrometastatic colonies, recruit blood vessels, and ultimately give 
rise to full organ colonization. 
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Given the molecular complexity of the metastatic cascade, the cellular and molecular 
pathways regulating this fascinating process have remained unclear until recently. During the 
last decade, however, advances in transcriptomic profiling approaches, RNA interference 
tools, and the establishment of large clinical tumor specimen collections have facilitated our 
molecular and conceptual understanding of the metastatic process. Multiple interdisciplinary 
studies by independent investigators have identified a number of coding and non-coding 
genes as important regulators of the metastatic process (Kang et al., 2003; Minn et al., 2005; 
Ma et a., 2007; Tavazoie et al., 2008; Gao et al., 2012; Png et al., 2012).  A recurrent theme 
that emerged from these collective efforts was that metastatic colonization requires the 
concerted actions of many gene products.  Consistent with this, transcriptomic studies of 
human breast cancers have revealed large sets of transcripts to be recurrently overexpressed 
in primary tumors that metastasize (Wang et al., 2005).  This observation triggered rigorous 
investigations into the molecular mechanisms that govern such coordinated gene expression 
programs during cancer progression.  In recent years, it has become increasingly clear that 
post-transcriptional control represents a robust mechanism by which levels of multiple 
transcripts are deregulated in metastasis. The post-transcriptional regulators with the most 
pervasive activity shown up-to-date in conferring such concerted gene expression states in 
metastasis are a class of small non-coding RNAs known as microRNAs or miRNAs (Bartel, 
2004; He and Hannon, 2004; Lujambio and Lowe, 2012). 
   
Discovery, Biogenesis, and Function of miRNAs 
miRNAs were originally discovered in C. elegans in the early 1990s when elegant 
work by Victor Ambros, Gary Ruvkun, and colleagues showed that the protein abundance of 
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LIN-14, a gene essential for post-embryonic C. elegans development,  is post-
transcriptionally controlled by a short non-coding RNA transcript (lin-4) that negatively 
regulates the expression of LIN-14 during development (Lee et al., 1993; Wightman et al., 
1993). Two different lin-4 transcripts were detected of approximately 22 base pairs (bp) and 
61 bp in length and were later shown to correspond to the mature lin-4 miRNA and its 
precursor pre-miRNA form, respectively. The lin-4 short transcripts were found to exhibit 
sequence complementarity to a region in the 3’ untranslated region (3’-UTR) of the LIN-14 
mRNA. Based on this observation, it was proposed that lin-4 represses its target LIN-14 
through direct anti-sense RNA-RNA interactions (Lee et al., 1993; Wightman et al., 1993). 
This remarkable hypothesis, albeit controversial at first, has stood the test of time and 
ultimately shaped our current understanding of miRNA function.  
It was not until seven years after the discovery of lin-4 that a second miRNA, let-7, 
was cloned in C. elegans (Reinhart et al., 2000). Remarkably, let-7 was subsequently shown 
to exhibit wide conservation across a large number of animal species, including humans  
(Pasquinelli et al., 2000). The decade that followed was marked by a great surge in miRNA 
discoveries. Complimentary sequencing and computational efforts led to the identification of 
numerous unique miRNAs across multiple species, establishing these tiny RNAs as pervasive 
post-transcriptional regulators of gene expression. Presently, there are over 1,800 unique 
annotated human miRNAs (miRBase, v. 20.0), and their number is constantly increasing as 
new sequences are being discovered.  
 While the majority of human miRNAs reside in intergenic regions or within the 
introns of protein-coding or non-coding genes, miRNAs located in the exons of non-coding 
transcripts have also been reported (UI Hussain, 2012). Intergenic miRNAs possess their own 
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transcriptional start sites. Intronic and exonic miRNAs are usually transcribed from the same 
promoter as their host gene. However, in certain cases, these miRNAs can also possess their 
own transcriptional initiation sites, which allow for their decoding from the anti-sense strand 
(UI Hussain, 2012). Single or multiple concatenated miRNA-coding sequences (known as 
polycistrons) are primarily transcribed by RNA polymerase II, giving rise to a primary 
miRNA transcript known as the pri-miRNA. In a few rare cases, pri-miRNA transcription 
can also be mediated by RNA polymerase III (Kim, 2005).  
The processing of mammalian pri-miRNAs to mature miRNAs involves a series of 
cleavage events (Figure 1.2) (Kim, 2005; Winter et al., 2009). The first cleavage step is 
initiated when the RNA-binding protein DGCR8 detects and binds to a double-stranded 
hairpin embedded within the pri-miRNA.  This binding allows its partner, the ribonuclease 
Drosha (Lee et al., 2003), to cleave the pri-miRNA at the hairpin junction site, giving rise to 
a roughly 60-70-bp long stem-loop product known as the pre-miRNA. The pre-miRNA is 
then bound by Exportin-5 and its co-factor Ran-GTP, which mediate its export across the 
nuclear membrane and into the cytoplasm. In the cytosol, the endonuclease Dicer (Bernstein 
et al., 2001) along with its co-factor, the RNA-binding protein TARBP2, recognize and bind 
the pre-miRNA hairpin, triggering its cleavage at two sites adjacent to the hairpin loop. 
Ultimately, this final cleavage event yields the mature miRNA product, a 21-26-bp long 
duplex structure composed of the 5 prime (5p) and 3p strands of the pre-miRNA stem 
(Figure 1.2).  
The mature miRNA duplex is then loaded onto the RNA-induced silencing complex 
(RISC) (Gregory et al., 2005). The guide miRNA strand, which is typically located at the 5p 
end of the pre-miRNA loop owing to its higher thermodynamic stability, is preferentially 
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retained in the complex. The 3p arm, which is often known as the passenger strand and also 
designated as the star (*) form, is typically released and degraded, except for certain cases in 
which both the 3p (*) and 5p strands of the same pre-miRNA can mediate silencing.  At the 
core of RISC, a member of the Argonaut (Ago) family of proteins (Liu et al., 2004) directly 
binds to the retained mature miRNA strand and uses it as a guide to recognize and bind 
mRNA transcripts bearing sequences complementary to the miRNA seed sequence—a 6-8-
bp long region found within the 5p miRNA end (Meister et al., 2004; Czech and Hannon, 
2011). While the majority of validated miRNA regulatory sites lie within the 3’UTRs of 
transcripts, certain miRNAs have also been reported to repress their targets by directly 
interacting with the coding sequences of transcripts (Duursma et al., 2008; Forman et al., 
2008). The binding of Ago to target mRNA transcripts results in the recruitment of a set of 
silencing effector proteins such as GW182 (Ding and Han, 2007). The molecular interaction 
of multiple RISC-associated proteins with the target transcript ultimately triggers mRNA 

































Figure 1.2. The Basic Steps of Mammalian miRNA Biogenesis. Mature miRNA sequences 
are encoded within pri-miRNA transcripts located within genes, between genes, or within 
introns. Pri-miRNAs are transcribed by RNA Pol II  (or less frequently by PoI III) and 
processed into mature miRNAs through a series of cleavage events. First, Drosha in complex 
with DGCR8 recognizes and cleaves the pri-miRNA transcript, giving rise to the pre-miRNA 
stem-loop “hairpin”. The pre-miRNA is then exported into the cytoplasm via its interaction 
with Exportin-5 and its associated co-factors. In the cytosol, the pre-miRNA is bound and 
cleaved by Dicer, generating the mature miRNA duplex structure. In this final cleavage 
event, Dicer is assisted by its co-factor, TARBP2. The thermodynamically more stable 
miRNA strand (typically at the 5p end) is then loaded into the RISC complex and bound by 
an Ago protein. Ago then directs the bound miRNA to complementary seed sequences on 
target mRNAs, leading to mRNA cleavage, deadenylation, and/or translational repression. 
	   14 
Deregulated miRNA Expression as a Hallmark of Human Cancers  
Prior to the discovery of miRNAs as functional determinants of cancer progression, it 
had become clear that aberrant miRNA expression is a pervasive phenomenon across many 
tumor types  (Calin and Croce, 2006; Garzon et al., 2009). The development of whole-
genome transcriptomic approaches allowed for the global analyses of miRNA expression in 
various tumor types. Calin, Croce, and colleagues were the first to report abnormal miRNA 
expression in cancer by examining the miRNA expression signature of B cell chronic 
lymphocytic leukemia. This study found two clustered miRNAs, miR-15a and miR-16, to be 
deleted or downregulated in the majority (> 60%) of tumors tested (Calin et al., 2002). 
Subsequently, many more miRNAs were found to exhibit deregulated expression across 
diverse cancer types: For instance, let-7 was found to be silenced in lung cancers 
(Takamizawa et al., 2004; Yanaihara et al., 2006), while colon (Michael et al., 2003) and 
breast (Iorio et al., 2005) carcinomas displayed reduced miR-145 levels relative to normal 
tissues. Conversely, multiple groups observed overexpression of miR-155, miR-21, and the 
miR-17-92 cluster in breast and lung cancers (Iorio et al., 2005; Hayashita et al., 2005) as 
well as in B cell’s and Hodgkin’s lymphomas (Eis et al., 2005; Kluiver et al., 2005). The 
pervasive upregulation of miR-155, miR-21, and miR-17-92 observed across diverse types of 
cancer implicated these miRNAs as general oncogenically acting miRNAs, often referred to 
as “oncomiRs”.   
Despite individual studies reporting upregulation of a subset of specific miRNAs, 
findings by multiple groups, which performed transcriptomic analyses of large collections of 
human tumors, implicated global downregulation of miRNA expression and processing as a 
general phenomenon during tumorigenesis (Lu et al., 2005; Kumar et al., 2007; Yan et al., 
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2012). Importantly, these early miRNA profiling studies raised the intriguing possibility that 
distinct miRNA expression signatures could be used to classify distinct tumor types as well 
as to predict the clinical prognosis of these malignancies (Calin et al., 2004; Yanaihara et al., 
2006; Roldo et al., 2006).  
 
Regulation of Metastatic Progression by miRNAs 
miRNAs as Suppressors of Breast Cancer Metastasis 
Given that early studies pointed to pervasive downregulation of miRNAs in human 
cancers, a popular hypothesis that emerged in the field was that silencing of miRNAs could 
modulate metastasis by de-repressing the expression of pro-metastatic genes. The initial 
quest for miRNAs that possess endogenous metastasis regulatory activity originally focused 
on breast cancer. Using an in vivo selection-based mouse model of human breast cancer 
metastasis, Tavazoie and colleagues performed small RNA profiling of highly metastatic 
breast cancer cell derivatives and their poorly metastatic parental populations (Tavazoie et 
al., 2008). These analyses revealed a subset of miRNAs to be strongly downregulated in 
highly metastatic cells, hinting to a putative metastasis-suppressive role for these miRNAs. In 
agreement with this, overexpression of three miRNAs—miR-335, miR-206, or miR-126— in 
highly metastatic cell variants strongly inhibited metastatic colonization. Conversely, 
silencing of miR-335 and miR-126 in poorly metastatic breast cancer cells led to enhanced 
metastatic capacity (Tavazoie et al., 2008; Png et al., 2012), consistent with endogenous 
activity of these miRNAs in suppressing metastasis. Importantly, the expression levels of 
each of these miRNAs in primary breast tumors correlated with the likelihood of metastatic 
relapse in breast cancer patients (Tavazoie et al., 2008), supporting a role for these small 
	   16 
RNAs in human metastatic progression. Silenced expression of these specific metastasis 
suppressor miRNAs, originally identified in breast cancer, has also been observed across 
numerous additional human cancers including adrenal (Schmitz et al., 2011), liver (Dohi et 
al., 2013), renal (White et al., 2011), lung (Donnem et al., 2011), gastric (Xu et al., 2012), 
and rhabdomyosarcoma (Missiaglia et al., 2010; Taulli et al., 2009) malignancies. 
What was the mechanism by which these miRNAs inhibited metastasis? Both miR-
335 and miR-126 were found to silence the expression of distinct sets of pro-metastatic 
genes, attesting to the ability of miRNAs to modulate metastatic gene expression programs 
(Tavazoie et al., 2008; Png et al., 2012). Importantly, the expression levels of the target genes 
of each of these miRNAs were also found to significantly correlate with metastatic outcomes 
in breast cancer patients. Systematic functional analyses demonstrated that while miR-335 
directly targeted SOX4 and tenascin-C to limit breast cancer cell invasion and migration 
(Tavazoie et al., 2008; Figure 1.3a), miR-126 acted by silencing PITPNC1, MERTK, and 
IGFBP2 to limit cell-extrinsic endothelial recruitment capacity by breast cancer cells (Png et 
al., 2012; Figure 1.3b). Therefore, these two miRNAs were found to suppress breast cancer 
metastasis by divergently silencing unique sets of target genes that modulating distinct cell-


















Figure 1.3. miRNA Regulatory Networks that Suppress Breast Cancer Metastasis.  
a. miR-335 inhibits metastatic progression by targeting SOX4 and tenascin-C—genes that in 
turn promote cancer cell migration and invasion. Silencing of miR-335 in breast cancer 
metastatic cells is attained through both epigenetic mechanisms and copy number loss.  
b. miR-126 suppresses metastasis by targeting PITPNC1, IGFBP2, and MERTK. Each of 
these genes drives metastasis by enhancing endothelial recruitment and metastatic 
angiogenesis. c. let-7 inhibits metastasis by targeting BACH1 and HMGA2. The let-7 target 
genes act by inducing a pro-invasive gene expression program, leading to enhanced cancer 
cell invasion and metastasis. d. Metastasis suppression by miR-31 is conferred by miRNA-
mediated repression of ITGA5, Rdx, and RhoA—genes that promote metastatic colonization 
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Being the first miRNA to be discovered in humans (Pasquinelli et al., 2000), let-7 was 
also among the first miRNAs to be implicated in human breast cancer metastasis. Initially, 
overexpression of let-7 in human breast cancer cells was found to decrease the frequency of 
metastatic events to the liver and lung (Yu et al., 2007). Subsequent studies by an 
independent group confirmed the metastasis-suppressive role of let-7 and further 
demonstrated that let-7 suppressed breast cancer invasiveness and metastasis to the bone 
through the direct targeting of the transcription factor BACH1 and the chromatin remodeler 
HMGA2 (Figure 1.3c). Both BACH1 and HMGA2 were found to promote the transcription 
of multiple pro-invasive genes, thereby allowing for the broad activation of a pro-metastatic 
gene expression program in response to let-7 silencing (Dangi-Garimella et al., 2009; Yun et 
al., 2011). 
The miR-31 pathway represents another prominent example of a metastasis-
suppressive miRNA. This miRNA was initially implicated in breast cancer progression based 
on its observed downregulation in human breast cancer cells relative to mammary epithelial 
cells (Valastyan et al., 2009b). Subsequent functional studies demonstrated that miR-31 
robustly suppressed metastasis in both loss- and gain-of-function mouse experiments. 
Mechanistically, miR-31 was found to inhibit metastatic progression through the coordinate 
repression of three genes (ITGA5, RDX, and RhoA), each of which was shown to promote 
anoikis resistance, migration, invasion, and metastasis by breast cancer cells (Valastyan et al., 
2009a; Valastyan et al., 2009b) (Figure 1.3d). Importantly, consistent with these functional 
findings, the expression levels of each miR-31 and its target gene signature were found to 
segregate breast cancer patients into low and high risk of metastatic relapse (Valastyan et al., 
2009b), underscoring the clinical relevance of this miRNA regulatory network to human 
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cancer progression. Additional studies have reported reduced expression of miR-31 in 
multiple other cancer types, suggesting that the metastasis-suppressive role of miR-31 may 
not be limited to breast cancer (Wszolek et al., 2011; Schaefer et al., 2010; Creighton et al., 
2010; Zhang et al., 2010).  
Taken together, the findings on miR-335, miR-126, miR-31, and let-7 collectively 
illustrate that breast cancer cells can attain metastatic capacity through the silencing of 
specific metastasis suppressor miRNAs, allowing for the de-repression of key pro-invasive 
and pro-metastatic genes (Figure 1.3). The identification of these miRNAs as suppressors of 
breast cancer metastasis has led to the discovery of multiple miRNA target genes as novel 
promoters of metastasis and new promising therapeutic targets in breast cancer progression. 
 
miRNAs as Promoters of Breast Cancer Metastasis 
While early studies looking into the global expression profiles of miRNAs in human 
malignancies hinted to a suppressive role for these regulators in tumor progression, an 
outstanding question in the field was whether a miRNA could, on the contrary, drive 
metastasis by silencing metastasis-suppressive factors. Indeed, at roughly the same time as 
the discovery of the first metastasis suppressor miRNAs, the first breast cancer metastasis 
promoter miRNA was also identified (Ma et al., 2007). Upregulation of miR-10b in breast 
cancer cells relative to normal epithelia initially implicated an oncogenic role for this miRNA 
in cancer progression. As predicted from these expression-based studies, ectopic expression 
of miR-10b was found to drive metastasis by human breast cancer cells (Ma et al., 2007), 
while subsequent studies demonstrated that silencing of endogenous miR-10b inhibited 
metastasis (Ma et al., 2010a). This miRNA was shown to increase metastasis by directly 
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targeting a gene known as homeobox D10 (HOXD10). HOXD10 was found to act by 
inhibiting the expression of RhoC , a gene with a previously known metastasis-promoting 
function (Ma et al., 2007; Hakem et al., 2005). De-repression of RhoC in response to miR-
10b overexpression ultimately enhanced breast cancer cell migration, invasion, and 











                                                  Modified from Pencheva and Tavazoie, Nat Cell Biol, 2013 
 
Figure 1.4. miRNA Regulatory Networks that Promote Breast Cancer Metastasis.  
a. miR-10b promotes metastasis by directly targeting HOXD10. HOXD10 in turn represses 
RhoC—a promoter of cancer cell migration and invasion. miR-10b becomes upregulated in 
breast cancer cells through transcriptional activation by TWIST-1. b. miR-373 and miR-
520c, which belong to the same family of miRNAs, enhance cancer cell migration, invasion, 
and metastasis by targeting of CD44. c. miR-9, which is transcriptionally activated by 
MYC/MYCN, promotes metastasis via two distinct pathways. In E-cadherin-positive breast 
cancer cells, miR-9 targeting of E-cadherin enhances cancer cell migration and invasion. In 
breast cancer cells that do not express E-cadherin, miR-9-mediated repression of LIFR drives 
YAP-depended migration and invasion.   
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Parallel to the identification of miR-10b, an independent systematic analysis 
employing a forward genetic screen identified two additional miRNAs as promoters of breast 
cancer metastasis. In this study, human breast cancer cells were transduced with a miRNA-
expression library and assessed for their migration capacity. Cells that showed an 
enhancement in migratory ability were subsequently profiled for miRNA expression, leading 
to the identification of miR-373 and miR-520c as miRNAs that were preferentially enriched 
in highly migratory breast cancer cells in vitro (Huang et al., 2008). These miRNAs, which 
are members of the same miRNA family and share common seed sequences, were found to 
repress a common target gene, CD44, in promoting both cell migration and invasion (Figure 
1.4b). Importantly, non-metastatic cells engineered to overexpress each miR-373 or mR-520c 
exhibited a greatly enhanced metastatic capacity, providing important in vivo evidence for 
the metastasis promoting function of these miRNAs (Huang et al., 2008). 
Shortly after the discovery of the first metastasis-promoting miRNAs, miR-9 was also 
found to drive invasion and metastasis by breast cancer cells through directly repressing E-
cadherin (Ma et al., 2010b) (Figure 1.4c). Interestingly, follow-up work demonstrated a 
metastasis-promoting role for miR-9 that is independent of E-cadherin targeting (Chen et al., 
2012). Overexpression of miR-9 in E-cadherin-negative human breast cancer cells was 
sufficient to enhance metastasis, revealing miR-9 to act by repressing alternative target 
genes. Leukemia inhibitory factor receptor (LIFR) was identified as a direct miR-9 target in 
the absence of E-cadherin and was shown to act as a suppressor of invasion, migration, and 
metastasis through destabilization of YAP, a signaling effector in the Hippo pathway with a 
previously known oncogenic function (Chen et al., 2012)  (Figure 1.4c).  
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In addition to the cell-intrinsic role of miR-9 in promoting breast cancer metastasis 
(Ma et al., 2010b, Chen et al., 2012), a recent study has implicated an independent cell-
extrinsic role for miR-9 in regulating the tumor microenvironment. Work by Ferrara and 
colleagues demonstrated that cancer cell-expressed miR-9, which is secreted by cancer cells 
within microvesicles known as exosomes, gets transported into endothelial cells where it 
regulates endothelial cell migration by directly targeting gene expression programs within 
endothelial cells (Zhuang et al., 2012). While miR-9 represents the first example of a cancer 
cell-secreted miRNA acting directly on endothelial cell-signaling pathways, the relevance of 
such cell-extrinsic alterations by miRNA-containing vesicles to metastasis remains to be 
demonstrated. 
 
Metastasis Regulatory miRNAs with Pleiotropic Roles in Cancer Progression 
The phenotypically diverse control exerted by miRNAs on cancer progression is 
further nuanced by pleiotropically acting miRNAs that can simultaneously suppress and 
promote discrete stages of the metastatic process. The miR-200s family of miRNAs (miRs-
200a/b/c, miR-429, and miR-141) represents one of the best-studied examples of miRNAs 
with such dual metastasis regulatory roles. At roughly the same time, several independent 
groups showed that the tumor cell epithelial phenotype is in large part maintained by the 
miR-200s family (Gregory et al., 2008; Korpal et al., 2008; Park et al., 2008; Burk et al., 
2008). miR-200s were shown to block the epithelial-to-mesenchymal transition (EMT) 
exhibited by disseminating tumor cells, a molecular process that is thought to be a key 
determinant of human breast cancer metastasis (Yu et al., 2013). Consistent with this, it was 
demonstrated that overexpression of miR-200s can inhibit metastatic dissemination from an 
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orthotopic site in a syngeneic model of murine breast cancer (Gibbons et al., 2009). The miR-
200s family members were found to suppress cell migration and EMT by targeting a set of 
transcription factors (ZEB1 and ZEB2) that had previously been shown to transcriptionally 













                                Modified from Pencheva and Tavazoie, Nat Cell Biol, 2013 
 
 
Figure 1.5. Pleiotropic Control of Metastasis by miR-200s. The miR-200s family exerts 
dual metastasis-suppressive/promoting effects on metastasis. At the primary tumor stage, 
miR-200s-mediated targeting of ZEB1/2 leads to de-repression of E-cadherin, which in turn 
inhibits cancer cell migration and metastatic dissemination. Conversely, at a distal metastatic 
site, miR-200s promote colonization by directly targeting Sec23a—a COPII vesicle 
component that enhances secretion of the metastasis-suppressive factors IGFBP4 and 
TNAGL1. 
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These early reports on the role of miR-200s in inhibiting EMT suggested that the 
miR-200s family suppressed metastasis by limiting local tumor invasion and dissemination. 
However, recent findings have contrasted that notion by implicating a metastasis-promoting 
role for miR-200s through targeting of Sec23a, a COPII vesicle component, which was 
shown to decrease secretion of the metastasis-suppressive factors IGFBP4 and TINAGL1 
(Korpal et al., 2011) (Figure 1.5). Both overexpression of miR-200s as well as knockdown of 
each IGFBP4 and TINAGL1 were found to enhance lung colonization by murine breast 
cancer cells. Importantly, high expression levels of miR-200s correlated with shorter 
metastasis-free survival times in human breast cancer patients, further arguing in favor of a 
pro-metastatic role for this miRNA family in breast cancer (Korpal et al., 2011). 
Even though the metastasis regulatory role of miR-200s remains to be extended to 
human breast cancer cells and validated in loss-of-function studies testing endogenous 
activity of miR-200s, the present findings implicate the miR-200s family members as 
potential pleiotropically acting miRNAs with dual metastasis-suppressing/metastasis-
promoting roles in the control of metastatic progression phenotypes. How could one explain 
these seemingly opposing functions of miR-200s in metastasis?  Considering the 
multifaceted nature of metastasis, expression of miR-200s at the primary tumor level may 
inhibit metastasis by blocking ZEB1/2-dependent EMT and early orthotropic tumor cell 
dissemination, whereas upregulation of miR-200s at a metastatic site may drive metastasis 
through targeting of Sec23 and inhibiting secretion of factors that suppress colonization in a 
distal organ site such as the lung.  
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Search for Metastasis Regulatory miRNAs in Melanoma 
Inspired by early work in breast cancer that revealed robust metastasis control by 
specific metastasis suppressor and promoter miRNAs, subsequent studies investigated 
metastasis regulatory miRNAs in multiple additional human cancers, including melanoma.  
Several studies have examined the distinct miRNA expression signature associated with 
melanoma progression. Notably, high miR-191 levels but low miR-193b levels were 
associated with longer post-metastasis survival in cutaneous melanoma patients (Caramuta et 
al., 2010), while high let-7 and miR-199a-5p levels were found to correlate with uveal 
melanoma progression (Worley et al., 2008). However, the correlative nature of these 
findings has precluded conclusions about the functional roles of these miRNAs in metastasis.  
One of the first experimental attempts to functionally characterize the role of a 
particular miRNA in melanoma metastasis focused on a single miRNA: miR-182 (Segura et 
al., 2009). This miRNA initially captured the researchers’ interest given its genomic 
location—miR-182 is flanked by the c-Met and B-Raf oncogenes in a genomic region on 
chromosome 7 that is frequently amplified in human melanomas. Functional studies showed 
that overexpression of miR-182 was sufficient in promoting lung colonization by murine 
melanoma cells and implicated the major melanocyte-specific transcription factor MITF as a 
direct downstream target of miR-182 (Segura et al. 2009; Figure 1.6a). More recently, miR-
214 and miR-30b/30d were also reported to promote melanoma metastasis. While miR-214 
was found to directly target ITGA3 and TFAP2C in driving invasion, extravasation, and 
colonization by melanoma cells (Penna et al., 2011; Figure 1.6b), overexpression of miR-
30b/30d enhanced micrometastasis formation through targeting of GALNT1 and GALNT7 
(Gaziel-Sovran et al., 2011; Figure 1.6c). The miR-30b/30d target genes were found to 
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inhibit cell invasion, and GALNT7 was also implicated in immune cell activation by 
downregulating the immunosuppressive cytokine IL-10. Therefore, it was speculated that by 
indirectly activating the expression of IL-10, miR-30b/30d triggers immune cell suppression, 
which ultimately enhances melanoma metastatic progression. Importantly, the expression 
levels of miR-30b/30d in primary melanoma tumors were shown to correlate with metastatic 
outcomes of melanoma patients (Gaziel-Sovran et al., 2011), supporting previous findings 
that specific miRNAs may act as potential biomarkers in melanoma progression (Worley et 










                                                      Modified from Pencheva and Tavazoie, Nat Cell Biol, 2013 
 
Figure 1.6. miRNA Regulatory Networks that Promote Melanoma Metastasis.  
a. Overexpression of miR-182 promotes mouse melanoma metastasis by targeting MITF and 
FOXO3—genes that suppress cell migration and invasion. In addition, FOXO3 was also 
shown to suppress cell apoptosis. b. miR-214 enhances melanoma cell migration, extra-
vasation, and metastasis through targeting of TFAP2C and ITGA3. c. miR-30b/30d directly 
targets the galactosaminyltransferases GALNT1 and GALNT7, which in turn act as 
suppressors of melanoma invasion and metastasis. Additionally, GALNT7 also suppresses 
the secretion of the immunosuppressive cytokine IL-10.  
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Overview and Biological Significance  
Recent work by multiple independent groups has led to the emergence of miRNAs as 
robust regulators of metastatic progression (Pencheva and Tavazoie, 2013). Whereas the 
majority of early studies provided strong evidence for endogenous miRNA activity in the 
control of breast cancer metastasis through the use of loss-of-function mouse studies and 
clinicopathologic analyses, the role of endogenous miRNAs in other metastatic epithelial 
cancers is less well established. Melanoma, a highly prevalent malignancy with steadily 
increasing incidence, remains clinically intractable following metastasis of the primary tumor 
(Garbe et al., 2011). The molecular underpinnings of melanoma metastasis are still poorly 
understood, which has hindered the development and clinical implementation of effective 
therapeutic approaches to prevent and/or treat metastasis. Despite several studies reporting 
deregulated miRNA expression in melanoma and showing that overexpression of certain 
miRNAs can drive melanoma metastasis, no systematic analyses had been performed, prior 
to this work, to identify miRNAs with robust endogenous activity in melanoma metastatic 
progression. The discovery of endogenous miRNA as regulators of melanoma metastasis 
would further support the pervasive metastasis control exerted by these small RNAs across 
multiple human cancers. More importantly, these miRNAs can then be used as functionally 
guided probes to uncover novel molecular pathways regulating metastasis. Such mechanistic 
insights will not only deepen and diversify our molecular understanding of the biology 
underlying cancer metastasis, but also will ultimately lead to the emergence of novel 
molecules as potential therapeutic targets in melanoma metastasis, a poorly understood 
molecular process that results in a fatal outcome for more than 90% of advanced melanoma 
patients (Bhatia et al., 2009).  
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In this thesis, I describe the use of a systematic in vivo selection-based approach for 
the identification and functional characterization of miRNAs (Chapter II) and their effector 
genes (Chapter III) in the regulation of melanoma metastasis. Our unbiased interrogation of 
deregulated miRNA pathways in melanoma metastasis led to the identification of a single 
gene, ApoE, as a convergent target of multiple metastasis-promoting miRNAs in melanoma 
(Chapter III). The central position of ApoE in this miRNA regulatory network as well as the 
significant correlation of ApoE expression with melanoma progression outcomes motivated 
us to further investigate the molecular role of ApoE in melanoma metastasis, which is the 
focus of Chapter IV. Finally, in light of the robust metastasis suppression effects exerted by 
ApoE, I describe the development and implementation of a therapeutic approach to 
chronically activate ApoE expression in metastatic melanoma by pharmacologically targeting 
the liver X nuclear hormone receptor beta (LXRβ), a ubiquitously expressed transcriptional 
trans-activator of ApoE (Chapter V). In the final Chapter VI, I discuss the biological and 
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CHAPTER II: IDENTIFICATION, FUNCTIONAL 
CHARACTERIZATION, AND CLINICAL VALIDATION OF MIRNAS 
THAT PROMOTE MELANOMA METASTASIS 
 
In Vivo Enrichment for Highly Metastatic Melanoma Sub-Populations of Cells 
In order to enrich for highly metastatic cell derivatives from heterogeneous parental 
human melanoma cell populations, we employed an in vivo selection approach originally 
developed by Isaiah Fidler (Pollack and Fidler, 1982).  Hien Tran, a former clinical fellow in 
the lab, carried out in vivo selection with two independent human melanoma cell lines: the 
melanotic B-Raf wild-type MeWo line and the amelanotic B-Raf mutant A375 line. In brief, 
parental cells were injected via the tail-vein into immunocompromised Nod SCID mice. 
Following formation of macroscopic metastatic nodules in the lungs, nodules were extracted 
and melanoma cells were dissociated, yielding a first generation of lung metastatic (LM1) 
derivatives that were then re-injected into mice and subjected to another round of in vivo 
selection. Ultimately, cells dissociated from the LM1-forming metastatic nodules gave rise to 
a second generation of lung metastatic cells designated as LM2. 
I then tested whether the in vivo selected metastatic melanoma cells, generated using 
the approach described above, exhibited enhanced metastatic capacity relative to the parental 
population they were derived from. Indeed, in vivo bioluminescence imaging of luciferase-
expressing melanoma cells complemented with ex vivo gross lung histology revealed that the 
MeWo-LM2 metastatic derivatives colonized the lungs to a significantly greater extent than 
that of the parental population (Figure 2.1a). Similar results were obtained for the 
independently derived A375-LM3 (third generation) metastatic derivatives (Figure 2.1b). 









Figure 2.1. Lung Metastatic Colonization by In Vivo-Selected Metastatic Melanoma 
Derivatives and Their Parental Populations. a. Bioluminescence imaging plot of lung 
colonization by 4 × 104 MeWo parental (MeWo-Par) and MeWo lung metastatic derivatives 
(MeWo-LM2). Lungs were extracted at day 72 and H&E-stained. n ≥ 4. b. Lung 
colonization, quantified by weekly bioluminescence imaging, by 1 × 105 A375-Par and 
A375-LM3 melanoma cells. H&E-stained lungs correspond to lungs extracted at the final 
day of imaging, day 49. n ≥ 4. All data are represented as mean ± SEM. *p < 0.05. p-values 
based on Mann-Whitney’s t-tests. 
 
Identification of Metastasis-Promoting miRNAs in Human Melanoma 
Having obtained highly metastatic derivatives from an isogenic parental population, 
Hien Tran and I next examined whether there exist any molecular differences between poorly 
metastatic and highly metastatic human melanoma cells. In these early analyses, we focused 
on miRNA expression given previous evidence of deregulated miRNA expression in highly 
metastatic breast cancer cells (Tavazoie et al., 2008). Hybridization-based small RNA 
profiling of 894 mature miRNAs followed by stem-loop quantitative reverse-transcriptase 
PCR (qRT-PCR) validation revealed four miRNAs (miR-1908, miR-214, miR-199a-5p, and 
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miR-199a-3p) to be upregulated greater than two-fold in multiple A375 and MeWo 
metastatic derivatives relative to their respective parental cells (Figures 2.2a-b). This analysis 
also implicated two miRNAs (miR-7 and miR-18a) that exhibited modest downregulation 
(up to 2-fold decrease) in only a subset of the metastatic derivatives (data not shown). In 
comparison, the observed upregulation of miR-1908, miR-214, miR-199a-3p, and miR-199a-
5p was robust (up to 10,000-fold increase) and pervasive, as it was seen across all metastatic 












Figure 2.2. Identification of Deregulated miRNAs in Metastatic Melanoma Cells. 
 a-b. qRT-PCR validation of the expression levels of miR-1908, miR-214, miR-199a-5p, and 
miR-199a-3p in multiple lung metastatic derivatives and their respective parental populations 
for the MeWo (a) and A375 (b) human melanoma cell lines. The four miRNAs were chosen 
for qRT-PCR validation based on their greater than two-fold upregulation based on 
microarray analyses. n = 3. All data are represented as mean ± SEM. *p < 0.05, **p < 0.01, 
***p < 0.001. p-values based on unpaired student’s t-tests. 
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The significant induction of miR-199a-3p, miR-199a-5p, miR-214, and miR-1908 
across multiple metastatic derivatives prompted us to examine whether these miRNAs 
exhibit a metastasis-promoting role in human melanoma. To directly test this, I employed a 
retroviral transduction approach to overexpress the precursors for miR-199a-3p and miR-
199a-5p (overexpressed concomitantly as the miR-199a hairpin), miR-1908, or miR-214 in 
the poorly metastatic MeWo cells that exhibit relatively low endogenous levels of these 
miRNAs (Figure 2.3a). Subsequent lung colonization assays revealed that overexpression of 
miR-199a and miR-1908 led to a greater than 8-fold increase in lung metastatic colonization 
based on both bioluminescence signal quantification and gross lung histology, while miR-
214 overexpression did not significantly affect metastasis (Figure 2.3b). Importantly, each 
miR-199a or miR-1908 individually increased the number of metastatic nodules formed 
(Figure 2.3c), consistent with a role for these miRNAs in metastatic initiation.  
The lack of metastasis regulatory activity for miR-214 in the human MeWo line is in 
contrast to its previously reported role as a metastasis promoter in melanoma (Penna et al., 
2011) and suggests that this miRNA acts as a passenger in the MeWo system. Consistent 
with this, miR-214 is located within a polycistron together with miR-199a on chromosome 1, 
implying that both miR-214 and miR-199a are processed together and undergo upregulation 
in metastatic melanoma cells through a common mechanism. In regards to the other two 
miRNAs (miR-182 and miR-30b/30d) that were previously reported to promote melanoma 
metastasis (Penna et al., 2011; Gaziel-Sovran et al., 2011), we did not observe upregulation 
of miR-30b/30d across the metastatic derivatives, while miR-182 was upregulated in the 
MeWo metastatic variants, but not in the A375-LM3 cells. However, overexpression of miR-
182 in MeWo parental cells did not significantly modulate metastasis (data not shown). 
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We next asked if endogenous forms of miR-199a and miR-1908 promote metastasis. 
To test this, we silenced each of the miRNAs in the highly metastatic MeWo-LM2.3 cells 
(henceforth designated as MeWo-LM2) that express relatively high miRNA levels. Stable 
inhibition of mature miR-1908 and each of the two miRNAs arising from the miR-199a 
hairpin (miR-199a-3p and miR-199a-5p) through miR-Zip technology suppressed metastatic 
colonization in the highly metastatic MeWo-LM2 cells by more than 7-fold (Figure 2.4a) and 









Figure 2.3. Identification of miR-199a and miR-1908 as Promoters of Melanoma 
Metastasis to the Lung. a. Expression levels of miR-199a-3p, miR-199a-5p, miR-1908, and 
miR-214 determined by qRT-PCR in MeWo parental cells that were transduced with a 
retrovirus expressing a control hairpin or a miRNA precursor hairpin giving rise to miR-199a 
(both miR-199a-3p and miR-199a-5p), miR-1908, or miR-214, respectively. 
 b. Bioluminescence imaging quantification and representative H&E-stained lung images 
corresponding to lung colonization by 4 × 104 MeWo parental cells expressing a control 
hairpin or a precursor hairpin for miR-199a, miR-1908, or miR-214. n ≥ 4. c. Number of 
macroscopic nodules formed by MeWo control cells or MeWo cells overexpressing miR-
199a or miR-1908. n = 3. All data are represented as mean ± SEM. *p < 0.05, **p < 0.01. 
p-values based on Mann-Whitney’s t-tests (b) or unpaired student’s t-tests (c). 










Figure 2.4. Endogenous miR-199a-3p, miR-199a-5p, and miR-1908 Promote Lung 
Colonization and Metastatic Initiation. a. Lung colonization, quantified by 
bioluminescence imaging, by 4 × 104 MeWo-LM2 cells transduced with a control hairpin 
(miR-Zip) or a miR-Zip targeting each mature miR-199a-3p, miR-199a-5p, or miR-1908. 
H&E-stained lungs correspond to the final day 49 of imaging. n ≥ 5. b. Number of 
macroscopic lung nodules formed by MeWo-LM2 control cells or MeWo-LM2 cells with 
silenced expression of each miR-199a-3p, miR-199a-5p, or miR-1908. n = 3. All data are 
represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. p-values based on Mann-
Whitney’s t-tests (a) or unpaired student’s t-tests (b). 
 
To determine whether these miRNAs also promote metastasis in an independent cell 
line, I silenced their expression in the A375-LM3.2 cells (henceforth designated as A375-
LM3). Indeed, miR-Zip-mediated silencing of miR-1908, miR-199a-3p, or miR-199a-5p 
significantly reduced lung colonization by the highly metastatic A375-LM3 derivatives 
(Figure 2.5). Taken together, these findings establish miR-1908, miR-199a-3p, and miR-
199a-5p as endogenous promoters of metastasis by human melanoma cells.  
 









Figure 2.5. Endogenous miR-199a-3p, miR-199a-5p, and miR-1908 Promote Metastasis 
by an Independent Melanoma Cell Line. Lung photon flux measured by bioluminescence 
imaging 42 days following intravenous injection of 2  × 105 A375-LM3 cells expressing a 
control miR-Zip or a miR-Zip targeting miR-199a-3p, miR-199a-5p, or miR-1908. n ≥ 5.  All 
data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. p-values based on 
Mann-Whitney’s t-tests. 
 
We next wished to determine how pervasive the overexpression of miR-199a and 
miR-1908 is in the metastasis of different melanoma subtypes. To this end, I performed in 
vivo selection for highly metastatic derivatives of two independently derived primary human 
melanoma cell lines, SK-Mel-334 and SK-Mel-462 (Figure 2.6), which had had minimum 
expansion in vitro (up to passage 10) following their dissociation from patients’ tumors. 
Remarkably, consistent with our previous findings from the MeWo and A375 in vivo selected 
metastatic melanoma sub-lines, we observed upregulation of miR-199a-3p, miR-199a-5p, 
and miR-1908 across the metastatic derivatives of both patients’ primary melanoma lines as 
well as in additional metastatic derivatives of the HT-144 and WM-266-4 established 
melanoma lines (Figure 2.7). Our findings of pervasive deregulation of these three miRNAs 
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across multiple in vivo-selected metastatic derivatives from a total of six mutationally diverse 
melanoma lines isolated from different patients provide strong evidence that the observed 
upregulation of miR-199a-3p, miR-199a-5p, and miR-1908 during melanoma metastasis is 
robust and unlikely to be cell line-specific. Importantly, the induction of these miRNAs in 
primary melanoma metastatic derivatives indicates that this phenomenon is unlikely to be an 











Figure 2.6. In Vivo Selection for Metastatic Melanoma Derivatives of Primary Human 
Melanoma Cell Populations. a-b. Metastatic colonization following intravenous injection of 
2 × 105 parental or LM2 derivatives of the SK-Mel-334 (a) and SK-Mel-462 (b) primary 
melanoma lines that were derived from melanoma tumors of patients at the Memorial Sloan-
Kettering Cancer Center. Lung colonization was measured by weekly bioluminescence 























Figure 2.7. Pervasive Upregulation of miR-199a-3p, miR-199a-5p, and miR-1908 across 
Melanoma Metastatic Derivatives.  a-d. The levels of miR-199a-3p, miR-199a-5p, and 
miR-1908 were analyzed by qRT-PCR in multiple metastatic derivatives attained by in vivo 
selection of the primary SK-Mel-334 (a) and SK-Mel-462 (b) human melanoma cells, as well 
as the established WM-266-4 (c) and HT-144 (d) human melanoma lines. All data are 
represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. p-values based on 
unpaired student’s t-tests. 
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Cellular Phenotypes Conferred by Metastasis-Promoting miRNAs  
We next investigated the cellular mechanisms by which these miRNAs drive 
melanoma metastasis. With the help of Colin Buss, a former technician in the lab, we first 
tested if these miRNAs promote metastasis by enhancing proliferation/cell survival.  
Contrary to this, overexpression of each miRNA actually reduced cell proliferation/survival 
in vitro (Figure 2.8a). More importantly, miR-1908 overexpression did not increase primary 
tumor growth in vivo, while miR-199a overexpression led to a significant decrease (35%) in 
tumor volume (Figure 2.8b), indicating that the pro-metastatic effects of miR-1908 and miR-








Figure 2.8. Effects of miR-199a and miR-1908 on In Vitro Melanoma Cell Proliferation 
and In Vivo Melanoma Tumor Growth. a. In vitro cell proliferation, quantified by 
counting the number of live cells at days 0, 3, and 5 post-seeding, by MeWo melanoma cells 
expressing a control hairpin or a precursor hairpin giving rise to each miR-199a or miR-
1908. n = 3. b. Subcutaneous tumor growth by 1 × 106 MeWo cells expressing miR-199a or 
miR-1908 precursor hairpins or a control hairpin. n ≥ 4. All data are represented as mean ± 
SEM. *p < 0.05, **p < 0.01, ***p < 0.001. p-values based on unpaired student’s t-tests. 
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Next, we systematically examined a number of additional in vitro phenotypes 
implicated with enhanced in vivo metastatic capacity. While overexpression of each miR-
199a or miR-1908 did not affect cell survival under serum starvation, resistance to anoikis, 
colony formation, or adhesion to endothelial cells (Figures 2.9a-d), I found that each miRNA 
enhanced the ability of MeWo melanoma cells to invade through matrigel (Figure 2.10a) as 
well as their capacity to recruit endothelial cells in trans-well assays (Figure 2.10b). These 
two phenotypes were also elevated in the highly metastatic MeWo-LM2 derivatives (Figures 
2.10c-d), which express higher endogenous levels of miR-199a and miR-1908 relative to the 
parental cells (Figure 2.2a).  Importantly, silencing of each mature miRNA in the highly 
metastatic MeWo-LM2 cells suppressed matrigel invasion and endothelial recruitment, 
revealing a role for the endogenous forms of the three miRNAs in driving these in vitro 
phenotypes (Figure 2.11a-b).  Endogenous miR-199a and miR-1908 were also found to 
promote matrigel invasion and endothelial recruitment by the independent A375-LM3 highly 







Figure 2.9. Effects of miR-199a and miR-1908 on Pro-Metastatic In Vitro Phenotypes.  
a-d. Parental MeWo melanoma cells overexpressing the precursors for each miR-199a or 
miR-1908 or cells transduced with a control hairpin were tested for their capacity to adhere 
to endothelial monolayers (a), survive in the absence of attachment (b), survive during serum 
starvation (c), or form colonies (d). n ≥ 3. All data are represented as mean ± SEM.   


















Figure 2.10. Overexpression of miR-199a or miR-1908 Enhances Matrigel Invasion and 
Endothelial Recruitment Phenotypes.  a. Trans-well matrigel invasion by 1 × 105 
melanoma cells expressing a control hairpin or a pre-cursor hairpin giving rise to miR-199a 
or miR-1908. n ≥ 3.  b. Trans-well endothelial recruitment by 5 × 104 melanoma MeWo cells 
overexpressing miR-199a or miR-1908 or control MeWo cells. n ≥ 7. c-d. The highly 
metastatic MeWo-LM2 derivatives and their parental cells were assessed for their ability to 
invade through matrigel (c) and to recruit endothelial cells (d) in trans-well assays. n ≥ 3.  
Thresholded images represent melanoma cells (a, c) or endothelial cells (b, d) that had 
successfully migrated to the basal side of trans-well inserts. All data are represented as mean 
± SEM. Scale bar, 100 μm. *p < 0.05, ***p < 0.001. p-values based on unpaired student’s t-
tests. 
 


















Figure 2.11. Endogenous miR-199a-3p, miR-199a-5p, and miR-1908 Promote Matrigel 
Invasion and Endothelial Recruitment by Highly Metastatic Melanoma Cells. 
 a-b. Matrigel invasion (a) and endothelial recruitment (b) capacity displayed by MeWo-
LM2 cells transduced with a control hairpin or a miR-Zip hairpin targeting each miR-199a-
3p, miR-199a-5p, or miR-1908. n ≥ 4. c-d. A375-LM3 cells expressing a control hairpin or a 
miR-Zip targeting miR-199a-3p, miR-199a-5p, or miR-1908 were assessed for their matrigel 
invasion (c) and endothelial recruitment (d) ability. n ≥ 5. All data are represented as mean ± 
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The enhanced in vitro endothelial recruitment phenotype conferred by miR-199a-3p, 
miR-199a-5p, and miR-1908 prompted us to investigate whether the three miRNAs also 
regulate metastatic endothelial recruitment (MER) by melanoma cells in vivo. With the help 
of Colin Buss, we examined blood vessel density within lung metastatic nodules by 
performing co-immunostaining for human vimentin, which labels human MeWo melanoma 
cells, and the mouse endothelial cell antigen MECA-32, which labels mouse endothelial 
cells. We found that individual inhibition of miR-199a-3p, miR-199a-5p, or miR-1908 led to 
pronounced decreases (an average of 3-fold for miR-199a-3p and miR-199a-5p; 4.7-fold for 
miR-1908) in blood vessel density within metastatic nodules formed by highly metastatic 
MeWo-LM2 cells (Figure 2.12a). Conversely, overexpression of each miRNA in poorly 
metastatic melanoma cells dramatically increased metastatic blood vessel density (Figure 
2.12b). Consistent with functional angiogenesis impairment, inhibition of each mature 
miRNA in highly metastatic melanoma cells suppressed metastatic nodule perfusion, 
assessed by the rate of dextran perfusion following intravenous injection of biotinylated low-
molecular weight dextran (Figure 2.13). Taken together, our findings reveal endogenous 
miR-199a-3p, miR-199a-5p, and miR-1908 as promoters of melanoma cell invasion, 



























Figure 2.12. Endogenous miR-199a-3p, miR-199a-5p, and miR-1908 Enhance 
Metastatic Endothelial Recruitment In Vivo. a-b. Cumulative percentage plots depicting 
endothelial cell (marked by MECA-32) density within vimentin-positive lung metastatic 
nodules formed by MeWo-LM2 cells silenced for miR-199a-3p, miR-199a-5p, miR-1908, or 
a control (a) and MeWo parental cells transduced with a control hairpin or a pre-cursor 
hairpin giving rise to each miR-199a or miR-1908 (b). n ≥ 30 (a); n ≥ 43 (b). Scale bar,  
100 μm. p-values were obtained through Kolmogorov-Smirnov tests. 
 
 









Figure 2.13. Endogenous miR-199a-3p, miR-199a-5p, and miR-1908 Enhance 
Angiogenic Metastatic Perfusion. Cumulative percentage plots depicting the extent of 
dextran perfusion, expressed as the dextran-positive area out of the total nodule area, within 
metastatic lung nodules formed by MeWo-LM2 cells expressing a control miR-Zip or a miR-
Zip targeting each mature miR-199a-3p, miR-199a-5p, or miR-1908. Low-molecular weight 
(10 kDa) biotinylated dextran was introduced into the circulation and allowed to perfuse 
target tissues for 10 minutes, after which lungs were extracted and dextran perfusion was 
immunohistochemically visualized. n ≥ 18. Scale bar, 100 μm. p-values based on 
Kolmogorov-Smirnov tests.    
 
Clinical Association of miR-199a-3p, miR-199a-5p, and miR-1908 Expression with 
Human Melanoma Metastasis 
Given the robust effects exerted by miR-1908, miR-199a-3p, and miR-199a-5p in 
promoting melanoma metastasis in a mouse model of human cell metastasis, we next 
wondered whether expression levels of these miRNAs can predict the likelihood of a primary 
melanoma tumor to metastasize. To this end, Colin Buss and I extracted RNA from 71 
primary melanoma skin lesions, resected from patients at the Memorial Sloan-Kettering 
Cancer Center (MSKCC). We then quantified in a blinded fashion the expression levels of 
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miR-199a-3p, miR-199a-5p, and miR-1908 in each primary melanoma lesion through stem-
loop qRT-PCR analyses. Consistent with our findings of a metastasis-promoting function of 
these miRNAs in the mouse studies described above, we found that all three miRNAs were 
significantly upregulated in primary melanoma tumors that had metastasized relative to 
tumors that had not (Figure 2.13). This clinical finding suggests that induced expression of 








Figure 2.14. miR-199a-3p, miR-199a-5p, and miR-1908 are Upregulated in Primary 
Melanoma Lesions with Metastatic Propensity. Expression levels of miR-199a-3p, miR-
199a-5p, and miR-1908, determined by qRT-PCR, in non-metastatic (n = 38) and metastatic 
(n = 33) primary melanoma skin lesions from the MSKCC melanoma patient cohort. All data 
are represented as mean ± SEM. p-values based on unpaired student’s t-tests. 
 
Previously documented clinical information regarding each patient’s melanoma 
metastasis outcome allowed us to retrospectively determine the relationship between the 
levels of these miRNAs in primary melanoma lesions and metastatic relapse outcomes.  
Importantly, patients whose primary melanoma lesions expressed high (greater than the 
median for the population) levels of each individual miR-199a-3p, miR-199a-5p, or miR-
1908 were more likely to develop distal metastases and exhibited significantly shorter 
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metastasis-free survival times than patients whose primary melanomas expressed low levels 
of each of these miRNAs (Figures 2.15a-c).  Strikingly, the combined expression levels of 
the three miRNAs displayed the strongest power in stratifying patients at high risk from those 
at low risk for metastatic relapse (Figure 2.15d), indicative of prognostic cooperativity 
among the three miRNAs. These clinical findings suggest utility for these small RNAs as 
clinical biomarkers in informing melanoma metastatic outcomes. Consistent with our 
findings in cutaneous melanoma, miR-199a-5p expression was previously shown to also be 










Figure 2.15. Prognostic Capacity of miR-199a-3p, miR-199a-5p, and miR-1908 in 
Metastatic Melanoma. Kaplan-Meier curves depicting metastasis-free survival times for 
patients from the MSKCC cohort (n = 71) as a function of the individual miR-199a-3p (a), 
miR-199a-5p (b), or miR-1908 (c) expression levels or the combined expression levels of the 
three miRNAs (d) determined by qRT-PCR in primary melanoma skin lesions.  Patients 
whose melanoma tumors had miRNA expression levels below or above the median of the 
population were classified as miRNA negative (low, blue) or miRNA positive (high, red), 
respectively. p-values based on Mantel-Cox (log-rank) tests. 
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Therapeutic Targeting of Metastasis-Promoting miRNAs in Melanoma  
In light of the current lack of effective treatment options for metastatic melanoma 
(Garbe et al., 2011) and the clinical relevance of miR-199a-3p, miR-199a-5p, and miR-1908 
expression to melanoma metastatic progression, we next wondered whether we could 
therapeutically target the three miRNAs for the suppression of melanoma metastasis. We 
utilized locked nucleic acids (LNAs), which are modified oligonucleotides that display high 
specificity and stability in binding to short single-stranded RNAs (Obad et al., 2011). Given 
that LNAs have recently shown remarkable efficacy for the in vivo silencing of mature 
miRNAs (Elmén et al., 2008), we examined whether specific LNAs targeting miR-199a-3p, 
miR-199a-5p, or miR-1908 could have activity in metastasis. To this end, I first transfected 
highly metastatic MeWo-LM2 cells with individual LNA oligonucleotides antisense to each 
mature miRNA (miR-199a-3p, miR-199a-5p, or miR-1908) and injected them into mice 48 
hours later. Such single LNA pre-treatment of highly metastatic melanoma cells led to a 
roughly four-fold decrease in metastatic activity (Figure 2.16a). In light of our clinical 
evidence of cooperativity among these miRNAs, I next tested the impact of concurrently 
silencing all three miRNAs on metastatic progression. Co-transfection of LNAs against all 
three miRNAs suppressed metastatic colonization by over seventy-fold, revealing synergy 
between endogenous miR-199a-3p, miR-199a-5p, and miR-1908 in driving melanoma 
metastasis (Figure 2.16a). Importantly, inhibition of these miRNAs upon triple LNA 
transfection did not decrease in vitro melanoma cell proliferation (Figure 2.16b), consistent 
with our previous findings that miR-199a and miR-1908 do not enhance melanoma cell 
proliferation (Figure 2.8) and indicating that the dramatic metastasis suppression phenotype 
	   49 
upon combinatorial LNA-based miRNA targeting is not secondary to impaired cell 
proliferation and/or survival, as measured in vitro.  
Remarkably, we further found that combinatorial LNA-mediated miRNA inhibition 
robustly inhibited lung colonization by the independent and mutationally diverse SK-Mel-2 
(24-fold), WM-266-4 (77-fold), HT-144 (15-fold), A2058 (17-fold), A375-LM3 (3-fold), and 
SK-Mel-28 (2.5-fold) human melanoma cell lines (Figure 2.17). These findings indicate that 
combinatorial targeting of the three miRNAs exhibits robust therapeutic potential across a 
variety of melanotic and amelanotic human melanoma lines representative of B-Raf-mutant, 









Figure 2.16. LNA-Mediated Silencing of miR-199a-3p, miR-199a-5p, and miR-1908 
Cooperatively Suppresses Melanoma Metastasis. a. Lung colonization by 1 × 105 
melanoma cells transfected with single LNAs individually targeting miR-199a-3p, miR-
199a-5p, or miR-1908, a combination of LNAs targeting all three miRNAs (LNA-3 
miRNAs), or a control LNA (LNA-CTRL) 48 hours prior to cell injection. n ≥ 5.  
b.  In vitro melanoma cell proliferation was determined by counting the number of live cells 
at days 0, 3, and 5 post-seeding of 2.5 × 104 MeWo-LM2 cells transfected with LNA-CTRL 
or LNA-3 miRNAs. n = 3. All data are represented as mean ± SEM. *p < 0.05, **p < 0.01. p-
values based on Mann-Whitney’s t-tests (a) or an unpaired student’s t-test (b). 




















Figure 2.17. Broad Suppression of Melanoma Metastasis by Combinatorial miRNA 
Targeting. a-f. Following 48-hour pre-treatment with LNA-CTRL or LNA-3 miRNAs, 5 × 
105 SK-Mel-2 (a), WM-266-4 (b), HT-144 (c), A2058 (d), A375-LM3 (e), or SK-Mel-28 (f) 
human melanoma cells were intravenously injected into mice and lung colonization was 
quantified by bioluminescence imaging. All data are represented as mean ± SEM. *p < 0.05, 
**p < 0.01, ***p<0.001. p-values based on Mann-Whitney’s t-tests. 
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To determine whether the effect of miRNA inhibition is specific to the suppression of 
lung colonization, we tested the impact of LNA-based miRNA targeting on systemic 
melanoma metastasis. Consistent with a role of the three miRNAs in promoting multi-organ 
colonization, intracardiac injection of highly metastatic MeWo-LM2 cells pre-treated with a 
cocktail of LNAs targeting the three regulatory miRNAs revealed miR-199a-3p, miR-199a-
5p, and miR-1908 as endogenous promoters of systemic melanoma metastasis to multiple 








Figure 2.18. LNA-Mediated Combinatorial miRNA Targeting Suppresses Systemic 
Melanoma Metastasis to Multiple Organs. a-d. 1 × 105 MeWo-LM2 cells transfected with 
a LNA-CTRL or a cocktail of LNA-3 miRNAs were itnracardially injected into nude mice 
and systemic multi-organ colonization was assessed by measuring total systemic photon 
 flux (a), counting the number of systemic metastatic foci (b), and quantifying melanoma cell 
colonization ex vivo in brain (c) and bone (d) organs by bioluminescence imaging. n ≥ 5. All 
data are shown as mean ± SEM. *p < 0.05. p-values based on Mann-Whitney’s t-tests. 
 
Finally, we examined the therapeutic efficacy of systemically administered LNAs 
targeting the three miRNAs for the prevention of melanoma metastasis. To this end, I 
intravenously injected highly metastatic MeWo-LM2 cells into mice and the following day, I 
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began treating the mice by intravenous administration of a cocktail of LNAs targeting miR-
199a-3p, miR-199a-5p, and miR-1908 at a low dose (12.5 mg/kg total) on a bi-weekly basis 
for four weeks and then once weekly for seven weeks. Notably, such combinatorial LNA 
treatment reduced lung colonization by greater than 10-fold (Figure 2.19a) without causing 
any apparent weight loss (Figure 2.19b.)  Importantly, I found that these therapeutic LNAs 
downregulated the levels of the three miRNAs in human melanoma cells dissociated from 
lung metastatic nodules (Figure 2.20a) and they also silenced the mouse homologs of these 
miRNAs in mouse cardiac and liver tissues (Figures 2.20b-c), consistent with efficient in 









Figure 2.19. Therapeutic Delivery of LNAs Targeting miR-199a-3p, miR-199a-5p, and 
miR-1908 Suppresses Melanoma Metastasis. a.  Following intravenous injection of 4 × 104 
MeWo-LM2 cells, the next day mice were intravenously administered a cocktail of in vivo-
optimized LNAs targeting miR-199a-3p, miR-199a-5p, and miR-1908 (12.5 mg/kg total 
dose) or a mock PBS control treatment, as indicated. Lung colonization was quantified by 
weekly bioluminescence imaging, and representative H&E-stained lungs extracted at the 
final day of imaging (d80) are shown. n ≥ 5. b.  Weight of mice intravenously treated with a 
cocktail of LNAs targeting the three miRNAs or a mock PBS control. All data are 
represented as mean ± SEM. *p < 0.05. p-value based on an unpaired student’s t-test. 
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Figure 2.20. Efficiency of Therapeutically Delivered LNAs in Silencing Target miRNAs 
In Vivo. a. Expression levels of miR-199a-3p, miR-199a-5p, and miR-1908, determined by 
qRT-PCR, in MeWo-LM2 cells dissociated from lung metastatic nodules of mice 
intravenously treated with LNA-3 miRNAs (12.5 mg/kg) or a mock control. n ≥ 3.  
b-c. Total RNA was extracted from cardiac (b) and liver (c) tissues harvested from mice 
treated with LNA-3 miRNAs (12.5 mg/kg) or a mock control, and the expression levels of 
miR-199a-3p, miR-199a-5p, and miR-1908 in heart (b) and liver (c) mouse tissues were 
analyzed by qRT-PCR. n ≥ 3. All data are represented as mean ± SEM. *p < 0.05, 
 **p < 0.01, ***p < 0.001. p-values based on unpaired student’s t-tests. 
   
 Mechanisms Upstream of miRNA Overexpression in Melanoma Metastasis 
Deregulated Transcriptional Control of miR-199a and miR-1908  
In light of the broad upregulation of miR-199a and miR-1908 across multiple 
melanoma subtypes, we investigated the putative upstream mechanism(s) responsible for the 
induction of miR-199a-3p, miR-199a-5p, and miR-1908 in metastatic melanoma cells.  I first 
examined whether upregulation of the three miRNAs is due to genomic locus amplification. 
Contrary to this, the genomic copy number of miR-1908 and miR-199a, which can be 
transcribed from two independent chromosomal loci encoding miR-199a-1 and miR-199a-2, 
remained unchanged in the highly metastatic derivatives of two independent melanoma lines 
(Figure 2.21). 








Figure 2.21. Genomic Copy Number of miR-199a-1, miR-199a-2, and miR-1908 in 
Highly Metastatic Melanoma Cells and Their Respective Parental Populations. 
a-b. Genomic copy number levels of miR-199a-1, miR-199a-2, and miR-1908 were assessed 
by qRT-PCR using genomic DNA extracted from MeWo-parental cells and metastatic 
MeWo-LM2 derivatives (a) or A375-parental cells and A375-LM3 metastatic derivatives 
(b). Two independent primer pair sets (designated as A and B, respectively) were used to 
amplify genomic regions spanning each miRNA sequence. n = 3. All data are represented as 
mean ± SEM.     
 
I next tested whether the upregulation of miR-199a and miR-1908 could be attained 
through transcriptional mechanisms. To this end, I examined the expression levels of the pri-
miRNA transcripts, which represent the initial precursor miRNA products generated by RNA 
Pol II/III-mediated transcription (Figure 1.2). The pri-miRNA transcript levels for each miR-
199a (encoded by either the miR-199a-1 and miR-199a-2 paralogs) and miR-1908 were 
elevated in a subset of highly metastatic melanoma derivatives relative to their parental cells 
in two independent melanoma lines (Figure 2.22), consistent with enhanced transcriptional 
regulation as a potential mechanism contributing to the enhanced expression levels of miR-
199a and miR-1908 in metastatic melanoma.  








Figure 2.22. Transcriptional Induction of miR-199a and miR-1908 in Highly Metastatic 
Melanoma Cells. a-b. Expression levels of pri-miR-199a-1, pri-miR-199a-2, and pri-miR-
1908, determined by qRT-PCR, in MeWo-LM2 metastatic derivatives and their parental cells 
(a) and A375-LM3 metastatic derivatives and their respective parental population (b). n = 3. 
All data are represented as mean ± SEM. **p < 0.01, ***p < 0.001.  
 
    In light of our findings that metastatic cells display enhanced transcriptional 
activation at the miR-199a-1 and miR-199a-2 paralogous loci, which encode miR-199a-5p 
and miR-199a-3p, as well as the miR-1908 locus, I next sought to identify transcription 
factors whose activity may contribute to the augmented expression of these miRNAs in 
metastatic melanoma cells. In light of the phenotypic commonalities displayed by miR-199a 
and miR-1908 with respect to their cellular and in vivo phenotypes (invasion, endothelial 
recruitment, and metastasis), we hypothesized that a common transcription factor (TF) might 
enhance the expression of both miR-199a and miR-1908 in metastatic melanoma cells.  
Indeed, promoter sequence analysis of the miR-199a-1, miR-199a-2, and miR-1908 loci 
using the P-Match 1.0 algorithm revealed all three miRNA promoter regions to contain 
common elements corresponding to the CREB (CREB1) transcription factor binding motif 
TGACG (Table 2.1, Figure 2.23).  
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Table 2.1.  Conserved Transcription Factor (TF) Binding Sites Present in the Putative 


























Figure 2.23.  Schematic of CREB Binding Motifs Found within the Putative Promoter 
Regions of miR-199a-1, miR-199a-2, and miR-1908. CREB elements within the putative 
promoter sequences (3000 bp upstream and 1000 bp downstream) of the miR-199a-1, miR-
199a-2, and miR-1908 loci were found and annotated using the P-Match 1.0 algorithm.  
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We next wondered whether endogenous CREB1 regulates the expression of miR-
199a-3p, miR-199a-5p and miR-1908 in metastatic melanoma cells. Indeed, silencing of 
CREB1 with independent siRNAs in the highly metastatic MeWo-LM2 and A375-LM3 
derivatives significantly reduced the expression levels of all three mature miRNAs as well as 
their corresponding pri-miRNA transcripts (Figure 2.24). Importantly, I further found that the 
levels of active (phosphorylated) CREB1 (phospho-CREB1) were upregulaed in melanoma 
metastatic derivatives relative to their parental cells (Figure 2.25), suggesting that enhanced 
CREB1 activity might account for the elevated transcriptional activation of miR-199a and 
miR-1908 in metastatic melanoma cells. Consistent with this, the levels of CREB1 were 
upregulated in clinical melanoma metastases samples relative to primary melanoma lesions 








Figure 2.24.  Endogenous CREB1 Promotes miR-199a-3p, miR-199a-5p, and miR-1908 
Expression in Metastatic Melanoma Cells a-b. Expression levels of mature miR-199a-3p, 
miR-199a-5p, and miR-1908, determined by qRT-PCR, in highly metastatic MeWo-LM2 (a) 
and A375-LM3 (b) melanoma cells in response to siRNA-mediated CREB silencing. n = 3. 
c. Expression levels of pri-miR-199a-1, pri-miR-199a-2 and pri-miR-1908 in response to 
siRNA-based CREB1 knockdown in MeWo-LM2 cell. n ≥  3. All data are represented as 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. p-values based on student’s t-tests. 







Figure 2.25.  CREB Activation is Enhanced in Metastatic Melanoma Cells. a. Expression 
levels of total CREB and phosphorylated (“phospho”) CREB, assessed by western blotting, 
in highly metastatic MeWo-LM2 cells and their parental MeWo cells. b. Quantification of 
active CREB levels, determined as the ratio of phosphorylated over total CREB, in MeWo-
Par and MeWo-LM2 cells. n = 3. Total CREB levels were normalized to GAPDH. Data are 









Figure 2.26.  CREB Expression is Upregulated in Clinical Melanoma Metastases. 
Expression levels of CREB mRNA transcript, determined based on a previously published 
array-based clinical melanoma dataset (Haqq et al., 2005), in primary melanoma lesions and 
distal melanoma metastases. n = 6 (primary), 19 (metastases). Data are shown as mean ± 
SEM. * p <0.05.  p-value based on an unpaired student’s t-test. 
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Further chromatin immunoprecipitation (ChIP) analyses are needed to determine 
whether CREB directly interacts with the promoter regions of miR-199a and miR-1908. 
Consistent with the promoting effects of miR-199a and miR-1908 on melanoma cell invasion 
and metastasis, multiple previous studies have implicated CREB as a promoter of melanoma 
invasion and metastasis (Dobroff et al., 2009; Aucoin et al., 2004). Future work will examine 
whether CREB also regulates the miRNA-dependent non-cell-autonomous phenotype of 
endothelial recruitment. Additionally, it will be of interest to determine how much of the 
downstream effects of CREB activation on melanoma invasion and metastasis are potentially 
mediated through the transcriptional induction of the metastasis-promoting miRNAs, miR-
199a-3p, miR-199a-5p, and miR-1908. 
Deregulated Post-Transcriptional Processing of miR-199a and miR-1908  
Interestingly, in two of the MeWo metastatic derivatives, the pri-miRNAs levels were 
either unchanged or actually downregulated (Figure 2.22). Furthermore, even in cases where 
the pri-miRNAs were elevated, the fold-changes in pri-miR-199a were more than an order of 
magnitude lower compared to the fold-changes in mature miR-199a-3p and miR-199a-5p 
(Figure 2.2), suggestive of processing deregulation of the abovementioned miRNAs in 
metastatic melanoma cells. Consistent with this, the ratios of mature- to pri-miR-199a-3p and 
mature- to pri-miR-199a-5p expression levels were elevated across all MeWo and A375 
metastatic derivatives, albeit to different extents (Figure 2.27). In comparison, the ratio of 
mature- to pri-miR-1908 was modestly increased in the MeWo-LM2 metastatic derivatives 
(Figure 2.27c), but actually decreased in the A375-LM3 metastatic derivatives (Figure 
2.27e), suggesting that miR-1908 overexpression in the A375-LM3 system might be 
primarily attained through transcriptional regulation and/or additional mechanisms.  













Figure 2.27.  Deregulated Processing of miR-199a-3p, miR-199a-5p, and miR-1908 in 
Metastatic Melanoma Cells.  a-f. Ratios of mature to pri-miRNA expression levels for miR-
199a-3p, miR-199a-5p, and miR-1908 across multiple MeWo-LM2 (a-c) and A375-LM3 (d-
f) metastatic derivatives relative to their respective parental cell lines. n = 3. *p < 0.05,  
**p < 0.01, ***p < 0.001. p-values based on unpaired student’s t-tests. 
 
Taken together, these findings suggest that both enhanced CREB-dependent 
transcription and miRNA processing alterations might contribute to miRNA induction across 
the various metastatic derivatives we have examined. Future work will characterize the 
precise molecular effectors in the miRNA processing pathway that may be deregulated in 
metastatic melanoma cells and ultimately investigate the extent to which transcription and 
miRNA processing interplay in determining miR-199a and miR-1908 overexpression in 
metastatic melanoma. 
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Summary of Findings from Chapter II 
In this chapter, I describe an in vivo-selection based approach for the generation of 
highly metastatic melanoma variants from poorly metastatic parental populations isolated 
from the tumors of different melanoma patients. By performing small RNA profiling coupled 
with qRT-PCR validation, we identified four miRNAs to be robustly upregulated across 
multiple metastatic melanoma derivatives. Functional loss- and gain-of-function experiments 
revealed three of these miRNAs (miR-199a-3p, miR-199a-5p, and miR-1908) to act as 
endogenous promoters of melanoma metastasis. Importantly, we also found that the 
expression levels of these miRNAs correlated with the metastatic outcomes of melanoma 
patients. Consistent with clinical relevance of these miRNAs to melanoma metastatic 
progression, the three miRNAs exhibited robust therapeutic potential across a multitude of 
human melanoma lines, as evidenced by strong metastasis suppression upon combinatorial 
LNA-based miRNA silencing. Mechanistically, we found that the three miRNAs promoted 
metastasis by increasing melanoma invasion and also enhancing the ability of melanoma 
cells to recruit endothelial cells both in vitro and in vivo.  Finally, our preliminary analyses 
have suggested that these miRNAs become upregulated in metastatic melanoma cells through 
a combination of transcriptional and post-transcriptional mechanisms. I have identified 
CREB as a putative transcription factor that might contribute to the transcriptional induction 
of the three miRNAs in metastatic melanoma. Further work is necessary to determine the 
molecular alteration(s) responsible for the altered processing of these metastasis-promoting 
miRNAs. 
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CHAPTER III: IDENTIFICATION, FUNCTIONAL 
CHARACTERIZATION, AND CLINICAL VALIDATION OF MIRNA 
EFFECTOR GENES IN MELANOMA METASTASIS 
 
Systematic Identification of Genes Repressed by miR-199a-3p, miR-199a-5p, and miR-
1908 in Melanoma 
Mammalian miRNAs act predominantly by destabilizing target mRNA transcripts, 
which is reflected by reduced transcript levels and ultimately lower protein expression of 
target mRNAs (Guo et al., 2010).  In order to identify the direct molecular effectors of miR-
199a-3p, miR-199a-5p, and miR-1908, we employed a systematic and unbiased approach 
involving whole-genome transcriptomic profiling followed by qRT-PCR validation, reporter 
assays, and mutagenesis studies. Given our findings that miR-1908, miR-199a-3p, and miR-
199a-5p mediate the same sets of in vitro and in vivo phenotypes (Chapter II) and the fact 
that miR-199a-5p and miR-199a-3p arise from the same precursor hairpin, we hypothesized 
that the pro-metastatic phenotypes of these miRNAs may be mediated through the 
convergent silencing of common target genes. To identify putative target mRNA transcripts 
whose expression is repressed by each miRNA, we performed transcriptomic profiling of 
melanoma cells in the context of both loss- and gain-of-function for each miRNA (Figure 
3.1).  This analysis, followed by qRT-PCR validation (performed with the help of Dowoon 
Huh, a former technician), revealed a set of two genes, the metabolic factor ApoE and the 
heat-shock protein DNAJA4, that were repressed by both exogenous and endogenous miR-
199a and miR-1908 and that were also present at lower levels in the highly metastatic LM2 
derivatives, which display endogenously higher levels of the three miRNAs (Figure 3.2).  








Figure 3.1.  Identification of Putative miRNA Target Genes. Venn diagrams depicting the 
integrative experimental approach used to identify putative target genes common to miR-
199a-3p, miR-199a-5p, and miR-1908. Genes downregulated by greater than 1.5-fold based 
on transcriptomic profiling expression data upon overexpression of each miRNA were 
overlapped with transcripts upregulated by greater than 1.5-fold upon miRNA silencing as 
well as with transcripts, for which the expression levels were downregulated by more than 










Figure 3.2.  miR-199a and miR-1908 Repress the Expression of ApoE and DNAJA4. 
 a-c. Expression levels of ApoE and DNAJA4 in parental MeWo cells overexpressing the 
precursors for each miR-199a and miR-1908 (a), MeWo-LM2 cells with silenced expression 
of each miR-199a-3p, miR-199a-5p, and miR-1908 (b), and MeWo-LM2 relative to MeWo-
parental cells (c). n = 3. Error bars = SEM. *p < 0.05, **p < 0.01, ***p < 0.001. p-values 
based on unpaired student’s t-tests. 
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Validation of ApoE and DNAJA4 as Direct Target Genes of miR-199a and miR-1908 
I next performed heterologous luciferase reporter assays to determine whether ApoE 
and DNAJA4 are directly targeted by miR-1908, miR-199a-3p, and miR-199a-5p. In these 
experiments, the 3’ untranslated regions (UTR) of each ApoE and DNAJA4 were cloned 
downstream of luciferase’s stop codon, whereas each gene’s coding sequence (CDS) was 
chimerically fused to luciferase to mimic the active translation of the CDS during potential 
miRNA targeting, and the constructs were then transfected into human melanoma MeWo 
cells. The effects of each miRNA on the expression of its putative target constructs were 
examined by measuring luciferase activity as a read-out. I found that each miR-199a and 
miR-1908 individually repressed the expression levels of the 3’ untranslated regions (UTR) 
and coding sequences (CDS) of both ApoE and DNAJA4 (Figure 3.3a). Importantly, mutating 
the miRNA complementary sequences on each target abrogated the miRNA-mediated 
regulation, consistent with direct miRNA targeting of ApoE and DNAJA4 (Figure 3.3a). 
Additionally, in a direct test of endogenous miRNA targeting, silencing of the mature forms 
of each miR-199a-3p, miR-199a-5p, or miR-1908 in metastatic LM2 cells led to an enhanced 
target-driven luciferase activity (Figure 3.3b) that was abrogated upon mutating the miRNA 
target sites (Figure 3.3c). These experiments revealed ApoE to be directly targeted by miR-
1908 and miR-199a-5p and DNAJA4 to be directly targeted by all three miRNAs (Figure 
3.4a). Notably, luciferase activity driven off the CDSs and 3’UTRs of each gene was reduced 
in highly metastatic MeWo-LM2 cells (Figure 3.4b), which exhibit higher endogenous levels 
of the three regulatory miRNAs, relative to the parental MeWo cells. Collectively, these 
findings establish ApoE and DNAJA4 as common target genes of miR-199a and miR-1908. 
 




















Figure 3.3.  miR-199a and miR-1908 Directly Target ApoE and DNAJA4.  
a-c. Heterologous reporter assays measuring luciferase activity driven off ApoE’s and 
DNAJA4’s wild-type or miRNA target site mutant 3’UTRs and CDSs in MeWo parental cells 
overexpressing miR-199a or miR-1908 (a) and MeWo-LM2 cells with silenced expression of 
miR-199a-3p, miR-199a-5p, miR-1908, or a control (b-c). n ≥ 3. All data are shown as mean 
± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. p-values based on unpaired student’s t-tests. 








Figure 3.4.  Convergent Targeting of ApoE and DNAJA4 by miR-199a-3p, miR-199a-5p, 
and miR-1908. a. Experimentally derived model showing the convergent targeting of the 
CDSs and 3’UTRs of ApoE and DNAJA4 by the three metastasis-promoting miRNAs. 
b.  Heterologous reporter assay measuring the luciferase activity driven off the wild-type and 
miRNA target site mutant CDSs and 3’UTRs of each ApoE and DNAJA4 in MeWo parental 
and MeWo-LM2 cells. All data are represented as mean ± SEM.  n ≥ 3. **p < 0.01,  
***p < 0.001. p-values based on unpaired student’s t-tests. 
 
We next wished to determine the robustness of the regulation exerted by the three 
miRNAs on the expression of ApoE and DNAJA4 by examining the relationship between the 
expression levels of the three miRNAs and their target genes across a collection of parental 
and metastatic melanoma lines, which display varied levels of these miRNA (Figure 2.2). 
Consistent with direct targeting of ApoE and DNAJA4 by endogenous miR-199a and miR-
1908, we found a significant anti-correlation between the endogenous levels of each ApoE 
















Figure 3.5.  Anti-Correlation between the Aggregate Expression of miR-199a-3p/miR-
199a-5p/miR-1908 and Their Target Genes. a-b. Linear regression analyses of the 
correlation between the combined expression of the three miRNAs (determined as the 
average of the individual miRNA expression values) and the expression levels of ApoE (a) or 
DNAJA4 (b) across multiple MeWo and A375 metastatic derivatives and their respective 
parental lines. n = 12. R2 values and corresponding p-values were calculated based on the 
Pearson correlation coefficient for each dataset. 
 
Functional Validation of ApoE and DNAJA4 as Suppressors of Melanoma Progression 
Phenotypes 
Given our findings that the three miRNAs convergently repress ApoE and DNAJA4 
expression, we next sought to determine whether these two genes mediate the miRNA-
dependent effects on melanoma progression phenotypes—invasion and endothelial 
recruitment. I found that silencing each gene using independent shRNAs in parental MeWo 
melanoma cells, which express relatively high ApoE and DNAJA4 levels, led to an increase 
in invasion and endothelial recruitment (Figure 3.6). These findings are consistent with 
endogenous ApoE and DNAJA4 acting as suppressors of these in vitro melanoma progression 
phenotypes.  








Figure 3.6.  Suppression of Melanoma Invasion and Endothelial Recruitment by ApoE 
and DNAJA4. a-b. Trans-well matrigel invasion (a) and endothelial recruitment (b) by 
parental MeWo cells expressing a short hairpin (shRNA) targeting ApoE, DNAJA4, or a 
control sequence (shCTRL). Data are shown as mean ± SEM. Scale bar, 100 μm. n ≥ 4.  
*p < 0.05, **p < 0.01. p-values based on unpaired student’s t-tests. 
 
We next wondered whether ApoE and DNAJA4 epistatically interact with each 
miRNA in conferring the miRNA-dependent effects on melanoma progression phenotypes. 
To that end, we tested whether the suppression of melanoma phenotypes conferred upon 
miRNA inhibition is due to the de-repression and resulting elevated expression of ApoE or 
DNAJA4 in the absence of each miRNA.  Consistent with endogenous epistatic 
miRNA/target gene interactions, depletion of either ApoE or DNAJA4 in the setting of 
miRNA inhibition significantly occluded the suppression of invasion and endothelial 
recruitment seen upon silencing of each miRNA (Figures 3.7a-b) and fully rescued the 
suppression of metastatic colonization resulting from miRNA inhibition (Figures 3.7c-e). 
Notably, endogenous ApoE and DNAJA4 were also found to suppress metastatic endothelial 
recruitment in vivo, as metastatic nodules formed by highly metastatic melanoma cells with 
silenced expression of either ApoE or DNAJA4 in the context of miRNA inhibition exhibited 
enhanced endothelial cell content (Figure 3.8).  



















Figure 3.7. Endogenous Epistatic Interactions between miR-199a/miR-1908 and ApoE 
and DNAJA4. a-b. Cell invasion and endothelial recruitment by MeWo-LM2 cells 
transduced with shRNAs targeting ApoE, DNAJA4, or a control in the setting of miR-1908 
silencing (a) or miR-199a-5p silencing (b). n ≥ 6. c-e. Lung metastasis, quantified by 
bioluminescence imaging, by 1 × 105 MeWo-LM2 cells with shRNA-mediated knockdown 
of ApoE or DNAJA4 in the setting of miR-1908 (c, e) or miR-199a-5p inhibition. n = 5. All 
data are plotted as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. p-values based on an 
unpaired student’s t-tests (a-b) or Mann-Whitney’s t-tests (c-e). 







Figure 3.8. Endogenous ApoE and DNAJA4 suppress miRNA-dependent metastatic 
endothelial recruitment in vivo. Cumulative percentage plots depicting the density of 
endothelial content within metastatic nodules formed by 1 × 105 MeWo-LM2 cells 
expressing independent shRNAs targeting ApoE, DNAJA4, or a control sequence in the 
setting of miR-1908 inhibition. Thresholded images displaying only MECA-32 signal within 
the demarcated nodule area are shown in the lower panel. n ≥ 19. Scale bar, 100 μm. p-values 
based on Kolmogorov-Smirnov tests. 
 
Next, Colin Buss conducted the converse overexpression epistasis experiments where 
he ectopically expressed the protein-coding regions of ApoE or DNAJA4 in the setting of 
miRNA overexpression. Given that overexpression of each miR-199a or miR-1908 
significantly reduced the levels of both ApoE and DNAJA4, we wondered whether re-
introducing ApoE or DNAJA4 in that setting could occlude the ability of each miRNA to 
promote melanoma progression phenotypes. Indeed, the miRNA-mediated enhancement 
effects on cell invasion, endothelial recruitment, and metastatic colonization were inhibited 
upon concurrent overexpression of ApoE or DNAJA4 (Figure 3.9). Our findings implicate 
ApoE and DNAJA4 as direct downstream effectors of miRNA-dependent metastatic 
invasion, colonization, and endothelial recruitment phenotypes in melanoma.  
 















Figure 3.9. miR-199a/miR-1908-Mediated Effects on Melanoma Progression 
Phenotypes are Occluded by Concurrent Overexpression of ApoE or DNAJA4. 
a-b. Matrigel invasion and endothelial recruitment by parental MeWo cells ectopically 
expressing the protein-coding regions of ApoE or DNAJA4 in the setting of miR-1908 (a) or 
miR-199a (b) overexpression. n ≥ 7. c.  Bioluminescence imaging plot of lung metastasis by 
4 × 104 parental MeWo cells overexpressing ApoE or DNAJA4 or expressing a control 
vector in the setting of miR-1908 overexpression. n ≥ 4. All data are plotted as mean ± SEM.  
*p < 0.05, **p < 0.01, ***p < 0.001. p-values based on unpaired student’s t-tests (a-b) and 
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Mechanisms of Action by DNAJA4 in Melanoma 
DNAJA4 Positively Regulates ApoE Expression 
We next sought to determine the downstream mechanisms by which ApoE and 
DNAJA4 elicit metastasis suppression. First, we examined how DNAJA4, a poorly 
characterized heat-shock protein, suppresses melanoma progression phenotypes. Given that 
DNAJA4 was found to regulate cell-extrinsic endothelial recruitment—a phenotype poised to 
be mediated by an extracellular factor—we reasoned that the suppressive effects of 
melanoma cell-expressed DNAJA4 on endothelial migration might arise through the 
regulation of a downstream molecule secreted by melanoma cells. In light of the known role 
of ApoE as a secreted factor and our findings that ApoE and DNAJA4 mediate the same set 
of in vitro and in vivo melanoma progression phenotypes, we hypothesized that DNAJA4 
might positively regulate ApoE expression. Consistent with this, I found that depletion of 
DNAJA4 in melanoma cells led to a reduction in ApoE transcript levels (Figure 3.10a) and 
also decreased extracellular ApoE protein levels detected in melanoma cell-conditioned 
media (Figure 3.10b). Additionally, DNAJA4 knockdown in the setting of miRNA inhibition 
also inhibited the miRNA-dependent induction in ApoE levels (Figure 3.10c).  Conversely, 
overexpression of DNAJA4 robustly upregulated ApoE expression (Figure 3.10d). 
Collectively, these findings provide strong evidence for DNAJA4 acting as a positive 












Figure 3.10. Regulation of ApoE Expression by DNAJA4. a-c. Effect of shRNA-mediated 
DNAJA4 depletion in MeWo cells on ApoE transcript levels (a, c) and ApoE extracellular 
protein levels (b). n = 3. d. ApoE transcript levels, determined by qRT-PCR, in response to 
DNAJA4 overexpression in MeWo-LM2 cells. n = 3. All data are plotted as mean ± SEM. *p 
< 0.05, **p < 0.01, ***p < 0.001. p-values based on unpaired student’s t-tests. 
 
I next examined whether DNAJA4’s phenotypic effects on melanoma invasion and 
endothelia recruitment are mediated through ApoE. Consistent with our previous findings, 
shRNA-based depletion of DNAJA4 elevated the invasive capacity of melanoma cells and 
also increased their ability to recruit endothelial cells (Figures 3.11a-b). We hypothesized 
that if these effects are mediated through a respective decrease in ApoE expression, then 
addition of recombinant ApoE protein should prevent the increase in each respective 
phenotype elicited by DNAJA4 knockdown. Indeed, addition of ApoE to the cell media 
decreased both cell invasion and endothelial recruitment in the setting of DNAJA4 
knockdown (Figure 3.11a-b). Conversely, blocking ApoE with a neutralization antibody 
antagonized the suppression of the two phenotypes seen upon DNAJA4 overexpression in the 
highly metastatic MeWo-LM2 cells (Figures 3.11c-d). These findings suggest that the effects 
of DNAJA4 on melanoma progression phenotypes might at least in part be mediated through 
the downstream induction of ApoE expression.  








Figure 3.11. DNAJA4-Mediated Metastatic Phenotypes are Dependent on ApoE. 
 a-d. Matrigel invasion and endothelial recruitment by MeWo parental cells depleted of 
DNAJA4 and treated with recombinant ApoE or BSA (a-b) and MeWo-LM2 cells 
overexpressing DNAJA4 and treated with an ApoE neutralization antibody or a control IgG 
antibody (c-d). n = 4. All data are plotted as mean ± SEM. *p < 0.05, **p < 0.01,  
***p < 0.001. p-values based on unpaired student’s t-tests. 
 
Identification of Putative DNAJA4 Binding Partners in Melanoma Cells 
Presently, there are three annotated isoforms for the human DNAJA4 gene 
(DNAJA4.1, DNAJA4.2, and DNAJA4.3). While the majority of the DNAJA4 protein-coding 
region is conserved among the three isoforms, DNAJA4.1 and DNAJA4.3 exhibit distinct N-
terminal regions of 29 and 17 amino acids in length, respectively, that are absent in 
DNAJA4.2 (Figure 3.12a). Interestingly, these isoform-specific structural differences mirror 
the differential regulation of DNAJA4.2 versus DNAJA4.1/DNAJA4.3 transcript levels in 
highly metastatic melanoma cells. Whereas the expression levels of DNAJA4.2 remain 
relatively unchanged, the levels of DNAJA4.1 and DNAJA4.3 are more than 25-fold 
downregulated in the MeWo-LM2 metastatic derivatives relative to their parental cells 
(Figure 3.12b). Additionally, I further found that the three DNAJA4 isoforms display 
phenotypic differences in their ability to regulate matrigel invasion by melanoma cells in 
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vitro. Suppression of melanoma cell invasion was observed only in response to DNAJA4.3 
overexpression, while DNAJA4.1 or DNAJA4.2 overexpression had no appreciable effects 
on the ability of melanoma cells to invade through matrigel. These findings suggest that, in 
addition to differential mRNA expression regulation of the three DNAJA4 isoforms in highly 
metastatic melanoma cells, the suppression of melanoma progression phenotypes by 
DNAJA4 may also be isoform-specific, with DNAJA4.3 being the predominant isoform 



















Figure 3.12. Isoform-Specific Regulation of DNAJA4 Expression in Metastatic 
Melanoma Cells and Suppression of Melanoma Invasion by DNAJA4.3. a. Schematic 
representing the CDS structural differences between the three known isoforms of the 
DNAJA4 human gene. b. Expression levels of DNAJA4.1, DNAJA4.2, and DNAJA4.3, 
determined by qRT-PCR and using DNAJA4 isoform-specific primer pairs, in MeWo-LM2 
metastatic derivatives and their parental MeWo cells. n = 3. c. Matrigel invasion by MeWo 
parental cells overexpressing the C-terminally flag-tagged coding regions of each DNAJA4.1, 
DNAJA4.2, or DNAJA4.3 or the untagged CDS of DNAJA4.3. n ≥ 3. Data are depicted as 
mean ± SEM. *p < 0.05, ***p < 0.001. p-values based on unpaired student’s t-tests. 
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We hypothesized that the isoform-specific function of DNAJA4.3 in suppressing 
melanoma invasion might be due to its distinct N-terminus tail, which might allow for its 
unique interactions with proteins that regulate melanoma cell invasion.   To determine 
putative proteins specifically bound by DNAJA4.3, but not bound by a DNAJA4 isoform that 
lacks activity in suppressing cell invasion, I retrovirally expressed C-terminally flagged 
protein-coding regions encoding full-length DNAJA4.2 or DNAJA4.3 in MeWo parental and 
MeWo-LM2 melanoma cells. Subsequent flag immunoprecipitation followed by mass 
spectrometry analyses revealed a large number of common candidate proteins bound by both 
DNAJA4.2 and DNAJA4.3, as expected from the > 90% homology between the two 
DNAJA4 isoforms. Interestingly, five proteins (PFKFB3, HNRNPF, PSMD11, FLG, and 
TPM4) were only detected in the DNAJA4.3-Flag immunoprecipitation product, suggesting 
that they might represent interacting partners specific to DNAJA4.3 (Figure 3.13). 
Further work is needed to i.) validate the DNAJA4.3-specific interactions with each 
PFKFB3, HNRNPF, PSMD11, FLG, or TPM4, ii.) identify the domain(s) of DNAJA4.3 
responsible for these interactions, and iii.) examine whether any of these candidate proteins 
mediate the DNAJA4-dependent effects on melanoma metastatic phenotypes. Whereas our 
findings implicate some ApoE dependency of the DNAJA4 effects on melanoma invasion 
and endothelial recruitment, the incomplete rescue of the DNAJA4-dependent invasion 
phenotype upon ApoE modulation (Figures 3.11a, c) suggests the existence of additional 
downstream DNAJA4 mediators independent of ApoE. The functional implications of the 
interactions of DNAJA4.3 with each of its unique partners for the ApoE-dependent and 
ApoE-independent effects of DNAJA4 on melanoma suppression will be an interesting 
question for future work to explore. 

















Figure 3.13. Identification of Putative Binding Partners for DNAJA4.2 and DNAJA4.3 
in Melanoma Cells. Flag immunoprecipitation (IP) in protein lysates collected from MeWo-
parental or MeWo-LM2 cells overexpressing C-terminally flag-tagged DNAJA4.2 or 
DNAJA4.3 or an empty control vector. The IP product was separated by SDS-PAGE and 
protein bands of interest (stained in blue) were submitted for mass-spectrometry (MS) 
analyses. Protein identities shown on the right were ranked based on the number of unique 
peptides detected by MS for each protein hit. Only proteins for which three or more unique 
peptides were detected are listed. Candidate interacting protein bound by DNAJA4.3, but not 
DNAJA4.2, are highlighted in red. 
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Clinical Association of ApoE and DNAJA4 Expression with Melanoma Progression  
In light of the robust metastasis-suppressive roles of ApoE and DNAJA4, we next 
examined whether the expression levels of these two proteins correlate with human 
melanoma progression. While DNAJA4 was not a part of a previously published array-based 
clinical melanoma gene expression dataset (Haqq et al., 2005), we found that the transcript 
levels of ApoE were significantly lower in distal organ metastases relative to primary 
melanoma and nevi lesions (Figure 3.14a). To further validate the clinical correlation of 
ApoE expression with melanoma progression in a larger and independent patients’ cohort as 
well as to extend these findings to DNAJA4, we obtained a human melanoma tissue-
microarray (TMA) progression panel from the National Institute of Health (NIH). With the 
help of Colin Buss, we assessed the protein expression of each ApoE and DNAJA4 across 
the TMA progression set by performing blinded immunohistochemical analyses using a 
previously validated commercial antibody against ApoE as well as a custom-made antibody 
that we validated to be specific for isoform 3 of DNAJA4. We found that the protein levels of 
both ApoE and DNAJA4 were significantly reduced in nodal and distal melanoma metastases 
relative to primary melanoma skin lesions (Figures 3.14b-c).  
Even though the clinical correlation between reduced ApoE and DNAJA4 expression 
and melanoma progression is consistent with the metastasis-suppressive function exerted by 
these two proteins, this observation does not address whether ApoE or DNAJA4 at the early 
stages of melanoma progression could be used as prognostic biomarkers in the clinic to 
predict which patients will develop metastatic relapse and which ones will remain melanoma-
free. Additionally, in light of the significant prognostic capacity displayed by the combined 
expression of miR-199a-3p, miR-199a-5p, and miR-1908, we hypothesized that their  



















Figure 3.14. Clinical Correlation of ApoE and DNAJA4 Expression with Melanoma 
Progression Outcomes. a. ApoE transcript levels in nevi, primary melanomas, and distal 
metastases from a previously published array-based melanoma gene expression dataset 
(Haqq et al., 2005). b-c. Box and whisker plots of ApoE (b) and DNAJA4 (c) protein 
expression, assessed by double-blinded immunohistochemical analyses, in the NIH 
melanoma TMA progression sets. Data shown in (a) are represented as mean ± SEM.  
In (b) and (c): whiskers = 5th-95th population percentile, box extent = 25th-75th percentile. 
Scale bar, 100 μm. p-values based on unpaired student’s t-tests. 
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convergent targets, ApoE and DNAJA4, should also exhibit prognostic capacity in metastatic 
melanoma. To this end, we performed immunohistochemical analyses to assess the protein 
expression levels of ApoE and DNAJA4 in 71 primary melanoma skin lesions obtained from 
patients at the MSKCC. We found that primary melanoma tumors with a propensity to 
metastasize exhibited lower levels on average of each ApoE and DNAJA4 relative to primary 
melanomas that did not metastasize (Figures 3.15a-b). Importantly, retrospective analyses of 
the relationship between the expression levels of each ApoE or DNAJA4 and documented 
history of patients’ clinical melanoma outcomes revealed both ApoE and DNAJA4, as single 
molecular markers, to exhibit significant prognostic power in stratifying patients at high 
versus low risk of metastatic relapse in that cohort (Figures 3.15c-d). 
Finally, we wondered whether the combined expression of ApoE and DNAJA4 might 
exert additive prognostic effects compared to the expression of each protein alone. Indeed, 
more than 90% of MSKCC melanoma patients, whose tumors exhibited high levels of both 
ApoE and DNAJA4, remained melanoma-free at 10 years after diagnosis compared to less 
than 20% of the patients, whose tumors had low levels of both ApoE and DNAJA4 (Figure 
3.16a). Importantly, the prognostic stratification attained by the combined ApoE and 
DNAJA4 expression signature exceeded that seen with individual ApoE or DNAJA4 
expression (Figure 3.15a). Remarkably, adding the three miRNAs’ aggregate expression to 
the combined expression of ApoE and DNAJA4 further improved the signature’s prognostic 
power. Namely, the full fraction (100%) of patients in this cohort, whose tumors exhibited 
high levels of ApoE and DNAJA4 and low miR-199a-3p/miR-199a-5p/miR-1908 expression, 
remained melanoma-free at 10 years in comparison to only 13% of patients bearing tumors 
with low ApoE/DNAJA4 expression and high levels of the three miRNAs (Figure 3.16b). 
















Figure 3.15. Prognostic Capacity of ApoE and DNAJA4 Expression in Metastatic 
Melanoma. a-b. Protein expression levels, determined by blinded immunohistochemical 
analyses, for ApoE (a) and DNAJA4 (b) in non-metastatic (n = 39) and metastatic (n = 34) 
primary melanoma skin lesions resected from patients at the MSKCC. c-d. Kaplan-Meier 
curves for the MSKCC cohort depicting metastasis-free survival of patients as a function of 
ApoE (c) or DNAJA4 (d) protein expression in patients’ primary melanoma tumors. Tumors 
for which ApoE or DNAJA4 expression was above or below the population’s median were 
classified as positive or negative for ApoE or DNAJA4, respectively. Scale bar, 100 μm. For 
(a) and (b), data are depicted as mean ± SEM. p-values based on unpaired student’s t-tests 
(a-b) or Mantel-Cox (log-rank) tests (c-d). 
 



















Figure 3.16. Prognostic Capacity of Combined ApoE/DNAJA4 and Combined 
ApoE/DNAJA4/3 miRNAs Expression Signatures in Melanoma. a-b. Kaplan-Meier 
curves depicting patients’ metastasis-free survival times as a function of the combined 
expression of ApoE and DNAJA4 (a) or ApoE, DNAJA4, and the three miRNAs (miR-199a-
3p, miR-199a-5p, and miR-1908) (b) in their primary melanoma lesions. Tumors were 
classified as negative or positive in expression relative to the median expression levels of the 
population for each marker. p-values were determined using Mantel-Cox tests. 
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Our findings are consistent with clinical relevance to human melanoma progression 
and functional robustness of the miR-199a-3p/miR-199a-5p/miR-1908 convergent multi-
miRNA regulatory network. Interestingly, the inferior prognostic capacity of ApoE alone 
compared to that of the combined ApoE and DNAJA4 tumor expression signature suggests 
that DNAJA4 likely mediates additional downstream targets independent of ApoE that could 
account for the additive prognostic effects seen. If the full effect of DNAJA4 on melanoma 
suppression was mediated solely through the induction of ApoE, then one would not expect 
improved prognostic capacity upon combining ApoE and DNAJA4 expression relative to 
ApoE expression alone. While the potential use of these molecules as novel prognostic 
factors in metastatic melanoma is exciting in light of the present lack of reliable molecular 
biomarkers in the clinic for informing one’s likelihood of melanoma metastatic relapse, 
further studies are needed to validate the prognostic capacity of each ApoE, DNAJA4, miR-
199a-3p, miR-199a-5p, and miR-1908 as well as their combined expression signatures across 
multiple independent melanoma patient cohorts that would together constitute a larger total 
sample size. 
 
Summary of Findings from Chapter III 
In this chapter, I describe the whole-genome transcriptomic-based approach that we 
used in order to identify transcripts inhibited by each miR-199a-3p, miR-199a-5p, and miR-
1908. We found two genes (ApoE and DNAJA4) that were convergently repressed by the 
three miRNAs. By performing heterologous reporter assays coupled with mutagenesis 
studies, I demonstrated that ApoE was directly targeted by miR-199a-5p and miR-1908, and 
DNAJA4 was directly repressed by all three miR-199a-3p, miR-199a-5p, and miR-1908. In a 
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series of epistasis experiments, we then showed that the miRNA-based silencing of ApoE and 
DNAJA4 was necessary for the miRNA-dependent effects on melanoma invasion, endothelial 
recruitment, and metastasis. These findings reveal ApoE and DNAJA4 as novel suppressors 
of melanoma metastasis. Interestingly, I also found that DNAJA4 suppressed melanoma 
progression phenotypes through the positive regulation of ApoE. Out of the three DNAJA4 
isoforms expressed by melanoma cells, I found that only overexpression of DNAJA4.3 was 
sufficient to inhibit melanoma invasion. To this end, we performed immunoprecipitation 
studies coupled with mass spectrometry analyses, which led to the identification of PFKFB3, 
HNRNPF, PSMD11, FLG, and TPM4 as candidate interacting partners specific for 
DNAJA4.3. In the final section of this chapter, I describe our clinical findings that the 
expression levels of each ApoE and DNAJA4 correlated with melanoma progression stage 
and were also prognostic of patients’ likelihood for metastatic recurrence. Importantly, 
combining ApoE and DNAJA4 expression as well as ApoE, DNAJA4, and the aggregate 
expression of the three miRNAs displayed enhanced prognostic capacity relative to each 
individual signature, suggestive of clinical cooperativity among the miRNAs and their 
effector genes in predicting metastatic melanoma outcomes in patients. 
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CHAPTER IV: CELL-AUTONOMOUS AND NON-CELL-
AUTONOMOUS REGULATION OF MELANOMA PROGRESSION 
PHENOTYPES BY EXTRACELLULAR APOE 
 
Extracellular ApoE Suppresses Melanoma Invasion and Endothelial Recruitment 
Our findings of regulatory convergence of the metastasis-promoting miRNAs, miR-
199a and miR-1908, and the heat-shock factor DNAJA4 onto ApoE implicate ApoE as the 
central molecule in this convergent multi-miRNA regulatory network. The functional role of 
ApoE as a metastasis suppressor was further supported by the significant clinical correlation 
between reduced ApoE expression and melanoma metastasis outcomes (Chapter III). In light 
of ApoE’s role in suppressing metastatic colonization and angiogenesis as revealed by our 
experiments, I next sought to identify the downstream molecular mechanisms mediating 
ApoE’s effects on melanoma metastatic phenotypes. Consistent with the known role of ApoE 
as an extracellular factor, I found that highly metastatic melanoma cells secrete about five 
times less ApoE compared to their less metastatic parental derivatives (Figure 4.1a). 
Importantly, extracellular ApoE protein levels were also repressed by endogenous miR-199a 
and miR-1908 (Figures 4.1b-c).  
Our previous findings revealed that molecular depletion of melanoma-cell ApoE led 
to an increase in melanoma invasion and endothelial recruitment (Figure 3.6). We thus 
wondered whether the ApoE-dependent suppression of these phenotypes could be mediated 
by melanoma-derived extracellular ApoE. We found that neutralization of extracellular ApoE 
protein with a blocking antibody elevated the matrigel invasive capacity of melanoma cells 
and also enhanced in vitro endothelial recruitment by melanoma cells (Figures 4.2 a-b), 
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revealing endogenous melanoma-secreted ApoE as a suppressor of cell-autonomous and non-
cell-autonomous melanoma progression phenotypes. Conversely, adding recombinant ApoE 
to the cell media resulted in the suppression of both matrigel invasion and endothelial 
recruitment phenotypes displayed by the highly metastatic MeWo-LM2 cells (Figures 4.2c).  
I next tested whether the miRNA-dependent effects on melanoma invasion and 
endothelial recruitment are mediated through extracellular ApoE. Given that miRNA 
silencing upregulated melanoma cell-secreted ApoE expression, we hypothesized that the 
effects of miRNA depletion might be antagonized by the blockade of extracellular ApoE. 
Consistent with this, the suppression of both phenotypes seen with silencing of each mature 
miRNA was prevented by an antibody-mediated neutralization of extracellular ApoE. These 
findings reveal melanoma-derived extracellular ApoE as the downstream mediator of 







Figure 4.1. Endogenous miR-199a-5p and miR-1908 Repress Extracellular ApoE 
Levels. a-c. Extracellular ApoE protein levels quantified by ELISA in melanoma cell-
conditioned media from MeWo-parental and MeWo-LM2 cells (a), MeWo-LM2 cells 
silenced for each miR-199a-5p, miR-1908, or control (b), and parental MeWo cells 
overexpressing miR-199a, miR-1908, or control (c). n = 3. Data are depicted as mean ± 
SEM. *p < 0.05, **p < 0.01, ***p < 0.001. p-values based on unpaired student’s t-tests. 
 














Figure 4.2. Extracellular ApoE Suppresses Melanoma Invasion and Endothelial 
Recruitment a. Matrigel invasion by parental human melanoma MeWo cells that were 
incubated with a control IgG antibody or increasing doses of an ApoE neutralization 
antibody (1D7). n ≥ 4. b. Endothelial recruitment capacity by MeWo parental cells in 
response to a control IgG or an ApoE blocking antibody (1D7) treatment at 40 μg/mL. n = 4. 
c. Matrigel invasion and endothelial recruitment phenotypes displayed by highly metastatic 
MeWo-LM2 cells in response to addition of bovine serum albumin (BSA) or recombinant 
ApoE protein to the cell media. n ≥ 7. d-e.  MeWo-LM2 metastatic derivatives with silenced 
expression of each miR-199a-3p, miR-199a-5p, or miR-1908 were subjected to matrigel 
invasion (d) and endothelial recruitment (e) assays in the presence of IgG or ApoE blocking 
(1D7) antibodies. n ≥ 5. Scale bar, 100 μm. All data are plotted as mean ± SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001. p-values based on unpaired student’s t-tests. 
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Enhancement of Extracellular ApoE Levels Robustly Suppresses Melanoma Metastasis 
Our findings that the miRNA-dependent effects on the matrigel invasion and 
endothelial recruitment in vitro phenotypes are in large part mediated through extracellular 
ApoE motivated us to examine whether the modulation of extracellular ApoE levels also 
regulates in vivo metastatic colonization by melanoma cells. We thus tested whether pre-
incubation of melanoma cells with recombinant ApoE or bovine serum albumin (BSA) 
affects their subsequent lung colonization capacity. Remarkably, ApoE pre-treatment 
robustly suppressed (>300-fold) metastatic colonization by the highly metastatic MeWo-
LM2 line, as well as the independent A375-LM3 (145-fold), WM-266-4 (80-fold), HT-144 
(119-fold), and A2058 (85-fold) human melanoma lines (Figures 4.3a-e). This dramatic 
suppression of metastasis by ApoE pre-incubation of multiple human melanoma cell lines 
indicates that the melanoma cell-autonomous effects of ApoE are essential for metastatic 
initiation. Treatment of melanoma cells with ApoE did not appreciably affect the 
proliferation/survival of melanoma cells in vitro up to five days after treatment (Figure 4.3f), 
implying that the suppression of melanoma metastatic colonization in response to the ApoE 
protein treatment is likely not due to impaired cell proliferation and/or survival disadvantage, 
but it rather emerges through the inhibition of melanoma cell invasion and endothelial 
recruitment—phenotypes that can be rate-limiting for metastatic initiation. The strong 
inhibition of metastasis observed upon ApoE pre-treatment suggests that therapeutic 
approaches aimed at enhancing extracellular ApoE levels and ApoE signaling in melanoma 
cells might be therapeutically effective in preventing melanoma metastasis (see Chapter V). 
 
 






















Figure 4.3. ApoE Pre-Treatment Suppresses Metastatic Colonization by Melanoma 
Cells. a-e. Bioluminescence signal quantification plots corresponding to lung colonization by 
4 × 104 MeWo-LM2 (a), 2 × 105 A375-LM3 (b), 1.5 × 105 WM-266-4 (c), 3.5  × 105 HT-144 
(d), and 2 × 105 A2058 (e) human melanoma cells that were pre-treated with BSA or ApoE at 
100 μg/mL for 24 hours prior to intravenous injection into immunocompromised mice. n ≥ 5. 
f. In vitro cell proliferation by 3.5 × 104 MeWo-LM2 cells in response to BSA or ApoE 
treatment at 100 μg/mL. Live cells were counted on days 0, 1, 3, and 5. n = 3. All data are 
displayed as mean ± SEM. **p < 0.01, ***p < 0.001. p-values based Mann-Whitney’s t-tests. 
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In light of our findings that elevating extracellular ApoE levels in vitro (by adding 
ApoE protein to the cell media) subsequently impairs melanoma cells’ ability to metastasize, 
we wondered whether we could model the reverse scenario in vivo by removing stromally-
derived extracellular ApoE. To this end, we investigated the impact of genetic deletion of 
stromal ApoE on melanoma progression in an immunocompetent mouse model of melanoma 
metastasis. Consistent with a major suppressive role for extracellular ApoE in metastasis, 
B16F10 mouse melanoma cells injected into the circulation of syngeneic immunocompetent 
mice exhibited a 10-fold increase in metastatic colonization in mice genetically inactivated 
for ApoE compared to wild-type mice. Importantly, the metastatic capacity of B16F10 cells 
was dramatically abrogated by ApoE cell pre-treatment in both wild-type (60-fold inhibition) 









Figure 4.4. Genetic Inactivation of ApoE Accelerates Melanoma Lung Colonization. 
Lung colonization quantified by bioluminescence imaging 19 days following intravenous 
injection of 5 × 104 mouse melanoma cells into wild-type or ApoE genetically null mice. The 
cells were pre-incubated with ApoE at 100 μg/mL or control for 24 hours and subsequently 
injected via the tail-vein into C57BL/6 mice. Representative ex vivo lung images taken at day 
19 post-injection are shown on the right. n ≥ 12 (control); n ≥ 5 (ApoE pre-treatment). All 
data are displayed as mean ± SEM. ***p < 0.001, based on Mann-Whitley’s t-tests. 
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The metastasis suppression elicited by exogenously supplied ApoE (Figure 4.3) as 
well as the increase in metastatic colonization upon removal of endogenous stromal ApoE 
(Figure 4.4) reveal melanoma cell-extrinsic extracellular ApoE as a robust suppressor of 
melanoma progression. In addition, our molecular findings of convergent miRNA targeting 
of ApoE in melanoma cells (Chapter III) implicate melanoma cell-intrinsic ApoE as a 
downstream effector of the miRNA-dependent effects on melanoma progression phenotypes. 
Taken together, these findings implicate extracellular ApoE, derived either from melanoma 
cells or supplied from stromal tissues, as a key suppressor of melanoma metastasis. The 
relative contribution of melanoma versus stromally derived ApoE is discussed in Chapter V. 
 
ApoE Targeting of Melanoma LRP1 Receptors Suppresses Melanoma Cell Invasion 
We next examined the molecular mechanisms through which extracellular ApoE 
inhibits melanoma progression phenotypes. First, I investigated the downstream molecular 
mediators of ApoE’s effects on melanoma cell invasion. Given that there are only four 
known receptors for ApoE (VLDLR, LRP1, LRP8, and LDLR), I used RNA interference 
(RNAi) to individually silence the expression of each receptor in melanoma cells by 50% or 
more, as confirmed by mRNA transcript level analyses. I then examined what happens to the 
ApoE-induced suppression of invasion upon knocking down each receptor. Interestingly, 
melanoma cell depletion of LRP1, but not any of the other ApoE receptors, specifically 
prevented the ability of ApoE to inhibit matrigel invasion (Figure 4.5a). Additionally, LRP1 
knockdown in the setting of miRNA silencing rescued the reduced invasive capacity 
resulting from miRNA inhibition (which leads to de-repression of ApoE) and also modestly 
elevated the baseline invasion phenotype displayed by control MeWo-LM2 melanoma cells 
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(Figure 4.5b-d). Importantly, LRP1 depletion in the setting of miRNA silencing also 
enhanced in vivo lung colonization (Figure 4.6). These in vitro and in vivo findings together 
implicate melanoma-cell LRP1 as the downstream mediator of the miRNA/ApoE-dependent 














Figure 4.5. Identification of LRP1 as the ApoE Receptor on Melanoma Cells Mediating 
ApoE’s Effects on Invasion Suppression. a. Trans-well matrigel invasion by MeWo-LM2 
cells transfected with short interfering RNAs (siRNAs) targeting LDLR, VLDLR, LRP8, 
LRP1, or a control sequence. At the start of they assay, the cells were treated with BSA or 
ApoE. n  ≥ 3. b-c. MeWo-LM2 cells, with silenced expression of miR-1908 (b) or miR-199a 
-5p (c), were transfected with siRNAs targeting LRP1 or a control siRNAs and assessed for 
their matrigel invasion capacity. n = 4. d. Matrigel invasion by MeWo-LM2 cells expressing 
a control siRNA or siRNAs targeting LRP1. n ≥ 9. Scale bar, 100 μm. All data are plotted as 
mean ± SEM. *p<0.05, **p <0.01, ***p<0.001. p-values based on unpaired student’s t-test. 







Figure 4.6. Melanoma-Cell LRP1 Mediates miRNA-Dependent Metastatic Colonization. 
Lung metastasis, quantified by weekly bioluminescence imaging, by 1 × 105 MeWo-LM2 
cells with silenced expression of miR-1908 and transfected with siRNAs targeting LRP1 or a 
control. Representative H&E-stained lungs extracted at the final day 56 of imaging are 
shown of the right. n ≥ 4. Weekly bioluminescence data are shown as mean ± SEM.  
*p < 0.05. p-values based on Mann-Whitney’s t-tests. 
 
ApoE Targeting of Endothelial LRP8 Receptors Suppresses Endothelial Cell Migration 
The regulation of melanoma cell invasion by the miRNA/ApoE/LRP1 pathway 
reflects the cell-autonomous effects of melanoma-derived ApoE. The endothelial recruitment 
phenotype, on the other hand, is suggestive of non-cell autonomous effects of melanoma-
expressed and secreted ApoE on endothelial cell migration. Consistent with direct effects of 
ApoE on endothelial cells, pre-treatment of endothelial cells with ApoE diminished their 
subsequent ability to migrate towards melanoma cells (Figure 4.7a). To identify the ApoE 
receptor(s) on endothelial cells that mediate(s) ApoE’s effects on endothelial migration, I 
individually depleted each of the four ApoE receptors in endothelial cells using RNAi and 
confirmed silencing of each receptor by 50% or greater at the mRNA level.  I then tested the 
ability of endothelial cells to migrate towards melanoma cells with silenced miRNA 
expression, which results in endogenously elevated extracellular ApoE levels (Figure 4.1) 
and inhibition of endothelial recruitment (Figure 4.2). Contrary to our identification of LRP1 
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as the melanoma cell receptor mediating suppression of invasion by ApoE, we observed that, 
in endothelial cells, knockdown of a different receptor, LRP8, specifically blocked the 
inhibition in endothelial recruitment attained by miRNA silencing (Figure 4.7b-d).  These 
findings reveal LRP8 as the downstream endothelial cell mediator of the miRNA/ApoE-















Figure 4.7. Endothelial-Cell LRP8 Mediates miRNA/ApoE-Dependent Endothelial 
Recruitment. a. Endothelial recruitment by MeWo-LM2 cells following endothelial cell pre-
treatment with BSA or ApoE. n ≥ 3. b-d. Recruitment of endothelial cells (HUVEC) 
transfected with siRNAs targeting LDLR, VLDLR, LRP1, LRP8, or a control by MeWo-LM2 
cells with a silenced expression of miR-1908 (b), miR-199a-5p (d), or control MeWo-LM2 
cells (c). n ≥ 4. e. Relative expression levels of LRP1 and LRP8, determined by qRT-PCR, in 
endothelial cells (HUVECs) and MeWo human melanoma cells. n = 3. Scale bar, 100 μm. 
Error bars =cSEM. *p < 0.05, **p < 0.01, ***p < 0.001. p-values based on student’s t-tests. 
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We found that endothelial cells expressed 50-fold higher levels of LRP8 relative to 
LRP1 (Figure 4.7e), hinting that the greater abundance of endothelial LRP8 receptors may 
determine preferential ApoE/LRP8 targeting in endothelial cells. Human melanoma MeWo 
cells, on the other hand, exhibited higher levels of both LRP1 and LRP8 relative to endothelal 
cells, with melanoma cell LRP8 levels being 5-fold higher than melanoma cell LRP1 levels. 
These expression data suggest that i) the higher LRP1 levels in melanoma cells compared to 
endothelial cells could explain why ApoE/LRP1 targeting is more relevant in the melanoma 
cell type and ii) the choice of melanoma LRP1 receptors as the functional mediator of ApoE-
dependent invasion suppression is not solely determined by greater relative abundance of this 
receptor. 
I next examined whether targeting of LRP8 by ApoE might regulate general 
endothelial cell migration in a cancer cell-free system. Antibody neutralization of 
extracellular ApoE, which is present in the endothelial cell media, significantly elevated 
endothelial cell migration (Figure 4.8a). Conversely, addition of recombinant ApoE 
suppressed endothelial cell migration both in trans-well assays (Figure 4.8b) as well as in 
gradient-based migration assays (Figure 4.8c). Importantly, the ApoE-mediated suppression 
of endothelial migration was abolished in response to depletion of LRP8 in endothelial cells 
(Figures 4.8b-c).  
In light of the robust in vitro effects, we investigated whether ApoE could affect 
endothelial migration in vivo. In experiments performed by Colin Buss, we found that 
addition of ApoE blocked (> 40-fold) VEGF-induced in vivo endothelial recruitment into 
subcutaneously implanted matrigel plugs (Figure 4.9a), suggesting that ApoE acts as a strong 
repellant that can override the chemotactic positive VEGF signal.  Consistent with the robust 
	   96 
suppression of endothelial migration elicited by ApoE, we further found that mice that had 
been genetically inactivated for ApoE exhibited a significant increase in blood vessel density 
within metastatic nodules formed by B16F10 mouse melanoma cells (Figure 4.9b). These 
genetic findings implicate stromally supplied ApoE, in addition to melanoma-derived ApoE 














Figure 4.8. ApoE/LRP8 Targeting Suppresses Endothelial Cell Migration in a Cancer 
Cell-Free System. a. Trans-well endothelial cell migration in the presence of IgG or an 
ApoE neutralization antibody (1D7). n ≥ 6. b. Endothelial cells transfected with a control 
siRNAs or siRNAs targeting LRP8 were subjected to a trans-well migration assay in 
response to BSA or ApoE treatment. n ≥ 6. c. Trans-well migration along an ApoE matrigel 
gradient by endothelial cells transfected with a control siRNA or siRNAs targeting LRP8. n ≥ 
4. Scale bar, 100 μm. All data are represented as mean ± SEM. *p < 0.05, **p < 0.01,  
***p < 0.001. p-values based on unpaired student’s t-tests. 
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Figure 4.9. ApoE Inhibits In Vivo Endothelial Cell Recruitment and Angiogenesis.  
a. Endothelial cell recruitment into subcutaneously implanted matrigel plugs containing BSA 
(10 μg/mL), VEGF (400 ng/mL) + BSA (10 μg/mL), or VEGF (400 ng/mL) + ApoE (10 
μg/mL). Endothelial cells were immunohistochemically detected by staining for MECA-32, 
and the number of endothelial cells migrating into each plug was quantified 3 days post-
implantation. n ≥ 3. b. Endothelial cell density within lung metastatic nodules formed by 5 × 
104 B16F10 mouse melanoma cells 19 days post-intravenous cell injection into ApoE wild-
type or ApoE genetically null mice. n ≥ 17. Scale bar, 100 μm. All data are represented as 
mean ± SEM. **p < 0.01, ***p < 0.001. p-values based on unpaired student’s t-tests. 
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ApoE/LRP8-Dependent Regulation of Endothelial VEGFR2 Activity 
The identification of LRP8 as the endothelial cell mediator of extracellular ApoE’s 
effects on angiogenesis raised the question of how LRP8 targeting regulated endothelial cell 
migration.  Recently, an independent group reported that a synthetic dimer-peptide 
comprised of the ApoE receptor-binding domain inhibited phosphorylation of VEGFR2 
(Bhattacharjee et al., 2011), a receptor essential for multiple aspects of endothelial biology 
including migration and angiogenesis (Olsson et al., 2006; Carmeliet and Jain, 2011).  In 
light of this, I hypothesized that full-length ApoE might modulate VEGFR2 activation in an 
LRP8-dependent manner. Indeed, I found that addition of recombinant ApoE inhibited the 
VEGF-induced phosphorylation of endothelial cell VEGFR2, whereas siRNA-mediated 
depletion of LRP8 rendered ApoE ineffective in blunting VEGFR2 activation (Figure 4.10a).   
These findings prompted us to further examine the role of ApoE/LRP8 signaling as a 
novel regulator of VEGFR2 activity using a previously described genetic mouse model of 
LRP8 inactivation (Trommsdorff et al., 1999). In experiments conducted together with 
Jessica Posada, a medical student doing a one-year research project in the lab, we isolated 
primary endothelial cells from the lungs of wild-type, LRP8 heterozygous, or LRP8 null 
mice. Consistent with our findings in human endothelial cells (Figure 4.10a), ApoE addition 
decreased the VEGF-induced phosphorylation of VEGFR2 in primary mouse lung 
endothelial cells expressing one or both copies of LRP8 (Figure 4.10b-c). Importantly, 
deletion of LRP8 prevented the inhibitory effect of ApoE on VEGFR2 phosphorylation 
(Figure 4.10c), providing genetic evidence that LRP8 is the endothelial receptor mediating 
ApoE’s effects on VEGFR2 activation.  Interestingly, endothelial cells lacking one copy of 
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LRP8 exhibited elevated VEGFR2 activation in response to VEGF, suggesting that partial 
reduction in the levels of LRP8 might enhance ligand-mediated VEGFR2 phosphorylation. 
Consistent with ApoE’s suppressive effects on VEGFR2 activation, we further found 
that phosphorylated VEGFR2 levels were elevated in primary tumors formed by melanoma 
cells over-expressing the metastasis-promoting miR-1908 and miR-199a, each of which 
directly represses ApoE expression (Figure 4.8d). Given that the majority of VEGFR2 
expression is restricted to endothelial cells, these findings imply that melanoma-expressed 
miR-199a and miR-1908 positively regulate endothelial VEGFR2 activation in vivo, 
presumably through their downstream targeting of the ApoE/LRP8 pathway in endothelial 
cells. Future studies will investigate whether the non-cell-autonomous endothelial 
recruitment phenotype conferred by miR-199a and miR-1908 is functionally mediated 
through indirect ApoE-dependent modulation of endothelial VEGFR2 signaling by the 
miRNAs.  
Ongoing work in the lab is currently examining the role of LRP8 in VEGFR2-
dependent angiogenesis in the context of genetic inactivation of LRP8. Consistent with the 
enhanced ligand-induced VEGFR2 phosphorylation in endothelial cells lacking one copy of 
LRP8 (Figure 4.10c), preliminary experiments conducted by Jessica Posada have shown that 
LRP8 -/+ heterozygous mice exhibit a roughly 2-fold enhancement in tumor growth and a 
corresponding increase in tumor angiogenesis relative to wild-type mice (data not shown). 
Additionally, in aortic ring assays, LRP8 +/- aortas display an enhanced capacity to form 
VEGF-induced endothelial cell sprouts relative to wild-type aortas (data not shown), 
implying that the LRP8-mediated effects on VEGFR2 activation might also be relevant to 
physiological angiogenesis. 
















Figure 4.10. ApoE Inhibits VEGFR2 Activation in an LRP8-Dependent Manner.  
a. Western blotting for phosphorylated and total VEGFR2 in human umbilical vein 
endothelial cells (HUVEC) transfected with a control siRNA or an siRNA targeting LRP8 
and treated with BSA, VEGF, or VEGF + ApoE. b. Western blotting for LRP8 in endothelial 
cell lysates from LRP8 wild-type (+/+), heterozygous (+/-), or null (-/-) mice. c. Western 
blotting for phosphorylated and total VEGFR2 in primary mouse lung endothelial cells 
isolated from LRP8 +/+, LRP8 -/+, and LRP8 -/- mice and treated with either BSA, VEGF, or 
VEGF + ApoE. d. Phosphorylated and total VEGFR2 levels were assessed in total lysates 
from subcutaneous tumors formed by MeWo human melanoma cells overexpressing each 
miR-199a or miR-1908. VEGFR2 activation was quantified as the ratio of phosphorylated 
over total VEGFR2 expression. n = 3. Error bars = SEM. *p<0.05, based on student’s t-tests. 
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Interestingly, however, our preliminary analyses have revealed that the LRP8 -/- null mutants 
do not display any appreciable change in ligand-induced VEGFR2 phosphorylation (Figure 
4.10c) and do not exhibit any apparent angiogenic or tumor growth aberration compared to 
their wild-type littermates (data not shown), suggesting that the pro-angiogenic effects are 
restricted to partial loss of LRP8 expression in the heterozygous genetic context.  Future 
work will examine the molecular and cellular mechanism(s) by which ApoE/LRP8 targeting 
regulates VEGFR2 activation, which should facilitate our molecular understanding of the 
non-linear relationship between LRP8 expression and VEGFR2-dependent angiogenesis. 
 
Summary of Findings from Chapter IV 
In this chapter, I present our findings that extracellular ApoE, which can be derived 
either from melanoma cells or supplied stromally, acts as a robust suppressor of melanoma 
metastasis. This is supported by our observations that i.) neutralization of extracellular 
melanoma cell-secreted ApoE with an antibody prevented the suppression of invasion and 
endothelial recruitment phenotypes upon miRNA silencing, ii.) treatment of melanoma cells 
with ApoE protein impaired their invasive and endothelial recruitment capacities and blocked 
in vivo metastasis, and iii.) genetic inactivation of stromal ApoE accelerated melanoma 
metastasis. Extracellular ApoE was found to act in a dual cell-autonomous/non-cell-
autonomous fashion by divergently targeting distinct receptors on melanoma cells and 
endothelial cells, respectively. ApoE acting on LRP1 receptors on melanoma cells led to 
suppression of melanoma invasion and ApoE acting on endothelial LRP8 receptors inhibited 
endothelial recruitment by melanoma cells as well as endothelial cell migration in a cancer 
cell-free system. Whereas endothelial cells expressed substantially higher LRP8 than LRP1 
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levels, melanoma cells were found to display high levels of both LRP1 and LRP8, suggesting 
that the choice of ApoE receptor is not solely determined by relative target abundance, but 
receptor specificity, at least in melanoma cells, may rather be conferred by additional 
molecular coupling mechanisms (See Discussion). Finally, I describe our preliminary work 
on characterizing some of the endothelial cell biology downstream of LRP8 targeting. We 
found that ApoE inhibited ligand-induced VEGFR2 phosphorylation in an LRP8-dependent 
fashion both in primary human endothelial cells as well as primary mouse endothelial cells. 
We also observed that genetic inactivation of one LRP8 allele enhanced VEGFR2 activation 
by VEGF. These findings implicate the ApoE/LRP8 pathway as a potential novel regulator of 
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CHAPTER V: THERAPEUTIC ACTIVATION OF APOE IN 
METASTATIC MELANOMA THROUGH NUCLEAR HORMONE 
RECEPTOR TARGETING 
 
Identification of LXRβ as a Novel Therapeutic Target in Melanoma 
In light of our findings that extracellular ApoE robustly suppressed melanoma 
metastatic progression through its inhibitory effects on cell-autonomous invasion and non-
cell-autonomous endothelial recruitment, we hypothesized that increasing extracellular ApoE 
levels may represent a novel therapeutic approach in metastatic melanoma. Since the half-life 
of naked recombinant proteins in serum is very short in the range of minutes to a few hours 
(Kontermann, 2011), making exogenous administration of ApoE protein unfeasible as a 
potential therapeutic approach, we sought to identify an ApoE trans-activator that is 
expressed across melanoma as well as in normal tissues, allowing for global induction of 
endogenous extracellular ApoE protein. Given the well-known role of ApoE in cholesterol 
metabolism (Hatters et al., 2006) and previous work showing that nuclear hormone receptors, 
a well-studied class of transcription factors, can regulate the transcription of multiple 
downstream target genes involved in cellular homeostasis and metabolism (Calkin and 
Tontonoz, 2012; Deblois and Giguère, 2013), we wondered whether there was a specific 
nuclear hormone receptor that i.) exhibits stable expression in melanoma and ii.) regulates 
downstream ApoE signaling. To this end, I first examined the expression levels of all nuclear 
hormone receptor family members across the National Cancer Institute (NCI-60) collection 
of human melanoma cell lines. Consistent with previous analyses of nuclear hormone 
receptor expression in the NCI-60 series (Holbeck et al., 2010), I found that several receptors 
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displayed stable expression across multiple melanoma lines (Figure 5.1). Notably, of these 
stably expressed receptors, the liver X receptors (LXRs) and the retinoid X receptors (RXRs) 
had previously been shown to activate ApoE transcription in adipocytes and macrophages 
(Laffitte et al., 2001; Mak et al., 2002). We further validated the stable expression of select 
LXR and RXR isoforms in seven primary melanoma lines obtained from patients at the 
MSKCC (Figure 5.1c).  
The stable expression of specific LXR and RXR isoforms in melanoma suggested that 
they could represent druggable targets across diverse melanoma subtypes. In light of the 
availability of pharmacologic agents to activate LXRs and RXRs and the previously shown 
role of LXR/RXR heterodimers in activating ApoE transcription, we hypothesized that 
pharmacologic activation of LXR or RXR signaling might inhibit melanoma progression 
phenotypes through the downstream induction of ApoE expression. We first examined the 
effect of pharmacologic agonism of LXRs or RXRs on melanoma cell invasion and 
endothelial recruitment—phenotypes that we previously found to be displayed by highly 
metastatic melanoma cells and also to be robustly suppressed by ApoE. We found that LXR 
agonist (T0901317 or GW3965) treatment suppressed melanoma invasion and endothelial 
recruitment by four mutationally diverse melanoma lines: MeWo (B-Raf/N-Ras wild-type), 
HT-144 (B-Raf mutant), and SK-Mel-2 (N-Ras mutant) established human lines as well as 
the SK-Mel-334.2 (B-Raf mutant) primary human melanoma line (Figure 5.2). In contrast, 
treatment of melanoma cells with the RXR agonist bexarotene inhibited invasion in two of 
the four melanoma lines examined, and it was ineffective in suppressing endothelial 
recruitment by melanoma cells (Figure 5.2). 
 
















Figure 5.1. Analysis of Nuclear Hormone Receptor Expression in Melanoma.  
a-c. Heat-maps showing microarray-based expression levels of all nuclear hormone receptor 
family members (a) or an extracted heat-map of only LXR and RXR isoforms (b) across the 
NCI-60 melanoma line collection. Color-map key indicates the changes in standard 
deviations (z-score) for the expression value of each receptor relative to the average 
expression of all profiled genes (> 39,000 transcript variants) in each cell line. c. Heat-map of 
the qRT-PCR-based expression levels of LXR and RXR isoforms in seven primary 
melanoma lines dissociated from melanoma tumors of patients at the MSKCC.  Color-map 
corresponds to the standard deviations change in the expression of each receptor relative to 
the average expression value in each melanoma line. 
 
 



















Figure 5.2. Effects of LXR or RXR Agonists on In Vitro Melanoma Cell Invasion and 
Endothelial Recruitment. a-d. Trans-well matrigel invasion by 1 × 105 MeWo (a), 5 × 104 
HT-144 (b), 5 × 104 SK-Mel-2 (c), and 5 × 104 SK-Mel-334.2 (d) human melanoma cells. 
Cells were treated with DMSO, GW3965, T0901317, or bexarotene at 1 μM for 72 hours and 
subjected to trans-well matrigel invasion assays. n ≥ 4. e-h. Trans-well endothelial 
recruitment by 5 × 104 MeWo (e), HT-144 (f), SK-Mel-2 (g), and SM-Mel-334.2 (h) human 
melanoma cells, following treatment of the melanoma cells with DMSO, GW3965, 
T0901317, or bexarotene at 1 μM for 72 hours. n ≥ 4. All data are displayed as mean ± SEM. 
*p < 0.05, **p < 0.01, ****p < 0.0001. p-values based on unpaired student’s t-tests. 
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 Treatment of melanoma cells with the LXR agonists GW3965 or T0901317 or the RXR 
agonist bexarotene did not affect cell proliferation or survival rates (Figure 5.3), indicating 
that the suppression in melanoma progression phenotypes (invasion and endothelial 

















Figure 5.3. Effects of LXR or RXR Agonists on In Vitro Melanoma Cell Proliferation 
and Survival. a-c. 2.5 × 104 MeWo (a-b), HT-144 (c-d), or SK-Mel-334.2 (e-f) human 
melanoma cells were cultured in the presence of DMSO, GW3965, T0901317, or bexarotene 
at 1 μM. Viable cells were counted on days 0, 3, and 5 post-seeding (a, c, e). The number of 
dead cells was quantified on day 5 post-seeding using the trypan blue dead cell exclusion dye 
(b, d, f). n ≥ 3. Error bars = SEM. 
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The superiority of LXR activation over RXR agonism in broadly suppressing cell 
invasion and endothelial recruitment phenotypes prompted us to examine whether LXR 
signaling in melanoma cells is necessary for the inhibitory effects of GW3965 and T0901317 
on this set of in vitro phenotypes. To this end, I depleted each of the two LXR isoforms in 
melanoma cells and assessed the phenotypic effects of LXR agonists in the context of LXRα 
or LXRβ silencing. Consistent with LXRβ being the predominant LXR isoform expressed by 
melanoma cells (Figure 5.1, P < 0.0001), I found that knockdown of melanoma-cell LXRβ, 
but not LXRα, in two independent melanoma lines prevented the suppression of cell invasion 
and endothelial recruitment phenotypes incurred by LXR agonist treatment (Figure 5.4). 
These findings implicate melanoma-cell LXRβ as the primary downstream target and 
molecular effector of LXR agonists in inhibiting melanoma invasion and endothelial 
recruitment.   
To assess the expression of LXRβ during melanoma progression, we performed 
double-blinded immunohistochemical analyses for LXRβ protein expression in two 
independent melanoma tissue-microarray (TMA) progression sets. These experiments, 
performed and analyzed with the help of Jessica Posada, revealed that LXRβ is ubiquitously 
expressed in both primary melanoma lesions as well as melanoma metastases (Figure 5.5), 
consistent with our previous observations of broad LXRβ expression across the NCI-60 
series and various primary melanoma cells (Figure 5.1) as well as its previously reported 
ubiquitous expression in normal tissues (Song et al., 1994). Such pervasive expression of 
LXRβ during melanoma progression makes this receptor an attractive therapeutic target, as 
the stable basal presence of LXRβ could allow for a therapeutically broad pharmacologic 
activation of this target, both in primary tumors as well as in melanoma metastases.  


























Figure 5.4. LXRβ Mediates Invasion and Endothelial Recruitment Suppression by LXR 
Agonists. a-d. Matrigel invasion (a,c) and endothelial recruitment (b,d) by MeWo and HT-
144 melanoma cells expressing shRNAs targeting LXRα or LXRβ or a control shRNA in 
response to DMSO, GW3965, or T0901317 treatment at 1 μM for 72 hours. n ≥ 4. Scale bar, 
50 μm, Error bars = SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. p-values 
based on unpaired student’s t-tests	  































Figure 5.5. Expression of LXRβ during Melanoma Progression. a-b. Box and whisker 
plots of LXRβ protein expression assessed by double-blinded immunohistochemical analyses 
of cutaneous melanoma lesions from the US Biomax TMA (a, N = 126) and the NIH TMA 
(b, N = 170) melanoma progression sets. Whiskers indicate the 5th to 95th population 
percentile; box extent corresponds to the 25th-75th population percentile. Scale bars, 50 μm 
(a), 100 μm (b). ***p<0.001. p-value based on an unpaired student’s t-test. 
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Oral Delivery of LXR Agonists Inhibits Melanoma Tumor Progression  
LXR agonists were originally conceived as orally active drug candidates for the 
purpose of cholesterol lowering in patients with dyslipidemia (Collins et al., 2002; Joseph 
and Tontonoz, 2003; Barish and Evans, 2004). However, their clinical development was 
largely stalled when they were found to lack activity in reducing cholesterol levels in large 
animal models (Groot et al., 2005). Given the robust activity of LXR agonists in suppressing 
in vitro melanoma progression phenotypes (Figure 5.2), we wondered whether their clinical 
development could be revived for the management of melanoma progression. To this end, we 
investigated whether therapeutic delivery of LXR agonists could yield tumor-suppressive 
activity in various in vivo models of melanoma progression. In an extensive series of 
therapeutic mouse experiments conduced with the help of Colin Buss, we found that orally 
administering low doses (20 mg/kg) of the independent LXR agonists GW3965 or 
T0901317, subsequent to tumor formation, suppressed the growth of mouse melanoma 
tumors in an immunocompetent model by 67% and 61%, respectively (Figures 5.6a-b). 
Importantly, administering a higher LXR agonist dose (100 mg/kg) reduced tumor growth by 
80%, consistent with dose-dependent suppressive effects (Figure 5.6a).  
Given the superior potency of GW3965 over T0901317, likely due to the lower EC50 
of the GW3965 compound for LXRβ (Collins et al., 2002; Schultz et al., 2000), we utilized 
this LXR agonist for the remainder of our therapeutic experiments. To determine the 
robustness of LXR agonist treatment in conferring tumor suppression across different 
melanoma subtypes, we examined its effects on human melanoma progression in multiple 
mutationally diverse xenograft models. Notably, oral administration of GW3965 
substantially suppressed tumor growth by the B-Raf/N-Ras wild-type MeWo human 
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melanoma line (70% inhibition, Figure 5.6c) and the N-Ras mutant SK-Mel-2 human 
melanoma cells (49% inhibition, Figure 5.6d), as well as the B-Raf mutant SK-Mel-334.2 











                                  
 
Figure 5.6. Therapeutic Delivery of LXR Agonists Suppresses Melanoma Tumor 
Growth. a-b. Primary tumor growth by 5 × 104 B16F10 mouse melanoma cells 
subcutaneously injected into C57BL/6-WT mice. Following tumor growth to 5-10 mm3 in 
volume, mice were administered a control chow or a chow supplemented with GW3965 (20 
or 100 mg/kg/day) (a) or T0901317 (20 mg/kg/day) (b). Representative tumor images were 
taken at the final day 12. n ≥ 10 (a); n ≥  8 (b). c-e. Primary tumor growth by 1 × 106 MeWo 
(c), 2 × 106 SK-Mel-2 (d), and 7.5 × 105 SK-Mel-334.2 (e) human melanoma cells grafted 
onto immunocompromised mice. Following tumor growth to 5-10 mm3 in volume, mice were 
randomly assigned to a control diet or a diet supplemented with GW3965. n ≥ 6 (c); n = 5 
(d); n = 8 (e). f. Weight of mice administered a control diet, T0901317 diet, or GW3965 diet. 
n ≥ 5. Scale bar, 5 mm. Error bars = SEM. *p < 0.05, **p < 0.01, ***p < 0.001,  
****p < 0.0001. p-values based on unpaired student’s t-tests. 
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Importantly, the tumor-suppressive effects of LXR agonists occurred in the absence of any 
symptomatic animal health deterioration or weight loss in response to the LXR agonist 
treatment (Figure 5.6f) Our findings of robust melanoma suppression in response to LXR 
agonist treatment across multiple mutationally diverse human melanoma lines are consistent 
with broad-spectrum activity of LXR activation therapy in melanoma. 
Encouraged by the strong tumor-suppressive impact of LXR agonists on established 
small tumors (5-10 mm3) (Figure 5.6), we next investigated whether LXR activation therapy 
could inhibit the growth of substantially larger (~150 mm3) melanoma tumors. Notably, oral 
administration of GW3965 following the formation of tumors measuring at least 150 mm3 in 
volume led to a ~50% reduction in B16F10 melanoma tumor growth (Figure 5.7a), 
suggesting that LXR activation therapy could exhibit activity against more advanced 
melanoma tumors. We next wondered about the persistence of the LXR agonist-elicited 
suppression response. To that end, we monitored the long-term progression of GW3965-
treated tumors formed by the aggressive MeWo human melanoma line. Even though 
GW3965 treatment initially delayed tumor growth progression, the tumors resumed to grow 
at a constant rate for the first seven weeks. Remarkably, upon reaching a critical size of 
roughly 250 mm3, the GW3965-treated MeWo tumors exhibited partial regression and their 
size remained stable beyond 100 days (Figure 5.7b), consistent with long-term effects of the 
LXR agonist treatment on tumor growth suppression. Importantly, all members of this entire 
GW-treated cohort remained alive at 120 days (Figure 5.7c). Administration of GW3965 
after tumor establishment also prolonged, albeit to a less extent, the overall survival time of 
immunocompetent mice injected with B16F10 cells as well as immunocompromised mice 
bearing primary SK-Mel-334.2 human melanoma burden (Figures 5.7d-e).  



















Figure 5.7. Therapeutic Delivery of LXR Agonists Suppresses the Growth of Large 
Melanoma Tumors, Inhibits Long-Term Tumor Progression, and Extends Animal 
Survival. a.  Tumor growth by 5 × 104 B16F10 cells subcutaneously implanted into 
C57BL/6-WT mice. Upon tumor growth to 150 mm3, mice were administered a control chow 
or a chow containing GW3965 (100 mg/kg). n ≥ 6. b. NOD SCID mice bearing MeWo 
melanoma tumor burden were monitored for the long-term progression of their GW3965-
treated tumors. n ≥ 6. c-e. Overall survival of mice following subcutaneous grafting of 1 × 
106 MeWo cells (c), 5 × 104 B16F10 cells (d), or 7.5 × 105 SK-Mel-334.2 primary melanoma 
cells (e) and treatment of the mice with a control diet or a GW3965-supplemented diet (100 
mg/kg) upon formation of tumors measuring 5-10 mm3 in volume.  n ≥ 4 (c), n ≥ 6 (d, e). 
Error bars = SEM. **p < 0.01. p-values based on an unpaired student’s t-test (a) or Mantel-
Cox tests (c-e).	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We next sought to determine the cellular mechanisms by which LXR agonists 
suppress tumor growth. Consistent with the suppression of endothelial recruitment upon 
treatment of melanoma cells with LXR agonists in vitro, GW3965 administration 
substantially reduced the number as well as the size of endothelial vessels present in tumors, 
as evidenced by staining for two independent endothelial cell markers, CD31 (Figures 5.8a-c) 
and MECA-32 (Figures 5.8d-f). This was accompanied by a modest decrease (23%) in the 
number of actively proliferating Ki-67-positive tumor cells in vivo (Figure 5.8g) without a 
change in the number of Caspase-3-positive apoptotic cells (Figure 5.8h).  These results 
suggest that, in addition to reducing melanoma cell invasion, LXR activation suppresses 
melanoma tumor growth through inhibiting tumor angiogenesis and modestly decreasing in 












































Figure 5.8. LXR Agonist Treatment Suppresses Tumor Angiogenesis. a-f.  Average 
number and size of endothelial vessels and endothelial cell density, as determined by CD31 
staining (a-c) or MECA-32 staining (d-f), in MeWo tumors following mouse treatment with 
a GW3965-supplemented (20 mg/kg) or control diet for 35 days. n = 5. g-h. Number of 
proliferating (g) and apoptotic  (h) tumor cells, determined by staining for Ki-67 or cleaved 
caspase-3, respectively, in MeWo tumors in response to GW3965 treatment. n = 5. Error bars 
= SEM. **p < 0.01, ***p < 0.001. Scale bars, 10 μm (c), 50 μm (f), 80 μm (g), 25 μm (h). 
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LXR Agonist Therapy Suppresses Melanoma Metastatic Progression 
In light of the fact that nearly all melanoma patients die due to metastatic spread of 
their primary tumors and colonization of distal organs such as the lung and the brain (Bhatia 
et al., 2009), we next examined whether LXR activation could also suppress multi-organ 
metastatic colonization by melanoma cells. Remarkably, mice that were orally administered 
GW3965 or T0901317, starting 10 days prior to cancer cells injection, exhibited 31-fold and 
23-fold less lung metastatic colonization burden, respectively, from human MeWo cells 
(Figures 5.9a-b). Treatment with GW3965 also suppressed lung metastatic colonization by 
the independent HT-144 melanoma line (Figure 5.9c) as well as the SK-Mel-334.2 primary 
human melanoma line (Figure 5.9d).  Importantly, treatment of mice with GW3965 in this 
‘adjuvant’ pre-clinical context significantly prolonged their survival times following 
metastatic dissemination (Figure 5.9e). These findings from pre-clinical mouse models 
suggest efficacy of LXR activation therapy for the prevention of melanoma metastasis. 
GW3965 is a lipophilic molecule that can efficiently cross the blood-brain barrier and 
effectively activate LXR signaling in the brain (Jiang et al., 2008). We thus wondered 
whether LXR agonism could exhibit therapeutic activity for the suppression of melanoma 
brain metastasis—a devastating outcome affecting ~30% of metastatic melanoma patients, 
for which there is currently no available targeted therapeutic (Fonkem et al., 2012). Notably, 
oral administration of GW3965 inhibited both brain metastatic colonization and systemic 
metastasis following intracardiac injection of brain-metastatic melanoma cells derived by in 
vivo selection of the MeWo parental line (Figure 5.10). 
 
 














Figure 5.9. Therapeutic LXR Activation Inhibits Lung Metastatic Colonization by 
Melanoma Cells. a-b. Bioluminescence imaging of lung metastasis by 4 × 104 MeWo cells 
intravenously injected into NOD SCID mice fed a control chow or a chow containing 
GW3965 (20 mg/kg) (a) or T0901317 (20 mg/kg) (b), starting 10 days prior to cancer cell 
injection. Representative H&E-stained lungs correspond to the final imaging day. n ≥ 5. 
c-d. Lung metastasis following intravenous injection of 2.5 × 105 HT-144 cells (c) and 4 × 
104 primary SK-Mel-334.2 melanoma cells (d) into NOD SCID mice administered a control 
chow or a chow supplemented with GW3965 (20 mg/kg), starting 10 days prior to cancer cell 
injection. n ≥ 5. e. Overall mouse survival following intravenous injection of 4 × 104 MeWo 
cells into NOD SCID mice that were continuously fed a control chow or a GW3965-
supplemented chow (20 mg/kg) starting 10 days prior to cancer cell injection. n ≥ 5. All data 
are shown as mean ± SEM. *p < 0.05, **p < 0.01. p-values based on Mann-Whitney’s t-tests 
(a-d) or Mantel-Cox test (e). 
 








Figure 5.10. LXR Agonist Treatment Suppresses Melanoma Metastasis to the Brain. 
 a-b. Brain (a) and systemic (b) photon flux following intracardiac injection of 1 × 105 
MeWo brain metastatic derivative cells into athymic nude mice that were fed a control diet or 
a GW3965-supplemented diet (100 mg/kg) starting on day 0 post-injection. n ≥ 6. All data 
are shown as mean ± SEM. *p < 0.05, based on Mann-Whitney’s t-tests. 
 
Encouraged by the metastasis suppression effects observed in response to LXR 
agonist treatment initiated 10 days prior to (Figure 5.9) or immediately upon (Figure 5.10) 
cancer cell injection, we sought to determine whether LXR activation therapy could halt the 
progression of melanoma cells that had already metastatically disseminated. We first tested 
the ability of GW3965 to reduce lung colonization by melanoma cells disseminating from an 
orthotopic site following removal of the primary tumor (Figure 5.11a). Importantly, 
administration of GW3965 post-tumor resection inhibited lung colonization by 17-fold 
(Figure 5.11b). We next wondered whether LXR activation therapy could also be effective in 
inhibiting established melanoma lung metastases. Remarkably, treating mice with GW3965 
after incipient metastases had progressed by 8-fold from the baseline at seeding also 
dramatically suppressed (28-fold) metastatic colonization (Figure 5.11c). Consistent with 
LXR activation inhibiting metastatic initiation and the frequency of resulting metastatic 
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events, mice administered the LXR agonist treatment exhibited a reduced number of 





















Figure 5.11. LXR Activation Therapy Suppresses Colonization by Disseminated 
Melanoma Cells and Halts the Progression of Established Metastases. a Schematic of 
orthotopic metastasis model used to assess the ability of GW3965 treatment to suppress lung 
metastasis post-tumor excision. b. Ex vivo lung photon flux, determined by bioluminescence 
imaging, in NOD SCID mice that were administered a control chow or a chow containing 
GW3965 (100 mg/kg) for 1 month following the excision of size-matched (~300-mm3 in 
volume) subcutaneous tumors formed by 1 × 106 MeWo melanoma cells. Representative lung 
images stained for human vimentin are shown o the right. n ≥ 7. c. Lung colonization by 4 × 
104 MeWo cells intravenously injected into NOD SCID mice. Following formation of 
metastases, detected by bioluminescence imaging on d42, mice were assigned to a control 
diet or a GW3965 diet (100 mg/kg). n = 6. d. Number of lung macroscopic metastatic 
nodules quantified at the final day 77 in mice shown in (c). n ≥ 4. All data are shown as mean 
± SEM. *p<0.05, **p<0.01, based on Mann-Whitney’s t-tests (b, c) or a student’s t-test (d). 
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LXRβ Agonism Suppresses In Vitro Melanoma Progression Phenotypes by 
Transcriptionally Activating ApoE in Melanoma Cells 
We had initially hypothesized that LXRs might inhibit melanoma progression through 
transcriptionally activating ApoE, given that ApoE is a known target of LXRs in adipocytes 
and macrophages (Laffitte et al., 2001). However, whether ApoE expression is similarly 
regulated by LXR signaling in melanoma cells was unknown at the time. Additionally, LXRs 
can have a wide range of downstream targets, some of which might also be contributing to 
the suppression of melanoma phenotypes. Therefore, we undertook a systematic approach to 
determine the downstream molecular target(s) of LXRβ that mediate(s) melanoma 
suppression. The inhibitory effects of LXR agonists on cell-extrinsic endothelial recruitment 
by melanoma cells are consistent with the action of a secreted molecule. To identify such 
factors, we performed whole-genome transcriptomic profiling, which revealed a total of 41 
extracellular factors to be significantly induced in human MeWo melanoma cells in response 
to treatment with the LXR agonist GW3965 (Table 5.1). Out of these, ApoE was the top 
upregulated secreted factor in melanoma cells upon LXR activation. Subsequent validation 
by qRT-PCR confirmed the upregulation in ApoE transcript expression following treatment 
of multiple melanoma lines with independent LXR agonists (Figure 5.12). GW3965 and 
T0901317 also enhanced the melanoma cell-driven activity of a luciferase reporter construct 
containing the ApoE promoter fused to either one of two previously characterized LXR-
binding multi-enhancer elements (ME.1 and ME.2 (Laffitte et al., 2001)), suggestive of direct 
LXR-mediated transcriptional effects on ApoE expression (Figure 5.13a). Consistent with 
this, chromatin immunoprecipitation (ChIP) analyses confirmed a direct interaction between 
endogenous LXRβ and the ApoE multi-enhancer genomic DNA element in melanoma cells 
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(Figure 5.13b). Importantly, this transcriptional regulation resulted in elevated levels of both 
intracellular (Figures 5.13c-e) and secreted ApoE protein (Figures 5.13f-h). 
 
Table 5.1. List of Secreted Factors Significantly Upregulated in MeWo Cells in 

















Figure 5.12. Pharmacologic LXR Activation Enhances ApoE Transcript Levels.  
a-c. MeWo (a), HT-144 (b), and WM-266-4 (c) melanoma cells were treated with GW3965 
or T0901317 at the indicated concentrations for 48 hours, and the expression levels of ApoE 
were analyzed by qRT-PCR.  n = 3. Error bars = SEM. **p < 0.01, ***p < 0.001,  
****p < 0.0001. p-values based on unpaired student’s t-tests. 














Figure 5.13. LXR Agonism Transcriptionally Activates Melanoma Cell ApoE 
Expression. a. Luciferase activity driven off the ApoE promoter fused to multi-enhancer 
elements ME.1 or ME.2 and transfected into MeWo cells treated with DMSO, GW3965, or 
T0901317 at 1 μM for 24 hours. n ≥ 4. b. ChIP of genomic ME.2 DNA in MeWo cells using 
an antibody against endogenous LXRβ. The ChIP product was analyzed by qRT-PCR, and 
data are expressed as the fold-enrichment relative to a genomic region that lacks the LXR 
binding element (LXRE-neg).  MeWo cells were pulsed with DMSO or GW3965 (1 μM) for 
8 hours prior to performing ChIP. n=4. c-e. Intracellular ApoE protein levels, assessed by 
western blotting, in MeWo (c), HT-144 (d), and SK-Mel-334.2 (e) human melanoma cells 
treated with DMSO, GW3965, or T0901317 at 1 μM for 72 hours. Tubulin was used as an 
endogenous control. n = 3. f-h. Extracellular ApoE protein levels were quantified by ELISA 
in serum-free conditioned media from MeWo (f), HT-144 (g), or SK-Mel-334.2 (h) cells  
treated with DMSO, GW3965, or T0901317 at 1 μM for 72 hours. n ≥ 3. Error bars = SEM. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, based on unpaired student’s t-tests. 
	   124 
In light of the robust transcriptional activation of ApoE in melanoma cells upon 
LXRβ agonism, we next investigated whether ApoE is the functional determinant of the 
LXRβ -dependent suppression of metastatic phenotypes. We hypothesized that if the 
suppressive effects of LXR agonists on melanoma invasion and endothelial recruitment are 
elicited through an increase in ApoE signaling, then blockade of ApoE in the setting of LXR 
agonism should abrogate these effects. Indeed, we found that neutralization of extracellular 
ApoE with a blocking antibody (1D7) completely prevented the LXR agonist-mediated 
suppression of invasion and endothelial recruitment phenotypes across multiple melanoma 
lines (Figure 5.14), revealing the effects of LXR agonism to be functionally mediated 
through the downstream induction of extracellular ApoE. Notably, the ApoE antibody 
treatment further enhanced the melanoma invasion and endothelial recruitment phenotypes 
relative to the control antibody/DMSO baseline (Figures 5.14), unmasking an important role 
for endogenous ApoE in suppressing these phenotypes. Consistent with a requirement of 
endogenous LXRβ for the LXR agonist-dependent ApoE induction, depletion of LXRβ, but 
not LXRα, in melanoma cells abrogated the ability of GW3965 and T0901317 to induce 
ApoE transcription and ApoE protein expression (Figure 5.15). Collectively, these findings 
indicate that pharmacologic activation of LXRβ, the predominant LXR isoform expressed by 
melanoma cells, suppresses melanoma invasion and endothelial recruitment by melanoma 








































Figure 5.14. ApoE is the Downstream Determinant of LXRβ-Dependent Suppression of 
Melanoma Invasion and Endothelial Recruitment. a, c, e. Matrigel invasion by 1 × 105 
MeWo (a), 5 × 104 HT-144 (c), and 5 × 104 SK-Mel-334.2 (e) melanoma cells, treated with 
DMSO, GW3965, or T0901317 at 1 μM for 72 hours, in response to 1D7 or IgG antibodies 
(40 μg/mL). n ≥ 4. b, d, f. Endothelial recruitment by 5 × 104 MeWo (b), HT-144 (d), and 
SK-Mel-334.2 (f) cells, pre-treated with DMSO, GW3965, or T0901317 at 1 μM for 72 
hours, in response to 1D7 or IgG antibodies (40 μg/mL). n ≥ 4. Scale bars, 50 μm. Error bars 
= SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, based on unpaired student’s t-tests. 











Figure 5.15. LXRβ is Required for LXR Agonist-Mediated Transcriptional ApoE 
Induction. Relative expression of ApoE mRNA (a-b) and extracellular ApoE protein (c-d) in 
MeWo (a, c) and HT-144 (b, d) melanoma cells transduced with shRNAs targeting LXRα, 
LXRβ, or a control and treated with DMSO, GW3965, or T0901317 at 1 μM for 48 (a-b) or 
72 (c-d) hours. n ≥ 3. e. Luciferase-based activity of the ApoE promoter fused to ME.1/ME.2 
enhancer elements and transfected into MeWo melanoma cells expressing shRNAs against 
LXRα, LXRβ, or a control in the presence of DMSO or GW3965 (1μM) for 24 hours. n ≥ 3. 
All data are shown as mean ± SEM.*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.  


















































Figure 5.15. LXRβ is Required for LXR Agonist-Mediated Transcriptional ApoE 
Induction.  
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LXRβ Agonism Suppresses In Vivo Melanoma Progression through the Engagement of 
both Melanoma-Derived and Stromal ApoE 
In the in vivo LXR activation therapy experiments, the orally delivered LXR agonists 
can act systemically, exerting effects on both melanoma cells as well as various stromal 
tissues, which express LXRβ. Given the observed suppression of key melanoma phenotypes 
by extracellular ApoE in vitro, we hypothesized that the suppressive effects of LXR agonists 
in vivo might be further augmented by the activation of LXRs in peripheral tissues, which 
could serve as robust sources of extracellular ApoE released into the circulation. We thus 
investigated whether the suppression in melanoma tumor progression in vivo, attained upon 
LXR agonist treatment, is mediated by ApoE derived from melanoma cells or that derived 
from stromal tissues.  Consistent with LXRβ agonism increasing ApoE expression in 
melanoma cells in vivo, ApoE transcript levels were upregulated in melanoma primary 
tumors as well as in melanoma lung and brain metastases dissociated from mice that were fed 
a diet containing LXR agonists (Figures 5.16a-d). Additionally, treatment of mice with either 
GW3965 or T0901317 significantly elevated ApoE protein expression in systemic adipose, 
lung, and brain tissues of mice (Figures 5.16e-f) and also upregulated ApoE transcript levels 
in circulating white blood cells (Figure 5.16g). These results indicate that LXR agonist-based 
therapy globally activates ApoE expression in both the tumoral and stromal tissue 
compartment, as indicated by the elevated expression levels of ApoE across melanoma 
tumors, metastases, as well as various peripheral stromal tissues following in vivo LXR 















Figure 5.16. LXR Agonist Therapy Activates Melanoma-Derived and Stromal ApoE 
Expression. a-c. ApoE transcript levels in primary tumors (a), lung metastases (b), and brain 
metastases (c) formed by MeWo human melanoma cells following grafting of the cells onto 
immunocompromised mice that were administered a control chow or a chow supplemented 
with GW3965. ApoE levels were assessed on day 35 (a), day 153 (b), or day 34 (c) post-
injection of the cancer cells, respectively. n ≥ 3. d. ApoE expression levels, quantified by 
qRT-PCR, in subcutaneous tumors formed by B16F10 mouse melanoma cells injected into 
C57BL/6-WT mice. Upon 5-10 mm3 tumor formation, mice were fed a control diet or a diet 
containing GW3965 or T0901317 at 20 mg/kg for 7 days. n ≥ 3. e. Western blot 
measurements of ApoE protein levels in adipose, lung, and brain tissue lysates extracted 
from immunocompromised mice that were administered a control chow or a chow 
supplemented with GW3965 (20 mg/kg) or T0901317 (20 mg/kg) for 10 days.  
f. Quantification of ApoE protein expression based on western blots shown in (e). Total 
tubulin was used as an endogenous control for normalization. n ≥ 3. g, Expression levels of 
ApoE, determined by qRT-PCR, in circulating white blood cells collected from NOD SCID 
mice that were fed a control diet or a diet supplemented with GW3965 or T0901317 at 20 
mg/kg for 10 days. n ≥ 3. All data are displayed as mean ± SEM. *p < 0.05; **p < 0.01;  
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We next sough to determine the relative contribution of ApoE produced by melanoma 
cells versus that of ApoE supplied by stromal tissue compartments to the suppression of 
melanoma progression upon LXR activation therapy. We first focused on tumor growth.  
Interestingly, GW3965 fully inhibited the growth of primary tumors formed by LXRβ-
depleted melanoma cells (Figure 5.17a,d), indicating that loss of melanoma cell LXRβ is 
dispensable for the LXR-mediated growth inhibition and implicating a role for melanoma-
extrinsic (stromal) LXR activation in tumor suppression by GW3965. To identify the LXR 
isoform that mediated this non-tumor autonomous melanoma suppressive effect, we 
examined the effects of GW3965 on tumors implanted onto LXRα or LXRβ genetically null 
mice (Peet et al., 1998). Importantly, genetic inactivation of stromal LXRβ rendered GW3965 
completely ineffective, while LXRα inactivation had no effect on the ability of GW3965 to 
suppress tumor growth (Figure 5.17d). Consistent with LXRβ being the main molecular 
target and effector of GW3965 in mediating ApoE-dependent melanoma tumor growth 
suppression, GW3965 failed to induce ApoE expression in circulating white blood cells 
collected from LXRβ null mice, but not from LXRα null mice (Figure 5.17b). This LXRβ 
dependency was not restricted to ApoE expression since ABCA1 (a well-characterized LXR 
target gene (Laffitte et al., 2001)) showed comparable upregulation in circulating LXRα -/-
white blood cells, but not in LXRβ -/- cells, in response to the GW3965 treatment (Figure 
5.17c), consistent with this agonist’s 6-fold greater activity towards LXRβ over LXRα.	  
In agreement with our findings that tumor growth suppression is primarily mediated 
by stromal LXRβ activation, we observed that genetic inactivation of stromal ApoE fully 
rescued the LXR agonist-based suppression in melanoma tumor growth (Figure 5.17e). 
Accordingly, depletion of ApoE in melanoma cells had no effect on GW3965-induced tumor 
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growth suppression (Figure 5.17a,e). These findings reveal that the tumor-suppressive effects 
of GW3965 are primarily mediated through stromal LXRβ activation and the resulting 
induction of extracellular ApoE derived from various peripheral tissues and supplied to the 
tumor via the circulation and/or ApoE produced by local stromal cells present in the tumor 
microenvironment. To this end, we sought to identify specific stromal cell types in the tumor 
microenvironment that induce ApoE in response to LXRβ activation and may thus contribute 
to melanoma suppression. In immunohistochemical co-localization experiments conducted 
by Jessica Posada, we found that GW3965 treatment significantly upregulated ApoE protein 
expression within tumor-infiltrating macrophages (~2.6-fold) and leukocytes (~2-fold) and 
modestly increased endothelial cell ApoE expression (~1.2-fold) (Figure 5.18). 
In contrast to primary tumor growth regulation, neither knockdown of melanoma cell 
ApoE nor genetic inactivation of stromal ApoE completely occluded the effects of GW3965 
on metastasis suppression (Figure 5.19a). The metastasis-suppressive activity of the GW3965 
treatment was entirely prevented only upon combined silencing of both melanoma-derived 
and stromal ApoE (Figure 5.19a). Based on these findings, we conclude that while tumor 
growth inhibition is primarily driven by ApoE induction in stromal cells, metastasis 
suppression by GW3965 is elicited through the activation of both stromal and melanoma-
derived ApoE. Tissue-specific differences in microenvironmental ApoE expression levels in 
the lung relative to the skin could explain the differential contribution of melanoma-derived 










Figure 5.17. Activation of Stromal LXRβ Inhibits Melanoma Tumor Growth through 
Induction of Stromal ApoE. a. Expression of LXRα, LXRβ, and ApoE mRNA in B16F10 
cells expressing a control hairpin or an shRNA targeting LXRα, LXRβ, or ApoE.  
b-c. ApoE (b) and ABCA1 (b) mRNA levels in circulating white blood cells extracted from 
LXRα -/- or LXRβ -/- mice that were administered a control diet or a GW3965 diet (20 
mg/kg) for 10 days. n ≥ 3. d. B16F10 control cells or B16F10 cells expressing shRNAs 
targeting LXRα or LXRβ were subcutaneously injected into C57BL/6-WT, LXRα-/-, or 
LXRβ-/- mice. Once the tumors reached 5-10 mm3 in volume, mice were fed a control diet or 
a diet supplemented with GW3965 (20 mg/kg) for 7 days, after which final tumor volume 
was measured. Representative tumor images extracted at the end point are shown in the right 
panel.  n ≥ 6. e.  Subcutaneous tumor growth by 5 × 104 B16F10 control cells or B16F10-
shApoE cells grafted onto C57BL/6-WT or ApoE-/- mice. Following the formation of tumors 
measuring 5-10 mm3 in volume, mice were fed a control diet or a diet supplemented with 
GW3965 (20 mg/kg) for 7 days, and final tumor volume was quantified. n ≥ 8. All data are 
displayed as mean ± SEM. Scale bar, 5 mm. *p < 0.05, **p < 0.01, ***p < 0.001. p-values 



























Figure 5.17. Activation of Stromal LXRβ Inhibits Melanoma Tumor Growth through 





























Figure 5.18. Identification of Stromal Cells in the Tumor Microenvironment that 
Upregulate ApoE upon LXR Agonist Treatment. a-c. Cumulative percentage plots 
depicting mean ApoE staining intensity per cell unit within F4/80-postivie macrophages (a), 
CD45-positive leukocytes (b), and CD31-postivie endothelial cells (c) in B16F10 
subcutaneous tumors in response to mouse treatment with a control diet or a GW3965 diet. n 
≥ 290 cells (a), n ≥ 280 cells (b), n ≥ 224 cells (c). d. Representative confocal images 
showing ApoE co-localization with macrophages (F4/80), leukocytes (CD45), and 





















Figure 5.19. LXRβ Therapy Engages both Melanoma-Intrinsic and Stromal ApoE in 
Metastasis Suppression. a. Lung colonization by 5 × 104 B16F10 cells transduced with a 
control shRNA or shApoE and intravenously injected into C57BL/6-WT or ApoE-/- mice.  
Ten days prior to cancer cell injection, mice were assigned to a control diet or a GW3965 diet 
(20 mg/kg) treatment. Representative lungs extracted at the end point (d22) are shown in the 
right panel. n ≥ 5. b. Relative expression of ApoE mRNA, expressed as the frequency of 
SAGE tags, in mouse and human skin and lung tissues was determined using the publicly 
available mouse and human SAGE Expression Matrix databases accessible through the NCI-
funded Cancer Genome Anatomy Project (CGAP). c. ApoE mRNA expression levels in 
parental MeWo cells or in vivo selected MeWo cells dissociated from lung metastatic 
nodules (LM2) or primary tumors. n = 3. All data are displayed as mean ± SEM. *p < 0.05, 
***p < 0.001. p-values based on Mann Whitney’s t-tests (a) or unpaired student’s t-tests (c). 
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For instance, a primary melanoma tumor that is exposed to high extracellular levels of 
stromally supplied ApoE may fail to respond to the relatively weak ApoE signal coming 
from the tumor itself. In contrast, melanoma metastases at a distal site such as the lung, 
which has lower relative ApoE tissue abundance, would be expected to be more sensitive to 
melanoma-secreted ApoE. Consistent with this, the relative levels of ApoE in both human 
and mouse lung are three to four-fold lower than its respective expression in human and 
mouse skin (Figure 5.19b). Additionally, tumorigenic and metastatic melanoma cells face 
differential selective pressures for ApoE silencing. Whereas in vivo selected metastatic 
melanoma cells dissociated from mouse lung nodules exhibited a 4-fold reduction in ApoE, 
melanoma cells dissociated from primary tumors were not found to downregulate ApoE 
(Figure 5.19c). These findings from in vivo selection are consistent with our genetic and 
molecular findings on ApoE’s role in primary tumor growth: with microenvironmental/ 
stromal ApoE exerting a dominant influence on tumor growth suppression. Metastasis 
contrasts this: we found that in vivo selected melanoma metastases were dependent on 
melanoma cell ApoE silencing, and their progression was impaired by melanoma-
autonomous re-activation of ApoE in addition to stromal induction of extracellular ApoE.  
	  
LXRβ Therapy Inhibits Melanoma Progression in a Genetically Initiated Melanoma 
Model 
To further evaluate the robustness of LXRβ activation as a new therapeutic approach 
in melanoma, we examined the efficacy of LXR agonist therapy in a genetically-initiated 
mouse model of melanoma progression driven by mutational alterations frequently found in 
human melanomas—activation of the B-Raf oncogene and loss of the Pten tumor-suppressor. 
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Nearly 60% of human melanoma tumors are marked by activating mutations in the Braf 
oncogene, with one single amino acid variant, B-RafV600E, being the predominant mutation 
found (Davies et al., 2002). Roughly 20-40% of melanomas exhibit activating mutations in 
B-Raf with concurrent silencing of the Pten tumor-suppressor, which drives progression to a 
malignant melanoma state (Hodis et al., 2012).  Recently, Tyrosinase (Tyr)-driven 
conditional B-RafV600E expression and Pten loss were shown to cooperate in driving mouse 
melanoma progression (Dankort et al., 2009). We thus investigated whether LXR activation 
could suppress melanoma progression in this genetically initiated melanoma model. Notably, 
oral administration of GW3965 following melanoma initiation attenuated tumor progression 
and significantly prolonged the overall survival times of both Pten heterozygous (Ptenlox/+) 
and Pten null (Ptenlox/lox) Tyr::CreER; B-RafV600E/+; mice (Figure 5.20). Next, we examined the 
ability of GW3965 to suppress melanoma metastasis in this genetic context. While we did 
not detect macroscopic metastases in the lungs or brains of Tyr::CreER; B-RafV600E/+; Ptenlox/lox 
mice at the late stages of melanoma progression, we consistently observed melanoma 
metastases to the salivary gland lymph nodes. Importantly, Tyr::CreER; B-RafV600E/+; Ptenlox/lox 
mice treated with GW3965 exhibited a significant reduction in the number of lymphatic 
metastases detected post-mortem (Figure 5.20). These findings indicate that LXR activation 
inhibits orthotopic metastasis in a genetically driven melanoma model, in addition to its 



















Figure 5.20. LXR Agonist Treatment Inhibits Melanoma Progression in a B-RafV600E/ 
Pten-Null Genetically Driven Model. a-b. Overall survival of Tyr::CreER; BrafV600E/+; 
Ptenlox/+ (a) and Tyr::CreER; BrafV600E/+; Ptenlox/lox  (b)  C57BL/6 mice following general 
melanoma induction by intraperitoneal administration of 4-hydroxytamoxifen (4-HT) (25 
mg/kg) on three consecutive days. After the first 4-HT injection, mice were randomly 
assigned to a control diet or a diet supplemented with GW3965 (100 mg/kg). n ≥ 10 (a), 
 n ≥ 7 (b). c. Melanoma tumor burden, expressed as the percentage of dorsal skin area, 
measured on day 35 in Tyr::CreER; BrafV600E/+; Ptenlox/lox  mice administered a control chow 
or a chow supplemented with GW3965 (100 mg/kg) upon melanoma induction. n ≥ 4.  
d. Number of macroscopic metastatic nodules in the salivary gland lymph nodes detected 
post-mortem in Tyr::CreER; BrafV600E/+; Ptenlox/lox mice that were fed a control chow or a 
chow containing GW3965 (100 mg/kg) following global melanoma induction as described in 
(a). n ≥ 7. Error bars = SEM.  Scale bar, 2 mm. *p < 0.05. p-values based on Mantel-Cox 
tests (a, b) or unpaired student’s t-tests (c, d). 
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The cooperativity between B-Raf activation and Pten loss in driving melanoma 
progression can be further enhanced by inactivation of CDKN2A, a cell cycle regulator 
frequently mutated in familial melanomas (Hussussian et al., 1994; Kamb et al., 1994).  We 
thus examined the effect of LXR activation on B-RafV600E/+; Pten-/-; CDKN2A-/- melanomas, 
allowing us to test the therapeutic efficacy of LXR agonism in this more aggressive 
genetically driven melanoma progression model. Importantly, therapeutic administration of 
GW3965 robustly inhibited primary tumor progression and lung colonization by B-RafV600E/+; 
Pten-/-; CDKN2A-/- primary mouse melanoma cells injected into syngeneic immunocompetent 
mice. LXR agonist treatment also extended the survival times of mice bearing B-RafV600E/+; 






































Figure 5.21. LXR Agonist Therapy Suppresses Melanoma Progression in a B-RafV600E/ 
Pten-Null/ CDKN2A-Null Genetic Model. a. Tumor growth by 1 × 105 BrafV600E/+; Pten-/-; 
CDKN2A-/- primary melanoma cells (designated as YUMM) subcutaneously injected into 
syngeneic C57BL/6-WT mice that were treated with a control diet or a GW3965 diet (100 
mg/kg). n ≥ 16. b. Overall mouse survival following subcutaneous injection of 1 × 105 
YUMM cells and mouse treatment with a control diet or a GW3965 diet (100 mg/kg) as 
indicated. n ≥ 7. c. Lung colonization by 1 × 105 YUMM cells intravenously injected into 
C57BL/6-WT mice. Immediately following cancer cell injection, mice were randomly 
assigned to a control diet or a GW3965-supplemented diet (100 mg/kg). n ≥ 14. Data are 
displayed as mean ± SEM. Scale bar, 5 mm. *p < 0.05; ****p < 0.0001. p-values based on an 
unpaired student’s t-test (a), Mantel-Cox test (b), or Mann-Whitney’s t-test (c) 
 
	   142 
ApoE Activation Therapy Inhibits Melanomas Resistant to Mainstay Therapeutics 
Dacarbazine and Vemurafenib 
Dacarbazine (DTIC) and vemurafenib represent two of the modern frontline agents 
used for the treatment of metastatic melanoma. DTIC is a chemotherapeutic alkylating agent 
that inhibits tumor growth by incurring DNA damage in tumor cells. It was FDA-approved in 
the early 1970s based on its demonstrated improvement of overall response rates and, for a 
long time, DTIC was the only available therapeutic to metastatic melanoma patients. 
However, large randomized clinical trials have failed to find any significant effects of DTIC 
on overall patient survival (Chapman et al., 1999; Middleton et al., 2000), as the majority of 
DTIC-treated melanoma patients quickly develop resistance to this chemotherapeutic. For 
these reasons, we sought to determine whether melanomas that had acquired resistance to 
DTIC could still respond to LXRβ activation therapy. We generated B16F10 clones resistant 
to DTIC by continuously culturing melanoma cells in the presence of DTIC for two months, 
yielding a sub-line that exhibited a 7-fold increase in survival capacity when cultured in high-
dose DTIC in vitro (Figure 5.22a). Accordingly, DTIC treatment in vivo significantly 
suppressed tumor growth by the parental line (Figure 5.22b), whereas it had no effect on the 
growth of the DTIC-resistant sub-line (Figure 5.22c). Importantly, GW3965 administration 
robustly suppressed tumor growth by the DTIC-resistant sub-line by more than 70% (Figure 
5.22c). Additionally, we confirmed the suppressive effect of GW3965 in an independent in 
vivo selected DTIC-resistant human melanoma sub-line, as evidenced by the strong inhibition 
(~70%) of DTIC-resistant tumors upon oral delivery of GW3965 (Figure 5.22d-e).  
We next tested the impact of LXRβ activation therapy on melanoma cells resistant to 
the recently approved B-Raf kinase inhibitor, vemurafenib—a regimen that shows activity 
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against B-Raf-mutant melanomas on both overall response rates as well as survival outcomes 
(Chapman et al., 2011; Sosman et al., 2012). However, this targeted therapeutic is notorious 
for resistance emergence, with more than 90% of treated melanoma tumors acquiring drug 
resistance after prolonged vemurafenib treatment. To this end, numerous investigators have 
derived melanoma lines resistant to vemurafenib (Poulikakos et al., 2011; Shi et al., 2012; 
Das Thakur et al., 2013; Haq et al., 2013). To test whether LXR agonist treatment exhibited 
activity in vemurafenib-resistant melanomas, we obtained two previously derived 
independent SK-Mel-239 vemurafenib-resistant clones (C1 and C5), which attain resistance 
to vemurafenib through distinct molecular mechanisms (Poulikakos et al., 2011). Notably, 
GW3965 treatment suppressed the growth of tumors formed by both the C1 and C5 clones by 
72% and 39%, respectively (Figure 5.23a, c) and significantly prolonged the survival of mice 
bearing vemurafenib-resistant melanoma burden (Figure 5.23b). Treatment also significantly 
inhibited tumor growth by the A375 vemurafenib-resistant human melanoma sub-line that we 
independently generated (Figure 5.23d). Additionally, we generated a vemurafenib-resistant 
sub-line from B-Raf-mutant primary mouse melanoma cells following in vivo treatment of 
tumors with vemurafenib  (Figure 5.23e), thereby allowing us to test the effect of LXRβ 
agonism on vemurafenib-resistant melanoma cells in an immunocompetent syngeneic mouse 
model.  We observed that even though vemurafenib was ineffective in suppressing melanoma 
progression by the resistant sub-line, GW3965 administration led to a greater than 50% 
reduction in tumor growth (Figure 5.23f). 
These results reveal that LXRβ agonism is effective in suppressing multiple 
melanoma sub-lines resistant to the widely used B-Raf kinase inhibitor vemurafenib and the 
sole FDA-approved cytotoxic chemotherapeutic in melanoma, dacarbazine. Our findings 
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have important clinical implications for melanoma treatment since nearly all stage IV 
metastatic patients who are treated with dacarbazine and/or vemurafenib ultimately relapse 
and experience lethal melanoma progression as a direct consequence of resistance emergence 


















Figure 5.22. LXR Agonist Treatment Suppresses Melanomas Resistant to the 
Chemotherapeutic Dacarbazine. a. In vitro cell growth by 2.5 × 104 B16F10 parental and 
DTIC-resistant cells in response to increasing doses of DTIC added to the cell media for 4 
days. n = 3. b-c. Tumor growth by 5 × 104 B16F10 parental cells (b) or 5 × 104 DTIC-
resistant B16F10 cells (c) subcutaneously injected into C57BL/6-WT mice. Following tumor 
growth to 5-10 mm3 in volume, mice were treated with a control vehicle, dacarbazine (50 
mg/kg, i.p., daily), or GW3965-supplemented diet (100 mg/kg). n ≥  7. d-e. Tumor growth by 
5 × 105 MeWo parental cells (d) and 5 × 105 in vivo-selected DTIC-resistant MeWo human 
melanoma cells (e) in response to DTIC (50 mg/kg, i.p., daily, 5 days on, 2 days off) or 
GW3965 (100 mg/kg) treatments. n ≥ 6. All data are represented as mean ± SEM. Scale bars, 
5 mm. *p < 0.05; **p < 0.01; ****p < 0.0001. p-values based on unpaired student’s t-tests. 







Figure 5.23. LXR Agonist Treatment Suppresses Melanomas Resistant to Vemurafenib. 
a, c. Tumor growth by 2 × 106 SK-Mel-239 vemurafenib-resistant sub-lines, clone 1 (C1) (a) 
or clone 5 (C5) (c), subcutaneously injected into NOD SCID gamma mice that were assigned 
to a control diet or a GW3965 diet (100 mg/kg), as indicated. n ≥ 7 (a), n = 5 (c). b. Overall 
mouse survival post-grafting of 2 × 106 SK-Mel-239 vemurafenib-resistant C1 cells onto 
mice treated with a control diet or a GW3965 diet. n = 7. d. Tumor growth by 5 × 105 
vemurafenib-resistant A375 melanoma cells upon treatment with a control diet, GW3965 diet 
(100 mg/kg), or a vemurafenib diet (50 mg/kg), as indicated. n ≥ 6.  e. Tumor growth by 1 × 
105 vemurafenib-sensitive B-Raf-mutant primary mouse YUMM melanoma cells. Cells were 
subcutaneously implanted onto C57BL/6 mice that were treated with a vemurafenib diet 
following detection of palpable tumors (5-10 mm3 in volume). Melanoma cells were 
dissociated from vemurafenib-resistant tumors that eventually grew in the presence of 
vemurafenib at day 52, as indicated in the figure. n ≥ 8. f. Tumor growth by 2 × 105 
vemurafenib-resistant YUMM cells subcutaneously grafted onto C57BL/6 mice. Following 
formation of palpable tumors, mice were administered a control diet, vemurafenib diet (50 
mg/kg), or a GW3965 diet (100 mg/kg). n ≥ 8. All data are represented as mean ± SEM. 
Scale bar, 5 mm. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. p-values based on 
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Cooperativity between LXRβ Activation Therapy and Mainstay Melanoma Therapeutics 
Given that the median survival time of advanced melanoma patients rarely exceeds 
two years even with present FDA-approved therapeutics, owing to limited response rates 
and/or emergence of resistance to single-agent treatments, we wondered whether combining 
LXRβ/ApoE activation therapy with modern frontline agents could provide further 
therapeutic benefit. To this end, we examined whether LXR agonist therapy can elicit 
additive melanoma-suppressive responses when combined with any of the three FDA-
approved therapeutics for the treatment of metastatic melanoma: dacarbazine, vemurafenib, 
and the anti-CTLA-4 antibody (Ab). Remarkably, we found that combining GW3965 
treatment with either dacarbazine, vemurafenib, or anti-CTLA-4 Ab led to greater melanoma 
suppression that each treatment alone (Figures 5.24, 5.25, 5.26).   
For instance, while either GW3965 or DTIC treatment alone inhibited B16F10 
melanoma growth by 65% and 70%, respectively, combined GW3965 and DTIC therapy led 
to greater than 90% suppression of tumor growth (Figure 5.24a). We further found that 
combined GW3965 and vemurafenib treatment suppressed tumor progression by the B-Raf-
mutant A375 line by 82%, which exceeded the inhibition of tumor growth seen with each 
drug alone: 44% for GW3965 and 65% for vemurafenib (Figure 5.24b). Additionally, 
alternating vemurafenib and LXR agonist therapy was more effective (~72% inhibition) in 
suppressing tumor growth by the independent B-Raf-mutant SK-Mel-239 line compared to 
single-agent GW3965 (56% inhibition) or vemurafenib (50% inhibition) treatment (Figure 
5.24d). Importantly, combined GW3965 and vemurafenib therapy also improved survival 
outcomes in these models relative to each drug alone (Figures 5.24c, e).  
 







Figure 5.24. LXR Agonist Treatment Cooperates with Dacarbazine and Vemurafenib 
in Suppressing Melanoma Tumor Growth. a. Primary tumor growth by 5 × 104 B16F10 
mouse melanoma cells grafted onto C57BL/6-WT mice. Following formation of tumors 
measuring 5-10 mm3 in volume, mice were randomly assigned to a control treatment, 
GW3965 diet (100 mg/kg), DTIC (50 mg/kg, i.p., daily), or combined GW3965 (100 mg/kg) 
and DTIC (50 mg/kg) treatment. n ≥ 8. b. 8 × 105 B-Raf-mutant A375 human melanoma cells 
were subcutaneously injected into immunocompromised mice, and melanoma tumor 
progression was monitored in response to a control diet, GW3965 diet (75 mg/kg), 
vemurafenib diet (50 mg/kg), or a combined GW3965 (75 mg/kg) and vemurafenib (50 
mg/kg) diet treatment. n ≥ 8. c. Overall post-tumor survival of mice bearing A375 melanoma 
tumor burden in response to the various treatments shown in (b).  n ≥ 4. d. Subcutaneous 
tumor growth by 1.25 × 106 B-Raf-mutant SK-Mel-239 human melanoma cells in response to 
a control diet, GW3965 diet (75 mg/kg), vemurafenib diet (50 mg/kg), or an alternating 
vemurafenib/GW3965 diet treatment, as indicated. n ≥ 8. e. Overall post-tumor survival of 
mice following subcutaneous grafting of SK-Mel-239 melanoma cells in response to the 
various treatments shown in (d). n ≥ 7. Error bars = SEM. Scale bar, 5 mm. *p < 0.05,  
**p < 0.01, ***p < 0.001, ****p < 0.0001. p-value based on unpaired student’s t-tests (a, b, 















































Figure 5.24. LXR Agonist Treatment Cooperates with Dacarbazine and Vemurafenib 
in Suppressing Melanoma Tumor Growth 
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The melanoma-suppressive cooperativity between vemurafenib and GW3965 was 
also seen in lung colonization assays. Whereas vemurafenib and GW3965 each suppressed 
metastasis of the B-Raf-mutant primary SK-Mel-334.2 melanoma line by roughly 50%, 
combined treatment led to a greater than 85% inhibition (Figure 5.25a). Additionally, 
GW3965 and vemurafenib each also inhibited lung colonization by the independent B-Raf-
mutant HT-144 melanoma cells by 84% and 76%, respectively, while the combined therapy 









Figure 5.25. Cooperativity between LXRβ Activation and Vemurafenib in Suppressing 
Melanoma Metastasis. a. Lung colonization by 1 × 105 primary B-Raf-mutant SK-Mel-
334.2 human melanoma cells in response to a control diet, GW3965 diet (75 mg/kg), 
vemurafenib diet (50 mg/kg), or a combined GW3965 and vemurafenib diet treatment. Lung 
colonization was assessed by weekly bioluminescence imaging. Various treatments were 
initiated 3 days preceding cancer cell injection. n ≥  5.b. Lung colonization by 7.5 × 104 B-
Raf-mutant HT-144 human melanoma cells measured by bioluminescence imaging at day 33. 
Melanoma cells were intravenously injected into immunocompromised mice that were 
administered a control diet, GW3965 diet (75 mg/kg), vemurafenib diet (50 mg/kg), or a 
combined GW3965 and vemurafenib diet, starting 3 days prior to cancer cell injection. n ≥  
5. All data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, based on 
Mann-Whitney’s t-tests. 
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Finally, we examined the impact of combining GW3965 treatment with 
immunomodulatory anti-CTLA-4 therapy on melanoma progression. Consistent with earlier 
findings (van Elsas et al., 1999), we observed roughly 20% suppression of tumor growth in 
response to anti-CTLA-4 Ab monotherapy in the syngeneic immunocompetent B16F10 
melanoma murine model (Figure 5.26a). In comparison, GW3965 therapy inhibited B16F10 
tumor growth by over 60%. Remarkably, combining the LXR agonist treatment with the anti-
CTLA-4 Ab elicited a greater than 80% inhibition in tumor growth, revealing additivity 
between the effects of GW3965 treatment and anti-CTLA-4 Ab therapy (Figure 5.26a). 
Importantly, combined GW3965 and anti-CTLA-4 Ab treatment significantly improved 













Figure 5.26. Additive Effects of LXRβ Activation and Immunotherapy in Melanoma. 
a. Tumor growth by 5 × 104 B16F10 cells grafted onto C57BL/6-WT mice in response to a 
control diet/IgG treatment, GW diet/IgG treatment, anti-CTLA-4 Ab monotherapy, anti-
CTLA-4 Ab + GM-CSF vaccine treatment, or anti-CTLA-4 Ab + GW3965 combined 
therapy. n ≥ 8. b. Overall post-tumor survival of mice bearing B16F10 tumors in response to 
anti-CTLA-4 Ab or GW3965 monotherapy or anti-CTLA-4 Ab + GW3965 combined 
therapy.  n ≥ 8. Error bars = SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.  
p-values based on student’s t-tests (a) or Mantel-Cox tests (b). 
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Summary of Findings form Chapter V 
This chapter describes our experimental efforts to activate ApoE expression as a new 
therapeutic approach in metastatic melanoma. To this end, we identified a transcriptional 
activator of ApoE, the nuclear hormone receptor LXRβ, as a new therapeutic target that 
exhibits ubiquitous expression in melanoma tumors. We showed that pharmacologic LXR 
activation robustly suppressed melanoma progression phenotypes of invasion, endothelial 
recruitment, tumor growth, and metastasis across multiple pre-clinical melanoma models of 
diverse mutational backgrounds. LXR activation inhibited melanoma progression in 
xenograft, immunocompetent, and genetically driven mouse models of melanoma.  Through 
a series of molecular and genetic experiments, we identified LXRβ as the LXR isoform that 
mediates the effects of LXR agonists on melanoma suppression. Next, we demonstrated that 
the melanoma-suppressive effects of LXRβ agonism were mediated through the 
transcriptional activation ApoE. We further validated the robustness of LXRβ activation as a 
new promising therapeutic approach by showing that LXR agonism suppressed melanoma 
brain metastasis, which presently lacks effective therapies, and also inhibited melanomas 
resistant to the mainstay melanoma therapeutics dacarbazine and vemurafenib. Finally, we 
investigated whether LXR activation could elicit additive responses in suppressing melanoma 
progression upon its combination with present frontline agents used to manage metastatic 
melanoma. Remarkably, we observed melanoma-suppressive cooperativity upon combining 
LXRβ therapy with each of the three frontline melanoma regimens—dacarbazine, B-Raf 
inhibition, and immunotherapy. Our findings implicate LXRβ agonism as a promising 
therapeutic approach for the treatment of metastatic melanoma. 
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CHAPTER VI: DISCUSSION 
 
Overview of Major Findings 
The complexity and heterogeneity of human cancers necessitate the application of 
systematic and global analyses addressing multiple aspects of cancer progression. In this 
thesis, I describe a functionally guided systematic approach that led to the identification of 
endogenous metastasis regulatory miRNAs and effector genes in human melanoma. We 
identified three miRNAs (miR-199a-3p, miR-199a-5p, and miR-1908) that displayed broad 
and robust upregulation across multiple metastatic melanoma sub-lines, which were 
generated by in vivo selection of amelanotic and melanotic melanoma cell populations 
derived from independent patients. Consistent with their pervasive upregulation in metastatic 
melanoma cells of diverse mutational backgrounds and pigmentation status, we found that 
the three miRNAs can act as strong pathologic predictors of human melanoma metastatic 
recurrence. Importantly, targeting of these miRNAs using therapeutic LNA technology 
strongly suppressed metastasis in a pre-clinical melanoma model.  
By performing global transcriptomic analyses, we uncovered DNAJA4 and ApoE, 
genes with previously unknown roles in metastasis, as common molecular targets and 
functional effectors of miR-199a-3p, miR-199a-5p, and miR-1908 in melanoma metastasis. 
Furthermore, we found that ApoE was positively regulated by DNAJA4, revealing an 
additional level of convergence and highlighting the central role of ApoE in this metastasis 
regulatory pathway (Figure 6.1). Accordingly, we observed reduced ApoE protein expression 
levels in clinical melanoma metastases relative to primary melanoma lesions, while low 
ApoE expression in patients’ primary tumors significantly correlated with an increased risk 
of metastatic recurrence. The clinical relevance of ApoE expression to melanoma metastasis 
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motivated us to examine the mechanistic underpinnings of ApoE’s effects in melanoma. We 
found that extracellular ApoE exerted dual cell autonomous/non-cell-autonomous effects on 
melanoma progression: ApoE targeting of melanoma cell LRP1 receptors inhibited 
melanoma invasion, while ApoE targeting of endothelial cell LRP8 receptors suppressed 
endothelial cell migration/ recruitment (Figure 6.1). The metastasis-suppressive function of 
ApoE was further supported by our findings that genetic inactivation of stromal ApoE 
accelerated melanoma metastasis, indicating that both melanoma-derived and stromally 











                                         Adapted from Pencheva et al., Cell, 2012 
Figure 6.1. Convergent Regulation of Melanoma Metastasis by Multiple miRNAs. 
Experimentally elucidated model of multi-miRNA targeting of DNAJA4 and ApoE in 
melanoma metastasis. DNAJA4 was found to induce ApoE expression. Melanoma cell-
secreted ApoE was shown to exert dual cell-autonomous and non-cell-autonomous effects: 
ApoE inhibits melanoma invasion by acting on melanoma cell LRP1 receptors, whereas it 
blocks endothelial recruitment by targeting endothelial cell LRP8 receptors. 
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In light of the robust suppression exerted by ApoE on melanoma metastasis, we 
investigated therapeutic approaches to chronically activate ApoE expression in melanoma 
progression. While searching for ubiquitously expressed molecules that could activate ApoE 
expression upon pharmacologic modulation, we identified an ApoE transcriptional trans-
activator, the nuclear hormone receptor LXRβ, as a novel therapeutic target in metastatic 
melanoma. We showed that, in addition to its known ubiquitous expression across tissues 
(Song et al., 1994), LXRβ was also ubiquitously expressed across human melanoma tumors, 
regardless of their progression stage.  Consistent with its stable expression, therapeutic 
agonism of LXRβ displayed broad-spectrum activity in suppressing melanoma progression 
across diverse immunocompetent, xenograft, and genetically-driven melanoma models. 
LXRβ activation also displayed activity in inhibiting melanomas that had acquired resistance 
to frontline therapeutic agents, dacarbazine and vemurafenib. Importantly, we showed that 
the melanoma-suppressive activity of LXRβ activation therapy was mediated through the 
downstream induction of ApoE, which was derived from both melanoma (tumor-intrinsic) 
and stromal (tumor-extrinsic) tissue compartments (Figure 6.2).  
Our systematic interrogation of molecular pathways regulating melanoma metastasis 
has culminated in the discovery of LXRβ activation therapy as a promising new approach for 
the treatment and prevention of melanoma metastasis. The therapeutic potential of ApoE 
activation therapy in melanoma is further underscored by our observations of strong tumor-
suppressive cooperativity upon combining LXR agonist treatment with either of the three 
mainstay melanoma therapeutics: chemotherapy, B-Raf kinase inhibition, and 
immunotherapy. 
 















                                                                Adapted from Pencheva et al., Cell, 2014 
 
Figure 6.2. Suppression of Melanoma Progression by LXR/ApoE Activation.  Schematic 
depicting the experimentally derived model of the basis of action of LXRβ activation therapy 
in melanoma. The LXR agonist treatment activates LXRβ, which in turn induces ApoE 
expression both in melanoma cells as well as in various stromal tissue cells. The LXRβ-
dependent augmented expression of extracellular ApoE mediates suppression of melanoma 
progression phenotypes and extends animal survival times across various pre-clinical models 
of melanoma progression. 
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Role of Metastasis Regulatory miRNAs in Development  
While there is presently a lack of experimental evidence to support a role for miR-
199a-3p/miR-199a-5p/miR-1908 in regulating melanocyte development and differentiation, 
we speculate that the miRNAs’ ability to promote melanoma invasion and metastasis may 
stem from developmentally conserved programs allowing these miRNAs to regulate 
melanocyte migration during the course of normal development. Melanoblasts, the precursors 
for melanocytes, originally arise from the neural crest and are faced with the challenge to 
migrate over extensive distances in the body as they spread to peripheral skin. Therefore, 
melanoblasts likely possess intrinsic mechanisms governing their highly migratory nature 
during development. It is conceivable that the same pathways that regulate melanoblast 
migration (and are subsequently switched off in differentiated melanocytes) may be hijacked 
and reactivated by melanoma cells in facilitating their migration and invasion during 
metastatic dissemination throughout the body. It will be of interest for future studies to 
determine whether the three miRNAs impact melanocyte migration and examine the 
dynamics of their expression during melanoblast formation, migration, and subsequent 
differentiation into melanocytes.  
Previous studies have implicated roles for miR-199a-3p and miR-199a-5p in 
cardiomyocyte development and regeneration. For instance, a recent study demonstrated that 
miR-199a-3p plays a role in promoting neonatal cardiomyocyte proliferation and neonatal 
cardiac size, whereas introduction of miR-199a-3p in adult cardiomyocytes triggered cell 
cycle re-entry and cardiac regeneration following myocardial infraction (Eulalio et al., 2012). 
Similar to miR-199a-3p, miR-199a-5p has also been implicated in cardiac physiology by 
studies showing that miR-199a-5p may play a role in increasing cardiac cell size, while the 
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expression levels of miR-199a-5p were found to be upregulated during cardiac hypertrophy, 
a condition marked by an increase in heart size (Song et al., 2010). Consistent with a role for 
miR-199a in heart physiology, we detected high expression levels of mature miR-199a-3p 
and miR-199a-5p in mouse cardiac tissues (Figure 2.20b). Whereas the mouse homolog for 
miR-1908 was presently unknown at the time, we also detected expression of miR-1908, 
using human primers, in mouse heart tissue (Figure 2.20b), suggesting that the mouse miR-
1908 sequence is conserved with its human homolog and it is also expressed in the heart.  
Interestingly, we did not however detect expression of miR-1908 in the liver, implying that 
its expression may be at least in part restricted to the heart. The high expression of the three 
miRNAs in cardiac tissue suggests that they may play a prominent role in cardiomyocyte 
physiology. Given that cardiomyocyte migration has been linked to heart regeneration (Itou 
et al, 2012), it is possible that miR-199a (and possibly miR-1908) may promote cardiac 
regeneration through their effects on cardiomyocyte migration.  
Finally, while the effects of genetically inactivating miR-199a or miR-1908 on 
embryonic and/or post-embryonic development are presently unknown, there is some 
evidence that miR-199a is most highly expressed at mouse embryonic stage E12.5 and its 
expression is preferentially restricted to the mouse cerebellum, midbrain, nasal processes, 
and the fore- and hindlimb buds (Lee et al., 2009). Additionally, homozygous deletion of a 
region on chromosome one, encoding the miR-199a-2 paralog and its polycistronic partner, 
miR-214, was found to be post-embryonically lethal in the majority of cases, with pups dying 
within one month after birth. It was observed that pups lacking miR-199a-2/miR-214 
exhibited impaired skeletal development, including craniofacial hypoplasia and abnormalities 
in the dorsal neural arches and vertebrae spine formation (Watanabe et al., 2008). However, 
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in addition to miR-199a-2 loss, these mice also lacked miR-214, while the other miR-199a 
paralog, miR-199a-1, was presumably still expressed, confounding any potential 
interpretation of the specific role that mature miR-199a may play in embryonic and post-
embryonic development. In order to get a better understanding of how this multi-miRNA 
network has evolved to regulate melanoma metastasis, it will be important for future studies 
to address the functions of these miRNAs and their downstream targets in development and 
how they become co-opted during melanoma progression.  
 
Convergent versus Divergent Target Regulation by miRNAs 
The majority of past work on metastasis regulatory miRNAs has revealed divergent 
gene targeting to be the pervasive mode of regulation exerted by miRNAs on metastatic 
progression. This was initially demonstrated for miR-335 (Tavazoie et al., 2008) and 
subsequently shown to be the preferred mode of action for many other miRNAs in metastasis 
regulation, such as miR-31 (Valastyan et al., 2009b), miR-126, (Png et al., 2012), let-7 (Yun 
et al., 2011), and miR-9 (Ma et al., 2010b). In each of these instances, a single miRNA 
exerted robust metastasis control through the coordinate repression of multiple target genes. 
Since each of these target genes contributed to the metastasis phenotype, their concurrent 
silencing by the miRNA inflicted greater metastasis-promoting or metastasis-suppressive 
effects, respectively, compared to each target alone. This divergent mode of gene targeting 
by individual miRNAs likely arose through evolution and plays an important role during 
normal development, allowing certain miRNAs to fine-tune physiological processes through 
their ability to simultaneously modulate the expression of multiple downstream effector gene. 
For instance, miR-199a was recently found to be essential for neonatal cardiac cell 
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proliferation as well as cardiac cell regeneration in adult mice through its additive effects on 
multiple downstream target genes (Eulalio et al., 2012). Co-option of such divergent 
miRNA-target gene connectivity in cancer progression likely confers pervasiveness to the 
post-transcriptional control exerted on gene networks in metastasis, whose complexity 
requires the concerted action of multiple gene products.    
On the contrary, convergent target gene regulation by multiple distinct miRNAs is a 
molecular phenomenon only recently implicated in cancer progression, and its pervasiveness 
in the metastasis control of multiple cancer types remains to be seen. In addition to our 
findings of convergent miRNA regulation as a driving force in melanoma metastasis, recent 
work described miRNA cooperativity in an in vitro-based cell model of T-cell acute 
lymphoblastic leukemia (T-ALL). Combinatorial silencing of multiple miRNAs 
cooperatively decreased T-ALL cell proliferation and viability in vitro and increased 
expression of common target genes to an extent greater than that seen with silencing of any 
individual miRNA (Mavrakis et al., 2011), thereby allowing for a more robust gene 
expression control than that afforded by each single miRNA. Convergent miRNA regulation 
is not unique to cancer cells. Similar to divergent miRNA targeting, the need for convergent 
post-transcriptional gene regulation has presumably emerged developmentally and has been 
evolutionarily conserved to allow for multi-layered temporal fine-tuning of essential target 
genes’ expression. Consistent with this, examples of multi-miRNA convergence onto a 
common target gene are seen in neural development (Yoo et al., 2009; Clovis et al., 2012). 
For instance, convergent repression of BAF53a, a subunit of the SWI/SNF chromatin 
remodeling complex, by miR-24 and miR-9-3p was shown to mediate the key molecular step 
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in the transition of multipotent neural progenitor cells to post-mitotic neurons that give rise to 
stable dendritic connections in the developing vertebrate system (Yoo et a., 2009). 
 
Therapeutic Potential of miRNA Targeting 
The robust metastasis control afforded by specific miRNAs as well as their ability to 
act as strong pathologic predictors of human cancer outcomes has triggered extensive clinical 
interest in therapeutically targeting these small RNAs in metastasis (Ling et al., 2013). 
Despite the discovery of multiple miRNAs governing various aspects of cancer biology, the 
clinical translation of miRNA-based therapies has been hindered by two main issues: the 
limited half-life of systemically administered miRNAs and their insufficient delivery into 
target tissues. Two recent reports, which described an alternative approach to “naked” 
nucleic acid delivery through viral-based delivery of miRNAs, have offered renewed promise 
for the prospect of in vivo miRNA-based therapies (Kota et al., 2009; Miyazaki et al., 2012). 
Using an adeno-associated viral-based approach, therapeutic delivery of the metastasis 
suppressor miR-26a was found to significantly inhibit the formation and progression of 
hepatocellular carcinoma (HCC) in a pre-clinical murine model (Kota et al., 2009). In 
addition to viral-based delivery methods, miRNA mimics can also be formulated in 
liposome-based nanoparticles, which are coated with tumor specific antibodies, ensuring 
specific delivery into target tumors (Ling et al., 2013). This approach has yielded the first 
clinically developed miRNA-based therapeutic, MRX34—a liposome-encapsulated mimetic 
for miR-34a, a tumor-suppressive miRNA that is transcriptionally induced by p53 (Chang et 
al., 2007).  Pre-clinical findings of reduced tumor growth and enhanced survival in a murine 
model of hepatocellular carcinoma in response to intravenous administration of MRX34 
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motivated the evaluation of this miRNA mimetic agent in the clinic (Bader, 2012). 
Accordingly, MRX34 entered phase I clinical trial testing in the spring of 2013. 
The in vivo inhibition of miRNAs has also shown great promise in pre-clinical arenas 
and is actively pursued in clinical studies. The development of locked nucleic acid (LNA) 
technology for the targeting of specific mature miRNAs has spearheaded the experimental 
assessment of miRNA inhibition as a potential therapeutic approach across various disease 
contexts. LNAs are short anti-sense oligonucleotides that display high affinity for single-
stranded RNAs, enhanced serum stability owing to their short sequence and  “locked” ribose 
ring, and efficient delivery into target tissues (Obad et al., 2011). In a series of seminal 
papers, systemic delivery of an LNA targeting the cholesterol regulatory miR-122 was shown 
to significantly decrease plasma cholesterol levels in non-human primates (Elmén et al., 
2008), whereas targeting this same miRNA in a primate model of hepatitis C virus (HCV) 
replication was found to suppress HCV viremia (Lanford et al., 2010).  Based on its pre-
clinical promise, an LNA antisense to miR-122, termed miravirsen, was the first miRNA-
targeted inhibitor to be clinically developed. Miravirsen was recently evaluated in a phase 2 
clinical trial for the treatment of HCV infection and showed promising results in suppressing 
HCV propagation in patients (Janssen et al., 2013). 
Following the initial success in efficiently targeting miR-122 for the in vivo inhibition 
of HCV propagation, therapeutic delivery of LNAs antisense to metastasis-promoting 
miRNAs was also shown to display metastasis-suppressive activity in pre-clinical models of 
cancer metastasis (Ling et al., 2013). Proof-of-principle evidence for the feasibility of LNA-
based miRNA targeting for the inhibition of cancer metastasis was initially demonstrated for 
miR-10b, the first metastasis-promoter miRNA to be described (Ma et al., 2007). In that 
	   163 
study, systemic delivery of an LNA targeting miR-10b was found to modestly suppress 
metastasis in a murine model of breast cancer (Ma et al., 2010a).  
The results described in this thesis provide further evidence that LNA-based miRNA 
targeting displays therapeutic potential for the prevention of human melanoma metastasis, a 
dreaded and aggressive disease that currently lacks effective preventative and/or curative 
therapies (Garbe et al., 2011). Remarkably, we found that combinatorial transfection of 
LNAs targeting miR-199a-3p, miR-199a-5p, and miR-1908 robustly suppressed lung 
colonization across a multitude of human melanoma cells of diverse mutational backgrounds 
(Figures 2.16-2.18). Importantly, therapeutically silencing these miRNAs by intravenous 
administration of a cocktail of such miRNA inhibitors at a low dose dramatically (> 12-fold) 
suppressed human melanoma metastasis in a mouse model (Figure 2.19).  These pre-clinical 
findings offer promise for the clinical development of combinatorial LNA-based miRNA 
inhibitors targeting miR-199a-3p, miR-199a-5p, and miR-1908 as potential new agents for 
the treatment of metastatic melanoma.  
 
Mechanisms Underlying miRNA Deregulation in Metastasis 
The emergence of miRNAs as essential regulators of tumor progression and 
metastasis triggered much interest in the upstream molecular mechanisms that give rise to 
deregulated expression of these tiny RNAs in human cancers. Multiple studies have shown 
that miRNA deregulation in cancer can be attained through diverse mechanisms, including 
genomic copy alterations, epigenetic changes, transcriptional regulation, and post-
transcriptional processing aberrations (Ma et al., 2007; Png et al., 2011; Kumar et al., 2007). 
We herein found that upregulation of miR-199a-3p, miR-199a-5p, and miR-1908 in 
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metastatic melanoma cells was attained through a combination of transcriptional and post-
transcriptional/processing mechanisms.  By searching for transcription factor binding sites 
present in the promoter regions of miR-199a-1, miR-199a-2, and miR-1908, I identified 
CREB as a putative transcription factor that regulates the expression of miR-199a-3p, miR-
199a-5p, and miR-1908 in metastatic melanoma cells (Table 2.1, Figures 2.23-2.24). 
Consistent with our findings on the three miRNAs, CREB was previously implicated as a 
promoter of melanoma invasion and metastasis (Aucoin et al., 2004; Dobroff et al., 2009). 
While further ChIP experiments will be necessary to support a direct transcriptional 
interaction between CREB and the promoter regions of the three miRNAs in melanoma cells, 
our findings suggest that at least a part of the pro-invasive effects of CREB in melanoma may 
be mediated through the transcriptional induction of miR-199a-3p, miR-199a-5p, and miR-
1908.  
We observed that the levels of phosphorylated CREB were elevated in metastatic 
melanoma cells, suggesting one possible mechanism through which enhanced CREB activity 
might contribute to the elevated transcription of miR-199a-3p, miR-199a-5p, and miR-1908 
in highly metastatic melanoma cells. From a therapeutic standpoint, it will be of interest to 
identify the specific kinase that mediates phosphorylation and activation of CREB in 
metastatic melanoma cells. Small molecule-mediated inhibition of such a kinase could 
represent a viable therapeutic option in melanoma metastasis. The clinical interest in 
targeting CREB is further augmented by a recent report showing that elevated CREB 
activation conferred acquired resistance to the B-Raf kinase inhibitor vemurafenib in a subset 
of B-Raf-mutant melanomas (Johannessen et al., 2013). These findings raise the intriguing 
question of whether miR-199a-3p, miR-199a-5p, and miR-1908 become induced in 
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vemurafenib-resistant melanoma tumors following CREB activation and can thus contribute 
to the progression of vemurafenib-resistant melanomas. If this turns out to be the case, we 
hypothesize that potential vemurafenib resistance outcomes could be managed by LNA-
based combinatorial miRNA inhibition therapy. 
In addition to aberrant transcriptional regulation of miR-199a and miR-1908 in a 
subset of metastatic melanoma derivatives, we uncovered an important role for deregulated 
miRNA processing in metastatic melanoma. Our findings of increased mature to pri-miRNA 
expression ratios for miR-199a-3p and miR-199a-5p across all metastatic derivatives that we 
examined (Figure 2.27) suggest a pervasive deregulation in the processing of miR-199a-3p 
and miR-199a-5p in melanoma metastasis. In comparison, the mature to pri-miRNA 
expression ratios for miR-1908 were modestly elevated across the metastatic derivatives of 
the MeWo line, but not in the A375 metastatic variants, suggesting that overexpression of 
miR-1908 in the A375 metastatic cells might be primarily mediated transcriptionally. 
Interestingly, miR-1908 exhibited less pronounced upregulation (up to 5-fold) compared to 
that displayed by each miR-199a-3p (up to 100-fold) and miR-199a-5p (up to 10,000-fold) in 
metastatic melanoma cells, suggesting that aberrant miRNA processing may be a determinant 
of the substantially more dramatic overexpression observed for miR-199a-3p and miR-199a-
5p, which arise from the same precursor hairpin and are processed together. It will be of 
interest for future studies to explore the precise molecular step(s) in the miRNA processing 
pathway, at which potential deregulation occurs. Namely, a relevant question for future 
studies to address is whether the alteration happens at the pri-miRNA to pre-miRNA 
Drosha/DGCR8-mediated conversion, the nuclear to cytoplasmic pre-miRNA trafficking 
mediated by Exportin-5, or the Dicer/TARBP2-mediated cleavage of the pre-miRNA to 
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generate the mature miRNA. The fact that the miRNA overexpression observed in highly 
metastatic melanoma cells was restricted to a subset of four specific miRNAs suggests the 
effect to be mediated by miRNA-specific processing regulator(s) as opposed to global 
miRNA processing effectors such as Dicer or Drosha. Systematic computational and 
biochemical approaches should provide exciting insights into the precise molecular 
effector(s) responsible for the processing alteration(s) of miR-199a-3p, miR-199a-5p, and 
miR-1908 in metastatic melanoma cells. 
 
Implications for the ApoE Variants (ApoE2, ApoE3, ApoE4) in Melanoma Progression  
Prior to our discovery of ApoE as a metastasis suppressor in melanoma, the biological 
role of ApoE had been well established in other disease contexts such as cardiovascular and 
neurodegenerative disorders (Hatters et al., 2006; Corder et al., 1993). ApoE exists as a 
polymorphic molecule with three major variants. Of the three known human ApoE alleles 
(ApoE2, ApoE3, and ApoE4), ApoE3 exhibits the highest prevalence and is present in ~78% 
of the population (Hatters et al., 2006). The three isoforms are identical apart from two 
distinct residues at amino acid positions 112 and 158 in the N-terminal region, which 
contains the ApoE receptor-binding domain. These structural variations are thought to give 
rise to distinct functional attributes among the variants. Consistent with this, the three ApoE 
isoforms differ in their binding affinity for members of the LDL receptor family, lipoprotein-
binding preferences, and N-terminus stability. Namely, ApoE2 has 50- to 100-fold attenuated 
LDL receptor binding ability compared to ApoE3 and ApoE4 (Weisgraber et al., 1982), 
while ApoE4, unlike the other two variants, preferentially binds to large low-density 
lipoproteins (Weisgraber et al., 1990) and exhibits the lowest N-terminus stability (Morrow 
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et al., 2000). These functional differences confer pathophysiological properties to select 
ApoE isoforms. While ApoE3 is considered a neutral allele, ApoE2 is associated with type III 
hyperlipoprotenemia (Hatters et al., 2006) and ApoE4 represents the major known genetic 
risk factor for Alzheimer’s disease (Corder et al., 1993) and also correlates with a modestly 
increased risk of developing cardiovascular disease (Luc et al., 1994). Our findings from 
melanoma cell lines homozygous for the ApoE3 allele and observations on recombinant 
ApoE3’s melanoma-suppressive activity are consistent with sufficiency of ApoE3 in 
suppressing melanoma metastasis. 
It will be of interest in the future to determine whether ApoE2 and ApoE4 can 
suppress pro-metastatic melanoma progression phenotypes to an extent similar to that 
observed for ApoE3. Additionally, large-scale epidemiologic studies are necessary to 
establish whether specific ApoE genotypes might confer enhanced genetic risk of melanoma 
development and/or likelihood of metastatic progression. Another outstanding question to 
address will be whether LXRβ/ApoE activation therapy could elicit similar melanoma-
suppressive responses in patients harboring the low-prevalence hypomorphic ApoE2 or 
ApoE4 variants, in the case that ApoE2 and ApoE4 are found to display inferior activity in 
suppressing melanoma progression. Given that the majority of ApoE2 /ApoE4-expressing 
patients also express an ApoE3 allele, we speculate that they may at least partially respond to 
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LRP1/LRP8 Targeting by Extracellular ApoE 
Our findings reveal an essential role for extracellular ApoE in the suppression of 
melanoma progression phenotypes. ApoE can distribute in the circulatory system both in a 
lipoprotein-bound and a lipid-free state (Hatters et al., 2006).  While we have shown that 
lipid-free recombinant ApoE was sufficient to suppress melanoma invasion and endothelial 
migration, it is possible that ApoE contained in lipoprotein particles could also suppress 
melanoma invasion and endothelial recruitment, especially in light of the fact lipid-associated 
ApoE exhibits even greater affinity for its receptors compared to lipid-free ApoE (Hatters et 
al., 2006). The ability of recombinant ApoE to inhibit these pro-metastatic phenotypes as 
well as the increased melanoma invasion and endothelial recruitment phenotypes seen with 
antibody-mediated ApoE neutralization suggest that the ApoE molecule itself, rather than 
any associated lipid particle, is the key mediator of these phenotypes.  
Our findings elucidated a dual melanoma cell-autonomous/non-cell-autonomous 
mode of action for extracellular ApoE. Melanoma-derived ApoE suppressed melanoma cell 
invasion and cell-extrinsic endothelial recruitment through its divergent targeting of 
melanoma-cell LRP1 and endothelial-cell LRP8 receptors, respectively. Importantly, the 
engagement of these two receptors by ApoE in mediating metastasis suppression implicates 
LRP1 and LRP8 as novel endogenous suppressors of pro-metastatic phenotypes in 
melanoma. While further work is necessary to examine the molecular pathways downstream 
of each LRP1 and LRP8 that confer the ApoE-dependent effects on melanoma invasiveness 
and endothelial migration, the possible implications of ApoE/LRP8 and ApoE/LRP1 
targeting to the modulation of each respective phenotype are discussed below. 
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Implications for LRP8 Receptor Targeting to Tumor Angiogenesis 
The identification of LRP8 as the endothelial cell mediator of ApoE’s effects on non-
cell autonomous endothelial recruitment raises the interesting possibility that ApoE/LRP8 
targeting might modulate tumor angiogenesis in additional epithelial cancer types that 
express ApoE. Therefore, understanding the molecular role of LRP8 in regulating cancer 
angiogenesis may have mechanistic implications for tumor angiogenesis beyond melanoma. 
Our preliminary work revealed that ApoE/LRP8 targeting could regulate VEGFR2 
activation. Namely, we showed that treatment of human endothelial cells with ApoE blunted 
ligand-induced VEGFR2 activation in an LRP8-dependent manner (Figure 4.10a). We 
subsequently validated these results in primary mouse endothelial cells genetically 
inactivated for one or both copies of LRP8 (Figures 4.10b-c). Our results are consistent with 
a requirement for LRP8 in mediating the ApoE-dependent suppression of VEGFR2 
activation. Given that the VEGFR2 receptor, an extensively studied determinant of 
endothelial cell biology, has been shown to play an essential role in mediating endothelial 
cell migration (Olsson et al., 2006), we speculate that ApoE/LRP8 targeting may suppress 
endothelial cell migration by decreasing VEGFR2 activation.  
Additionally, we also observed that in primary mouse endothelial cells genetically 
inactivated for only one allele of LRP8, ligand-based VEGFR2 activation was increased at 
baseline relative to wild-type cells, indicative of a role for endogenous LRP8 in inhibiting 
VEGFR2 activation. Interestingly, this increase in VEGFR2 phosphorylation was not seen 
upon complete inactivation of LRP8, suggesting that the effect is specific to partial silencing 
of LRP8 (Figure 4.10c). How could one reconcile these observations? Given the well-known 
function of LDL receptors in endocytosis and lysosomal trafficking (Hussain et al., 1999) as 
	   170 
well as recent findings that some basal rate of VEGFR2 endocytotic recycling and dynamic 
turnover is necessary for optimum VEGFR2 receptor activity (Nakayama et al., 2013), we 
speculate that the inhibitory role of LRP8 in regulating VEGFR2 activation, unmasked upon 
loss of one LRP8 allele, may be offset by a potential LRP8-based stabilization of VEGFR2 
trafficking that is lost only upon full inactivation of LRP8. We hypothesize that LRP8 
directly or indirectly associates with VEGFR2 at clathrin-coated pits at the plasma 
membrane. Upon treatment with ApoE, the LRP8 receptor likely undergoes internalization 
and recruits VEGFR2, thereby decreasing the effective amount of VEGFR2 present at the 
plasma membrane that is available for extracellular ligand activation. Ultimately, this is 
reflected by a decrease in VEGF-induced receptor phosphorylation. Similarly, the partial 
reduction of LRP8 in LRP8-heterozygous endothelial cells might result in less VEGFR2 
being internalized, allowing for more receptors present at the plasma membrane to become 
phosphorylated upon ligand activation. However, full loss of LRP8 contrasts this. We 
speculate that the disinhibition of VEGFR2 activation seen in the LRP8 -/+ context is 
cancelled out by a potential VEGFR2 receptor destabilization, due to impaired receptor 
endocytotitc trafficking, in the LRP8-/- context, resulting in a net VEGFR2 phosphorylation 
outcome that resembles the wild-type context. Further experiments are necessary to establish 
LRP8 as a novel regulator of VEGFR2 and to either support or disprove the experimental 
hypothesis described above. Given the well-known functions of VEGFR2 during endothelial 
cell development and endothelial stalk/tip cell fate specification (Olsson et al., 2006), this 
work will potentially have important implications for both tumor angiogenesis as well as 
physiological angiogenesis. 
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Potential Mechanisms Downstream of ApoE/LRP1 Targeting in Melanoma Cells 
Unlike the identification of LRP8 as the single endothelial-cell downstream mediator 
of ApoE, the great molecular heterogeneity displayed by melanoma tumors makes it possible 
that, besides LRP1, additional melanoma-expressed ApoE receptors could mediate the ApoE 
response in melanoma cells from diverse patients. Nevertheless, our identification of LRP1 
as one such melanoma-expressed receptor that can mediate ApoE’s effects on melanoma cell 
invasiveness raises the interesting question of how LRP1 regulates invasion. Previous work 
showed that LRP1 associates with the platelet-derived growth factor receptor beta (PDGFRβ) 
in the endosomal compartments, and depletion of LRP1 enhanced expression and activation 
of PDGFRβ in mouse fibroblasts and smooth muscle cells (SMCs) (Boucher et al., 2003; 
Takayama et al., 2005; Muratoglu et al., 2010). Consistent with our findings of ApoE/LRP1-
mediated suppression of melanoma invasion (Figure 4.5), ApoE was previously shown to 
suppress PDGF-induced SMC migration, whereas depletion of LRP1 prevented the 
inhibitory effect of ApoE on PDGF-dependent SMC migration (Swertfeger et al., 2002). 
Additionally, independent of mediating ApoE’s effects, LRP1 inactivation alone increased 
SMC migration at baseline and in response to PDGF (Zhou et al., 2009). In light of the 
known role of the ApoE/LRP1 pathway in suppressing SMC migration, it will be of interest 
to evaluate the effects of ApoE/LRP1 targeting on melanoma cell migration. Given that cell 
invasion and migration are two phenotypes that are often coupled in cancer cells since a 
metastatic cancer cell typically must be able to also migrate as it invades into surrounding 
tissues (Ma etal., 2007; Huang et al., 2008; Tavazoie et al., 2008; Valastyan et al., 2009b), it 
is possible that ApoE targeting of LRP1 suppresses melanoma invasion and/or possibly 
migration by engaging PDGFRβ signaling, as previously described in SMCs. In light of the 
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reported association of LRP1 with PDGFRβ in endosomes (Muratoglu et a., 2010) and the 
disinhibition of PDGFRβ expression and signaling seen upon LRP1 inactivation in SMCs 
(Boucher et al., 2003; Zhou et al., 2009), an interesting emerging hypothesis is that the 
ApoE-dependent suppression of melanoma cell invasion may arise through an increase in 
LRP1-induced PDGFRβ endocytotic trafficking with a resulting decrease in cell-surface 
PDGFRβ activation and signaling.  
The potential involvement of PDGFRβ in the ApoE/LRP1-dependent effects on 
melanoma invasion and metastasis is especially relevant in light of recent findings that 
PDGFRβ overexpression could determine resistance emergence to B-Raf inhibition therapy 
in a subset of B-Raf-mutated melanoma patients (Nazarian et al., 2010). This raises the 
interesting possibility that LXRβ/ApoE activation therapy may suppress the progression of 
B-Raf inhibitor-resistant melanomas (Figure 5.23) at least in part through triggering 
ApoE/LRP1-dependent repression of PDGFRβ signaling.  
Besides the well-known role of cell-surface LRP1 in mediating cellular endocytosis, 
there is some evidence that LRP1 can also play a cell-signaling role through gamma 
secretase-catalyzed cleavage of its intracellular domain (ICD). Accordingly, gamma 
secretase was found to inhibit inflammatory signaling in macrophages through the proteolytic 
generation of an LRP1-ICD fragment, which was found to translocate into the nucleus and 
indirectly repress the transcription of lipopolysaccharide-inducible genes by transcription 
factor sequestration and nuclear export (Zurhove et al., 2008). Interestingly, LRP8 can also 
be proteolytically processed to generate an ICD domain that is then released into the 
cytoplasm (May et al., 2003). Even though the ability of LRP8-ICD to translocate into the 
nucleus and regulate gene expression in a manner similar to that described for LRP1-ICD is 
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presently unknown, these findings suggest a regulatory role for LRP1/LRP8 targeting 
involving a cell-signaling mechanism alternative to endocytosis. Namely, ApoE/LRP1 and/or 
ApoE/LRP8 targeting might modulate gene expression programs in melanoma and/or 
endothelial cells, respectively, through proteolytic LRP1/LRP8 processing and generation of 
LRP-ICD fragments, which possess transcription regulatory activity. 
 
Metastatic Endothelial Recruitment  
Our systematic analyses of pro-metastatic phenotypes displayed by in vivo-selected 
highly metastatic melanoma cells have revealed that, in addition to the well-characterized 
phenotype of cancer cell invasion, metastatic melanoma cells also acquire an enhanced 
capacity to recruit endothelial cells both in vitro and in vivo. Importantly, we identified three 
metastasis-promoting miRNAs as novel regulators of metastatic endothelial recruitment 
(MER) in melanoma and showed that their convergent targets, ApoE and DNAJA4, act as 
suppressors of MER. Consistent with this, LXR activation therapy, which robustly 
suppresses melanoma progression by activating ApoE expression, was also found to inhibit 
endothelial recruitment and melanoma tumor angiogenesis, underscoring the importance of 
endothelial-cancer cell interactions for melanoma metastatic progression.  
Even though tumor angiogenesis has long been known to be essntial for tumor 
progression, MER—the active process of non-cell-autonomous recruitment of endothelial 
cells by incipient metastases—has only recently emerged as a key cellular phenotype in 
cancer progression. In addition to melanoma, previous findings from our group have 
indicated that MER plays a crucial role in breast cancer metastatic initiation as well (Png et 
al., 2012). Highly metastatic breast cancer cells were found to display an enhanced capacity 
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to recruit endothelial cells compared to poorly metastatic breast cancer cells. Additionally, 
the metastasis suppressor miR-126 was found to suppress breast cancer metastatic initiation 
by targeting a set of cancer cell-expressed genes (IGFBP2, PITPNC1, and MERTK), each of 
which was shown to act as a promoter of MER. By silencing miR-126, metastatic breast 
cancer cells upregulate secretion of IGFBP2 and the MERTK ectodomain, which in turn 
engage the IGF1 receptor and Gas-6/MERTK receptor signaling pathways on endothelial 
cells, respectively. Whereas IGFBP2 was found to directly interact with IGF-1 and promote 
IGF1R-dependent endothelial migration, cancer-derived MERTK was shown to act as a 
decoy receptor for Gas-6, the ligand for MERTK, and thus repress the endothelial cell 
MERTK receptor, which is inhibitory to endothelial migration (Png et al., 2012). Our 
collective findings from breast cancer and melanoma highlight MER as a common key 
attribute of metastatic cells from two different epithelial cancer types. The importance of 
endothelial cells for cancer progression phenotypes (Carmeliet and Jain, 2011) complements 
the diverse roles of these cells in developmental (Lammert et al., 2001) and regenerative 
biology (Ding et al., 2011; Ding et al., 2010; Kobayashi et al., 2010). In addition to their 
passive role in supplying oxygen and nutrients to the tumor, it will be of great interest to 
examine the potential active/signaling role(s) that endothelial cells may play within the tumor 
microenvironment in dynamically modulating metastatic progression. 
 
Metastasis Suppression by DNAJA4 
The identification of DNAJA4 as a novel suppressor of melanoma progression 
phenotypes raises the interesting question of how DNAJA4 suppresses melanoma metastasis. 
Our findings revealed that at least a part of the effects of DNAJA4 were mediated through its 
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positive regulation of the metastasis-suppressive extracellular factor ApoE. Through epistasis 
experiments, we showed that the DNAJA4-mediated suppression of melanoma invasion and 
cell-extrinsic endothelial recruitment was dependent on the downstream induction of ApoE 
expression (Figure 3.11). However, it still remains unclear how DNAJA4 regulates ApoE 
expression. Additionally, the incomplete rescue of the DNAJA4-dependent invasion 
phenotype upon modulation of ApoE levels suggests that additional DNAJA4-dependent 
target genes might be involved in conferring suppression of melanoma invasion by this heat-
shock factor in melanoma.  
DNAJA4, a poorly characterized heat-shock protein (HSP) that belongs to the Hsp40 
family of HSPs, has no previously implicated role in cancer progression. HSPs are normally 
present at basal levels in the cell and typically become induced in response to heat and/or 
other environmental stressors. In light of our identification of DNAJA4 as a suppressor of 
melanoma metastasis, this raises the interesting possibility that DNAJA4 induction upon UV 
light exposure might act as an endogenous tumor-suppressive mechanism guarding against 
melanoma development and/or progression. Future studies are needed to address whether 
DNAJA4 expression in benign melanocytic lesions and/or primary melanoma lesions is 
affected by UV radiation. 
HSPs can have diverse molecular functions such as protein folding and assembly, 
post-translational protein modification, control of protein aggregation, regulation of protein 
stability/degradation, intracellular transport, and chaperoning of protein-protein interactions. 
Even though the name of DNAJA4 suggests potential involvement in DNA binding and 
transcriptional regulation based on its Hsp40 bacterial homolog, DnaJ, which has known 
roles in chaperoning DNA-binding of bacterial replication factor RepA and thereby 
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facilitating bacterial replication (Wickner et al., 1991), the ability of mammalian DNAJA4 to 
directly and/or indirectly interact with DNA and regulate gene expression is presently 
unknown. Contrary to a potential transcriptional regulation of ApoE by DNAJA4, we did not 
observe any effect on the activity of an ApoE promoter construct by knocking down 
DNAJA4 (data not shown). Given that DNAJA4 increased both ApoE’s transcript and 
protein levels, our findings are consistent with post-transcriptional modulation of the ApoE 
mRNA stability and/or processing, which is also reflected at the protein levels.  
Alternatively, given that DNAJA4 harbors multiple miRNA binding sites both in its 
CDS and 3’UTR (Figure 3.4), it is possible that the DNAJA4 mRNA indirectly induces ApoE 
expression by competing with the ApoE transcript for miR-199a-5p and/or miR-1908 binding 
and sequestering away the miRNAs from acting on ApoE.  By strongly downregulating 
DNAJA4 expression, highly metastatic melanoma cells may ensure ApoE silencing through 
greater occupancy of the ApoE transcript by the metastasis-promoting miR-199a-5p and 
miR-1908. Interestingly, a similar mechanism of action was recently demonstrated for 
HMGA2, one of the target genes of the metastasis suppressor let-7. In addition to its protein-
coding function in metastasis, the HMGA2 transcript was found to indirectly promote lung 
cancer metastasis in a non-coding manner through its sponge effects on let-7 activity (Kumar 
et al., 2014). 
To gain further mechanistic insight into the biological function of DNAJA4, we 
performed mass-spectrometric analyses to identify potential interacting partners of DNAJA4 
in melanoma. Interestingly, we found a set of five proteins (PFKFB3, HNRNPF, PSMD11, 
FLG, or TPM4) that specifically associated with the metastasis-regulatory isoform 3 of 
DNAJA4, but not with isoform 2 that was found to lack activity in suppressing melanoma 
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invasion (Figures 3.12-3.13). Out of these putative interacting partners, PFKFB3 was 
recently implicated as an important regulator of vessel sprouting and endothelial tip cell 
directional migration. PFKFB3, an enzyme catalyzing the rate-limiting step in glycolysis, 
was found to localize with F-actin and compartmentalize at the leading edge of the cell, 
where ATP production by PFKFB3-driven glycolysis drives actin remodeling and cell 
migration (De Bock et al., 2013).  Interestingly, this report also showed that, in addition to 
interacting with F-actin, PFKFB3 also associates with tropomyosin 4 (TPM4), one of the 
other potential DNAJA4.3-specific interacting partners that we identified independently 
(Figure 3.13). Based on these findings, we hypothesize that the three proteins, DNAJA4.3, 
PFKFB3, and TPM4, may associate together in a complex. Given the putative interaction 
between DNAJA4.3 and PFKFB3/TPM4, the previously implicated role of PFKFB3 in cell 
migration, and the frequent coupling of cell invasion and migration phenotypes in cancer 
cells, we speculate that DNAJA4.3 might inhibit melanoma invasion at least in part through 
interacting with PFKFB3 and/or TPM4 and altering their actin-remodeling activity and/or 
localization to the leading edge of the cell. Future work will examine whether PFKFB3 and 
TPM4 regulate invasion and/or migration in melanoma cells and will characterize the 
biochemical interactions between DNAJA4.3 and these two proteins.  Finally, it will be of 
interest to examine whether any of the potential DNAJA4-interacting partners are also 
involved in the DNAJA4-dependent regulation of ApoE expression and/or additional 
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The LXRβ Receptor as a Novel Therapeutic Target in Metastatic Melanoma 
Our systematic analyses of multiple in vivo selected highly metastatic melanoma 
derivatives led to the discovery of a cooperative multi-miRNA regulatory network that 
converges onto a single molecule, ApoE. In the pathway that we uncovered, three metastasis-
promoting miRNAs silenced ApoE, whereas the metastasis-suppressor DNAJA4 induced 
ApoE. The tight control exerted on ApoE expression in melanoma highlights the importance 
of this gene as a metastasis suppressor. Indeed, epistasis experiments revealed the miRNA-
dependent effects on metastatic colonization to be fully mediated by ApoE (Figure 3.7).  
Based on these findings, we hypothesized that activation of ApoE expression might mimic 
the robust effects of miRNA inhibition and thus have efficacy in suppressing melanoma 
progression. Consistent with this, we observed that pre-treating melanoma cells from 
multiple patients with ApoE protein abolished their subsequent metastatic capacity (Figure 
4.3). Conversely, genetic inactivation of stromal ApoE accelerated lung colonization by 
melanoma cells (Figure 4.4). Taken together, these findings provide strong evidence that 
extracellular ApoE, derived either from melanoma cells or the stromal compartments, can act 
as a strong suppressor of melanoma progression and, as such, may represent an attractive 
therapeutic target in melanoma.  
We reasoned that an ideal therapeutic approach to activate ApoE in metastatic 
melanoma would be to induce circulating extracellular ApoE protein globally by activating 
ApoE production in both the tumoral and stromal compartments.  To that end, we identified 
the nuclear hormone receptor LXRβ, a previously known transcriptional trans-activator of 
ApoE (Laffitte et al., 2001) that is expressed across most tissues (Song et al., 1994), as a 
novel therapeutic target, which exhibited ubiquitous expression across melanoma as well 
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(Figures 5.1 and 5.5). Our findings of broad-spectrum metastasis suppression upon LXRβ 
activation across multiple xenograft and genetically initiated models highlight the promise of 
nuclear hormone receptor targeting as a novel therapeutic approach in metastatic melanoma. 
Nuclear hormone receptors such as the androgen and estrogen receptors have proven to be 
key therapeutic targets in prostate and breast cancers, whose initiation and progression are 
intricately linked to the androgen and estrogen sex hormones. Pharmacologic agents targeting 
the androgen and estrogen receptors, respectively, represent the mainstay of therapy in these 
two cancers (Scher et al., 2012; Deblois and Giguère, 2013). Our identification of LXRβ as a 
therapeutic target in melanoma further expands the therapeutic potential displayed by this 
class of transcription factors by revealing that nuclear hormone receptor targeting could 
represent a viable therapeutic strategy in epithelial cancers that originate from non-
reproductive tissues.  
While the ubiquitous basal expression of cellular LXRβ in melanoma and other tissue 
types is likely required for homeostatic metabolic needs, it leaves melanoma cells broadly 
vulnerable to its modulation for the induction of tumor-suppressive phenotypes. Even though 
nuclear hormone receptors such as LXRs transcriptionally regulate multiple downstream 
target genes (Calkin and Tontonoz 2012), our findings reveal that the suppression of 
melanoma progression in response to LXRβ activation is mediated by the transcriptional 
induction of a single target gene, ApoE.  While LXRβ likely retains many additional target 
genes that may or may not contribute to melanoma progression, our molecular and genetic 
evidence from ApoE silencing experiments indicates that, in the absence of ApoE, any 
melanoma-suppressive effects of LXRβ activation through ApoE and/or additional target 
genes are eliminated. Therefore, even if there were additional LXRβ target genes that 
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mediate various aspects of melanoma progression, they likely require ApoE for their 
function, as they fail to mediate tumor suppression in the absence of ApoE. Thus, we 
conclude that ApoE is the primary mediator of LXRβ-dependent melanoma suppression. 
Presently, there are two known isoforms of the liver-X receptor, LXRα and LXRβ, 
which were cloned at roughly the same time by multiple groups (Apfel et al., 1994; Willy et 
al., 1995; Song et al., 1994; Shinar et al., 1994; Teboul et al., 1995). LXRs belong to a family 
of nuclear hormone receptors that are endogenously activated by cholesterol and its various 
oxygenated derivatives known as oxysterols (Janowski et al., 1996). Thus, LXRs serve as 
intracellular cholesterol-sensors that provide a feedback signal to maintain systemic 
cholesterol levels. Upon high cholesterol supply, LXR activation mediates transcription of 
multiple genes involved in cholesterol and fatty acid metabolism (Calkin and Tonotnoz, 
2012). In light of our findings on melanoma suppression through pharmacologic LXRβ 
activation, the ability of cholesterol to activate LXRs may bear interesting implications for 
the interaction of dietary cholesterol and melanoma progression. Future studies are needed to 
determine whether high dietary cholesterol levels could sufficiently activate LXRβ to elicit 
melanoma tumor suppression. 
LXRs regulate target gene transcription by forming obligate heterodimers with RXRs 
(Willy et al., 1995). The LXR/RXR heterodimer resides in an inactive state within the 
enhancer region of target genes by recognizing and binding to cis-acting LXR response 
elements (LXRE). Structural studies have revealed that allosteric interaction of an LXR 
agonist with the ligand-binding domain of LXR (LXR-LBD) triggers a conformational 
change in the protein, resulting in the positioning of C-terminal helix 12 (also known as the 
activation function 2 (AF-2) domain) right above the ligand-binding pocket. This leads to the 
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release of any bound co-repressor and the introduction of a co-activator binding site.  Co-
activator binding ultimately allows for recruitment of the basal transcriptional machinery and 
activation of target gene transcription (Svensson et al., 2003; Calkin and Tontonoz, 2012). 
The LXR-LBD possesses a great extent of structural flexibility, allowing it to accommodate 
various endogenous and synthetic ligands that share very little structural homology, yet are 
able to trigger receptor activation through a common mechanism affecting the conformation 
of AF-2 and co-activator recruitment (Färnegårdth et al., 2003).    
Even though LXRs typically work in tandem with RXRs, we found that LXR 
activation exhibited more robust activity than RXR agonism in broadly suppressing 
melanoma cell invasion, with RXR activation failing to inhibit endothelial recruitment by 
melanoma cells. Additionally, in contrast to the robust suppression of melanoma metastasis 
observed upon LXR activation therapy, we found that RXR activation therapy lacks 
metastasis-suppressive activity in vivo and it might even promote melanoma metastasis at 
early time points (data not shown). Even though both LXRs and RXRs in tandem upregulate 
ApoE transcription, RXRs can retain additional heterodimeric partners such as farnesoid X 
receptors (FXRs), retinoid acid receptors (RARs), and peroxisome proliferator-activated 
receptors (PPARs) that activate alternative sets of transcriptional pathways (Barish and 
Evans, 2004; Calkin and Tontonoz, 2012). Thus, we speculate that the inferior ability of 
RXR agonism in suppressing melanoma progression phenotypes may stem from its 
modulation of additional secreted factor(s) that might antagonize ApoE’s suppressive effects. 
Consistent with this, transcriptomic profiling of melanoma cells treated with the RXR agonist 
bexarotene revealed that, in addition to upregulating ApoE expression, RXR activation 
induced the expression of a number of additional genes (data not shown) previously 
	   182 
implicated to have a pro-tumorigenic and pro-metastatic functions, such as MERTK (Png et 
al., 2012), and ANGPTL4 (Padua et al., 2008). Importantly, none of these genes were 
induced by the LXR agonist treatment, suggestive of downstream target decoupling between 
LXRs and RXRs.  
 
Potential Roles of LXR Targeting in Other Epithelial Cancer Types 
Prior to our discovery of LXRβ as a novel broadly expressed therapeutic target in 
melanoma, LXR signaling was implicated in the progression of several additional epithelial 
cancer types. Consistent with our findings of LXR-mediated suppressive effects in 
melanoma, oral administration of GW3965 was recently shown to inhibit tumor growth by 
glioblastoma cells (Guo et al., 2011). Although this study did not examine any potential 
effects on metastasis, this work found that GW3965 suppressed the tumor growth by an 
EGFR-mutant glioblastoma line through enhancement of tumor cell apoptosis (Guo et al., 
2011). In contrast, we found that LXR activation inhibited melanoma tumor angiogenesis and 
proliferation without any observed effects on tumor apoptosis, suggesting that the respective 
reductions of EGFR-mutant glioblastoma and melanoma tumor growth by LXR agonists are 
elicited through disparate mechanisms.  
Contrary to our findings of melanoma metastasis suppression upon LXR activation, 
27-hydroxycholesterol, an oxysterol that acts as a partial LXR agonist as well as an estrogen 
receptor agonist, was recently shown to modestly increase metastatic dissemination in an 
inflammatory model of murine breast cancer (Nelson et al., 2013). The potentially different 
roles played by LXR agonism in breast versus melanoma metastasis could be attributed to 
cancer type-specific differences or 27-hydroxycholesterol’s partial agonism of LXR 
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signaling. Further experiments are needed to determine whether LXR agonism actually 
increases metastatic colonization by breast cancer cells that are more representable of human 
breast cancer. 
Besides its stable expression in melanoma, LXRβ exhibits ubiquitous expression 
across multiple additional metastatic cancer types, as evidenced by previous analyses of 
nuclear hormone receptor expression in the NCI60 cancer cell line collection (Holbeck et al., 
2010). This suggests that LXRβ could represent a therapeutic target in other metastatic 
cancers as well. Our findings of a cell-extrinsic function of ApoE in inhibiting melanoma 
angiogenesis suggest that other angiogenic tumor types may also respond to LXRβ activation 
therapy in an ApoE-dependent fashion. However, for cancers to sustain the full impact of 
ApoE’s suppressive activity, they would need to also express LRP1 or a related ApoE 
receptor, which could mediate invasiveness suppression as we found for melanoma cells 
(Figure 4.5). The comprehensive pre-clinical analyses across multiple melanoma models 
described in the present thesis work will provide the framework for testing the therapeutic 
potential of LXRβ across additional cancer types in the future. 
 
Clinical Implications for LXRβ Activation Therapy in Melanoma 
The final results chapter of this thesis (Chapter V) describes the scientific basis for 
testing LXRβ activation therapy in clinical trials by demonstrating its broad-spectrum 
activity and safety across multiple pre-clinical mouse models of melanoma progression. 
Importantly, the strong melanoma-suppressive effects of LXR agonists occurred in the 
absence of any noted potential adverse effects such as weight loss or symptomatic health 
deterioration. LXR agonists were originally developed and conceived as life-long therapies 
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for the chronic management of dyslipidemia (Joseph and Tontonoz, 2003). Their clinical 
application, however, was stalled when they were found to modestly, yet reversibly, elevate 
LDL-cholesterol levels in primates—an effect stemming from LXRα-modulated induction of 
cholesteryl ester transfer protein (CETP) (Groot et al., 2005). Their failure to reduce 
cholesterol levels was a major setback for the clinical development of these agents in 
cardiovascular disease. However, such modest lipid-profile alterations would not pose an 
obstacle for the testing of these agents in metastatic melanoma, especially in light of the high 
mortality rate in melanoma, the accepted toxicities arising from approved melanoma drugs 
(2-3% mortality rate for anti-CTLA-4 Ab (Hodi et al., 2010); 18-26% risk of cutaneous 
squamous cell carcinoma for vemurafenib (Chapman et al., 2011)), and the clinically 
accepted dyslipidemia effects of a number of approved therapeutics such as retinoids and 
rexinoids (Duvic et al., 2001). Additionally, dyslipidemia can be readily managed by the use 
of statins (hypercholesterolemia) and fibrates (hypertriglyceridemia). To simulate this in a 
pre-clinical model, we tested the ability of GW3965 to suppress melanoma progression in the 
setting of its co-administration with lipitor and gemfibrozil—clinical agents widely used for 
lowering cholesterol and triglyceride levels, respectively. Importantly, neither of these drugs 
affected the ability of GW3965 to suppress tumor growth (data not shown), suggesting that 
any potential adverse effects of LXR agonists on cholesterol and triglyceride levels in 
humans could be managed by lipitor and/or gemfibrozil treatment, if need be, without 
compromising the tumor-suppressive activity of LXR agonists.  
 Based on our findings of broad-spectrum suppression of melanomas of diverse 
mutational subtypes, we propose that future clinical trials test the activity of LXRβ activation 
therapy in patients with advanced (stage IV) melanoma bearing B-Raf wild-type or B-Raf 
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mutant tumors that are insensitive to approved agents such as dacarbazine, vemurafenib, 
ipilimumab, or novel experimental agents targeting MEK or PD-1. Importantly, our 
observations of tumor-suppressive activity of the LXR agonist treatment in melanomas 
resistant to vemurafenib or dacarbazine motivates the clinical testing of LXR activation 
therapy in patients, whose melanomas have previously progressed on dacarbazine or 
vemurafenib. Furthermore, our findings of tumor-suppressive cooperativity between LXR 
activation and the three present melanoma mainstay therapeutics (dacarbazine, vemurafenib, 
and the CTLA-4 antibody) calls for the clinical testing of combination therapeutic regimens 
incorporating LXR agonist treatment (Figures 5.24-5.27). Finally, given the herein 
demonstrated activity of LXRβ activation therapy in suppressing brain metastatic 
colonization (Figure 5.10), the trial population should also contain melanoma patients with 
brain metastasis, who are prevalent (about 30% of all melanoma metastasis outcomes) and 
for whom there currently exist no approved therapies targeting brain metastasis (Fonkem et 
al., 2012).  
Demonstration of safety and efficacy in such advanced stage melanoma clinical trials 
will enable the subsequent testing of LXR agonist agents for the prevention of melanoma 
metastasis in clinical trials with stage II and III patients who are at risk for metastatic relapse.  
Importantly, the robust prognostic capacity of ApoE expression in stratifying melanoma 
patients into those at low risk versus high risk for metastatic relapse (Figure 3.15) suggests 
that expression levels of this gene may be a useful diagnostic for selecting high-risk patients 
in need of metastasis prevention therapy after resection of their primary tumors. 
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Potential Solutions to Emergence of Clinical Resistance to LXR Activation Therapy 
Despite the unprecedented clinical success of the two recently approved melanoma 
therapeutics, the B-Raf kinase inhibitor vemurafenib and the anti-CTLA-4 
immunomodulatory antibody, the present median survival time of advanced melanoma 
patients still remains less than two years. This is in large part due to the notorious propensity 
exhibited by advanced stage metastatic melanomas to develop resistance to single-agent 
targeted therapies such as the ones presently used in the clinic (Nazarian et al., 2010; 
Poulikakos et al., 2011; Prahallad et al., 2012). Cancer cells display a great extent of 
molecular plasticity, which allows them to re-wire and activate multiple compensatory 
pathways and/or mutate signaling effectors in response to a selection pressure, thereby 
escaping modulation by targeted therapeutics (Bernards, 2012). In contrast, non-transformed 
stromal tissues are less prone to re-wiring and the development of resistance to targeted 
agents. Our observations that the melanoma-suppressive activity of LXR agonists was in 
large part mediated through the sustained elevation of ApoE in peripheral tissues suggest that 
resistance to LXRβ activation therapy in melanoma may be less likely to emerge through 
LXRβ mutational and/or expression alteration mechanisms in stromal tissues, in which 
LXRβ plays an essential metabolic role and its activity is likely to be tightly maintained. This 
finding also makes the LXRβ activation therapy described herein unique since this is the first 
targeted therapy that we know of to work through the activation of a metastasis suppressor 
gene (ApoE) in both the tumoral and stromal compartments. However, if resistance does 
emerge in the clinic, the development of next-generation LXRβ agonists that are able to bind 
and activate the mutated/deregulated receptor with greater potency might offer a potential 
solution to such resistance outcomes, as previously demonstrated by the clinical development 
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of next generation antiandrogens for the treatment of metastatic prostate cancer (Tran et al., 
2009). 
Alternatively, potential resistance to ApoE activation therapy could also arise 
through post-transcriptional mechanisms that silence ApoE, such as modulation by the three 
metastasis-promoting miRNAs (miR-199a-3p, miR-199a-5p, and miR-1908), which were 
found to convergently target ApoE, and/or the metastasis-suppressive factor DNAJA4, which 
was shown to induce ApoE expression. We predict that potential resistance to LXRβ-based 
transcriptional activation of ApoE may be overcome, as least in part, by LNA-mediated 
silencing of miR-199a-3p, miR-199a-5p, and miR-1908. Given that the three miRNAs 
convergently target and maximally silence the expression of ApoE and DNAJA4, miRNA 
inhibition should lift the post-transcriptional brake imposed on ApoE expression in metastatic 
melanoma cells. We thus speculate that combinatorial LNA-based miRNA silencing might 
represent an effective therapeutic alternative in cases where LXRβ activation therapy fails to 
induce ApoE and elicit melanoma metastasis suppression.  This is supported by our findings 
of strong metastasis reduction upon LNA-based inhibition of miR-199a-3p, miR-199a-5p, 
and miR-1908 across multiple melanoma lines (Figure 2.17). Furthermore, it will be of 
interest to examine potential therapeutic synergy upon combining ApoE transcriptional 
activation (LXRβ therapy) and ApoE post-transcriptional de-repression (LNA therapy) in the 
suppression of melanoma metastasis.  
In the case that resistance emerges due to acquired unresponsiveness of melanoma 
tumors to sustained ApoE induction rather than an inability to activate ApoE expression, one 
could perform wide-genome RNAi synthetic lethality screens (Prahallad et al., 2012) to 
identify additional pathways in melanoma cells, whose concurrent molecular modulation 
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might confer responsiveness to LXRβ activation therapy. It will be of particular interest to 
determine whether mutational inactivation and/or expression deregulation of LRP1, the 
melanoma cell receptor found to mediate ApoE’s effects on melanoma invasion, could 
represent a potential mechanism of acquired resistance to ApoE activation therapy. Given 
ApoE’s effects in suppressing metastatic endothelial recruitment, we speculate that even if 
melanoma tumors lost their responsiveness to ApoE/LRP1 targeting, those tumors could still, 
at least partially, respond to ApoE activation therapy through ApoE/LRP8-dependent 
suppression of endothelial recruitment. LRP8’s activity in non-transformed endothelial cells 
is likely to be tightly maintained.   
Finally, our findings of melanoma-suppressive cooperativity in response to 
combining LXRβ activation with each of the three frontline melanoma therapeutics used in 
the clinic (dacarbazine, vemurafenib, and the CTLA-4 Ab) have important clinical 
implications and suggest that combination regimens incorporating LXR agonists could 
negatively impact the likelihood of clinical resistance emergence. Concurrent targeting of 
multiple pro-tumorigenic and/or pro-metastatic pathways will leave less room for melanoma 
cells to escape modulation by targeted therapeutics and may ultimately provide greater 
therapeutic benefit to patients. While the present findings are promising, future work is 
needed to determine the optimum dosing regimens to attain maximum melanoma suppression 
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Conclusions 
This thesis describes the systematic interrogation of molecular pathways regulating 
melanoma metastasis. The identification of a set of miRNAs with pervasive upregulation 
across multiple melanoma metastatic derivatives was functionally supported by our findings 
of robust metastasis control exerted by these miRNAs. We utilized the three miRNAs as 
unbiased probes into the downstream biology of melanoma metastasis and uncovered a novel 
molecular pathway that surprisingly converges onto a single target gene, ApoE. Through 
complementary molecular, genetic, and pharmacologic approaches, we found that ApoE acts 
as a strong suppressor of metastatic progression, while its therapeutic activation represents a 
promising new approach for the treatment of melanoma metastasis. These findings illustrate 
the power of functionally guided systematic approaches for the unbiased discovery of novel 
metastasis regulatory molecules and their rational therapeutic targeting in cancer progression. 
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For a full list of cell lines used in this study, see Appendix A. Established melanoma 
cell lines were obtained from ATCC and cultured in standard conditions, following 
recommendations by the supplier. Primary HUVEC cells were obtained from ATCC and 
cultured in EGM-2 media supplemented with 2% FBS (CC-3162, Lonza). Primary human 
melanoma lines were generated at MSKCC following dissociation of melanoma cells from 
the tumors of patients the MSKCC. These primary cells were generously provided by Taha 
Merghoub (MSKCC). Primary cells were maintained in RPMI medium supplemented with 
20% FBS. The SK-Mel-239 parental and vemurafenib-resistant clones (C1 and C5) were a 
gift from Poulikos Poulikakos (Mount Sinai Medical School), and the B-RafV600E/+; Pten-/-; 
CDKN2A-/- murine melanoma line (designated at YUMM) was generously provided by 
Marcus Rosenberg (Yale University).  
 
Mouse Experiments 
All mouse experiments were conducted in agreement with a protocol approved by 
the Institutional Animal Care and Use Committee (IACUC) at the Rockefeller University. 
NOD SCID, NOD SCID gamma, athymic nu/nu, and C57BL/6 (WT; Tyr::CreER, B-
RafV600E/+, Ptenlox/+ ; LXRa -/-; LXRβ -/-)  mice were obtained from the Jackson Laboratory. 
ApoE -/- mice were generously provided by Jan Breslow (Rockefeller University). All mouse 
genotyping was performed using standard PCR conditions and genotyping primers, as 
recommended by the Jackson Laboratory. 
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In Vivo Selection for Highly Metastatic Melanoma Derivatives  
To generate multiple metastatic derivatives from the MeWo and A375 human 
melanoma cell lines, in vivo selection was performed as previously described (Minn et al., 
2005; Pollack and Fidler, 1982). In brief, 1 × 106 MeWo or A375 melanoma parental cells 
were resuspended in 0.1 mL of PBS and intravenously injected into 6-8-week old 
immunocompromised NOD SCID mice. Following lung metastatic nodule formation, 
nodules were dissociated and cells were propagated in vitro, giving rise to first generation of 
lung metastatic derivatives (LM1). The LM1 cells were then subjected to another round of in 
vivo selection by injecting 2 × 105 LM1 cells into NOD SCID mice, giving rise to metastatic 
nodules, whose subsequent dissociation yielded a second generation of lung metastatic 
derivatives (LM2). For the A375 cell line, a third round of in vivo selection was performed, 
yielding the highly metastatic A375-LM3 derivatives. Cell dissociation of in vivo selected 
metastatic melanoma cells was performed by dissecting individual lung nodules, cutting them 
into small pieces, and dissociating individual cells by incubating the nodule pieces in 0.125% 
Collagenase Type I (XOM12195, Worthington Biochemical) and 0.1% Hyalouronidase 
(P1B12524, Worthington Biochemical) serum-free DMEM-based solutions for 3 hours at 
37°C shaking and in 0.25 % Trypsin-EDTA (25200-056, Invitrogen) solution for 10 minutes 
at 37°C shaking. Trypsin digestion was neutralized in 10% FBS DMEM-based cell media. 
Following DNAse I (51M13032, Worthington Biochemical) treatment (20 000 unitl/L in 25 
mM HEPES DMEM-based solution supplemented with 1 mg/mL BSA) for 10 min at 37°C 
shaking, single cells were filtered though a 70-μm cell strainer. 
In vivo selection of the primary SK-Mel-334 and SK-Mel-462 cell lines was 
performed as described above. 1 × 106 parental SK-Mel-334 or SK-Mel-462 cells were 
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intravenously injected into NOD SCID gamma mice. Following formation of lung metastatic 
nodules, melanoma cells were dissociated, and expanded in vitro. 5 × 105 cells were then re-
injected into NOD SCID mice for a second round of in vivo selection. For the generation of 
HT-144 and WM-266-4 metastatic derivatives, we injected 1.5 × 105 and 2 × 105 WM-266-4 
or HT-144 parental cells, respectively, into NOD SCID mice in the first round of selection, 
and 1.5 × 105 and 2 × 105  WM-266-4 or HT-144 LM1 derivatives were re-injected for a 
second round of in vivo selection. 
The MeWo brain-metastatic derivatives were generated by performing two successive 
rounds of in vivo selection with the MeWo parental cells. First, 5 × 105 parental MeWo cells 
resuspended in 0.1 mL of PBS were intracardially injected into athymic nu/nu mice. Upon 
formation of brain metastatic nodules, cells were dissociated, expanded in vitro, and re-
injected intracardially at 2 × 105 cells/ 0.1 mL PBS per mouse. Cells dissociated from brain 
metastatic nodules ultimately yielded a second-generation of brain-metastatic MeWo cell line 
derivatives that were used in this study to test the efficacy of orally delivered GW3965 in 
suppressing brain metastatic colonization.  
Experimental Metastasis Assays 
In order to monitor metastasis in vivo through bioluminescence imaging, cancer cells 
were transduced with a retroviral construct expressing a luciferase reporter (Ponomarev et al., 
2004). The indicated numbers of cancer cells were resuspended in 0.1 mL of PBS and 
administered via the lateral tail-vein or through an intracardiac injection, as indicated. For all 
metastasis experiments, lung, systemic, or brain colonization was monitored over time and 
quantified through non-invasive weekly bioluminescence imaging, as described previously 
(Minn et al., 2005). In all metastasis bioluminescence imaging experiments, photon flux was 
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normalized relative to the signal measured at day 0 immediately post-injection. Various 
numbers of cancer cells were injected in different experiments, as described below. 
In Vivo Selection Validation 
To determine whether in vivo selection for melanoma cells enriched in metastatic 
capacity had been achieved, 4 × 104 MeWo parental or MeWo-LM2 cells and 1 × 105 A375 
parental or A375-LM3 cells were injected via the lateral tail vein into 6-8-week old NOD 
SCID mice.  
Functional Testing of Metastasis Promoter miRNAs 
For experimental metastasis assays testing the effects of putative promoter miRNAs 
on lung colonization, 4 × 104 MeWo parental cells overexpressing miR-199a, miR-1908, 
miR-214, or a control hairpin, 4 × 104 MeWo-LM2 cells with miR-Zip-based silenced 
expression of miR-199a-3p, miR-199a-5p, miR-1908, or a control sequence, and 2 × 105 
A375-LM3 cells inhibited for miR-199a-3p, miR-199a-5p, miR-1908, or a control sequence 
were resuspended in 0.1 mL of PBS and tail-vein injected into NOD SCID mice.  
LNA Pre-Treatment Experiments 
To determine the effect of pre-treating melanoma cells with specific LNAs targeting 
miR-199a-3p, miR-199a-5p, or miR-1908 on metastasis, melanoma cells were transfected 
with LNAs targeting each miRNAs individually (50 nM), a cocktail of LNAs targeting all 
three regulatory miRNAs (50 nM), or a control LNA (50 nM) (426917, LNA-miR-199a-3p; 
426918, LNA-miR-199a-5p; 426878, LNA-miR-1908; 199005, LNA-control; Exiqon).  
After 48 hours, 1 × 105 MeWo-LM2 cells (NOD SCID), 2 × 105 A375-LM3 cells (NOD 
SCID), 5 × 105 SK-Mel-2 cells (NOD SCID gamma), 5 × 105 WM-266-4 cells (NOD SCID), 
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5 × 105 HT-144 cells (NOD SCID), 5 × 105 A2058 cells (NOD SCID), and 5 × 105 SK-Mel-
28 cells (NOD SCID gamma) were injected intravenously into NOD SCID or NOD SCID 
gamma mice, as indicated after each cell line. For systemic metastasis assays, 1 × 105 MeWo-
LM2 cells, pre-treated with LNA-CTRL or LNA-3 miRNAs for 48 hours, were intracardially 
injected into athymic nu/nu mice.  
In Vivo LNA Therapy 
In the LNA therapy experiment, mice were tail-vein injected with 4 × 104  MeWo-
LM2 cells and treated intravenously twice a week for four weeks and then once weekly with 
a cocktail of in vivo-optimized LNAs (Exiqon) antisense to mature miR-199a-3p, miR-199a-
5p, and miR-1908 at a total dose of 12.5 mg/kg. The LNAs were delivered in 0.2 mL of PBS 
via the lateral tail vein. 0.2 mL of PBS was administered as a control mock treatment. 
Epistasis Experiments 
For miRNA loss-of-function experiments, 1 × 105 MeWo-LM2 cells expressing an 
shRNA targeting ApoE, DNAJA4, or a control sequence or siRNAs inhibiting LRP1 or a 
control siRNA in the setting of miR-199a-5p or miR-1908 inhibition were intravenously 
injected into NOD SCID mice. For miRNA gain-of-function experiments, 4 × 104 MeWo 
parental cells overexpressing ApoE, DNAJA4, or an empty vector in the setting of miR-1908 
overexpression were intravenously injected into NOD SCID mice. 
ApoE Pre-Treatment Experiments 
For ApoE pre-treatment experiments, melanoma cells were incubated in the presence 
of recombinant human ApoE3 (4696, BioVision) or BSA (A2153, Sigma-Aldrich) at 100 
µg/mL at 37°C. After 24 hours, 4 × 104 MeWo-LM2 cells, 2 × 105 A375-LM3 cells, 1.5 × 105 
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WM-266-4 cells, 3.5 × 105 HT-144 cells, and 2 × 105 A2058 cells were injected via the tail-
vein into NOD SCID mice. To determine the effect of genetic deletion of ApoE on 
metastasis, C57BL/6-WT or C57BL/6-ApoE-/- mice were intravenously injected with 5 × 104 
B16F10 melanoma cells pre-treated with human recombinant ApoE3 (100 µg/mL) for 24 
hours or control untreated B16F10 cells.  
Effect of LXR Agonists on Metastasis 
The LXR agonists GW3965 (Sigma-Aldrich, AdooQ Bioscience) and T0901317 
(Tocris Bioscience) were formulated into mouse chow diet at the indicated doses (20, 75, or 
100 mg/kg/day) by Research Diets, Inc. To test the effect of LXR agonist treatment on 
melanoma metastasis prevention, the following numbers of melanoma cells, resuspended in 
0.1 mL of PBS, were injected intravenously via the tail-vein: 4 × 104 MeWo cells, 2.5 × 105 
HT-144 cells, 4 × 104 SK-Mel-334.2 cells, 5 × 104 B16F10 cells, or 1 × 105 YUMM cells. The 
MeWo, HT-144, and SK-Mel-334.2 cells were injected into 6-8 week-old sex-matched NOD 
SCID mice, while the B16F10 and YUMM cells were injected into 6-8 week-old sex-
matched C57BL/6-WT mice. In all experiments testing the effects of GW3965 on metastasis 
prevention, mice were pre-treated on a control regular chow diet, a GW3965-supplemented 
diet (20 mg/kg), or T0901317-supplemented diet (20 mg/kg) for 10 days prior to cancer cell 
injection and kept on each respective diet for the remainder of the experiment. In the 
experiment testing GW3965 effects on metastatic colonization by primary mouse YUMM 
melanoma cells, the mice were assigned to a GW3965 diet treatment (100 mg/kg) 
immediately after injection. To assess the effect of GW3965 treatment on brain metastasis,   
1 × 105 MeWo brain-metastatic derivatives were injected intracardially into athymic nu/nu 
mice. Immediately following injection, mice were randomly assigned to a control diet or a 
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GW3965-supplemented diet (100 mg/kg). To determine whether oral delivery of GW3965 
can inhibit the progression of incipient metastasis, NOD SCID mice were intravenously 
injected with 4 × 104 MeWo cells, and the cells were allowed to colonize the lungs for 42 
days (at which point lung colonization had progressed by 8-fold relative to the baseline at 
seeding), after which mice were blindedly assigned to a control diet or a GW3965-
supplemented diet (100 mg/kg) treatment. To test the effect of combined GW3965/ 
vemurafenib treatment on lung colonization, 1 × 105 SK-Mel-334.2 cells and 7.5 × 104 HT-
144 cells were intravenously injected into 6-8 week-old sex-matched NOD SCID gamma 
mice. In these experiments, mice were pre-treated on a control diet, GW3965 diet (75 
mg/kg), vemurafenib (Genentech) diet (50 mg/kg), or a combined GW3965 (75 mg/kg) and 
vemurafenib diet (50 mg/kg) starting three days prior to cancer cell injection. GW3965 and 
vemurafenib were formulated in the rodent chow by Research Diets, Inc. 
Orthotopic Metastasis Assay 
To determine the effect of GW3965 treatment on lung colonization by melanoma 
cells dissociated from an orthotopic site, 1 × 106 MeWo cells expressing a luciferase reporter 
were subcutaneously injected into both lower flanks of NOD SCID mice. Upon formation of 
tumors measuring ~300 mm3 in volume, the tumors were excised and the mice were 
randomly assigned to a control diet or a GW3965-supplemented diet (100 mg/kg). One 
month after tumor resection, the lungs were extracted and lung colonization was measured by 
ex vivo bioluminescence imaging. To histologically confirm the extent of melanoma lung 
colonization, lungs were then fixed in 4% PFA overnight, paraffin-embedded, sectioned into 
5-μm thick increments and stained for human vimentin (VP-V684, Vector Laboratories). 
 
	   197 
Primary Tumor Growth Assays 
Effects of miR-199a and miR-1908 on Tumor Growth 
1 × 106 parental MeWo cells overexpressing miR-199a, miR-1908, or a control 
hairpin were mixed 1:1 with matrigel (356231, BD Biosciences) and subcutaneously injected 
into the lower right flank of NOD SCID mice. Animals were palpated weekly for tumor 
formation, after which sizeable tumors were measured twice a week. Tumor dimensions were 
measured using digital calipers, and tumor volume was calculated as (small diameter)2  × 
(large diameter)/2. 
Effects of LXR Agonist Therapy on Tumor Growth  
To determine the effect of LXR agonists on in vivo subcutaneous tumor growth, we 
injected the following numbers of melanoma cells: 5 × 104 B16F10 cells, 1 × 106 MeWo cells, 
7.5 × 105 SK-Mel-334.2 cells, 2 × 106 SK-Mel-2 cells, 2 × 106 SK-Mel-239 vemurafenib-
resistant C1 or C5 cells, 1 × 105 YUMM parental cells, and 2 × 105 vemurafenib-resistant 
YUMM cells. For all tumor growth experiments, cells (suspension in 50 μL of PBS) were 
mixed 1:1 with matrigel and subcutaneously injected into the lower flank of 6-8 week-old 
sex-matched C57BL/6 (B16F10, YUMM), NOD SCID (MeWo and SK-Mel-334.2), athymic 
nu/nu (SK-Mel-2), and NOD SCID gamma (SK-Mel-239) mice. Animals were palpated 
every two days for tumor formation. Upon detection of tumors measuring 5-10 mm3 in 
volume, mice were randomly assigned to a control diet treatment, a GW3965-supplemented 
diet (20 mg/kg/day or 100 mg/kg/day), or a T0901317-supplemented diet (20 mg/kg/day) 
treatment, as indicated in each figure. To assess the effect of GW3965 on the growth of large 
established tumors, B16F10-tumors were allowed to reach 150 mm3 in volume, and mice 
were randomly assigned to a control chow or a chow supplemented with GW3965 (100 
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mg/kg).  To test the effect of combined GW3965/DTIC, GW3965/vemurafenib, or 
GW3965/anti-CTLA-4 Ab therapeutic regimens on tumor growth, the following numbers of 
cells were injected: 5 × 104 B16F10 cells, 8 × 105 A375 cells, and 1.25 × 106 SK-Mel-239 
cells. B16F10 cells were implanted onto C57BL/6-WT mice, whereas A375 and SK-Mel-239 
human cells were grafted onto NOD SCID gamma mice. Following formation of palpable 5-
10 mm3 tumors, mice were assigned to the following treatment groups, as described below.  
GW3965 + DTIC Therapy: i) control diet + vehicle, i.p. (citric acid, 50 mg/kg); ii) GW3965 
diet (100 mg/kg) + vehicle, i.p.; iii) control diet + DTIC (Sigma-Aldrich), i.p. (50 mg/kg);  
iv) GW3965 diet (100 mg/kg) + DTIC, i.p. (50 mg/kg). DTIC was co-dissolved with citric 
acid (1:1 by weight) in dH2O and administered daily by intraperitoneal injection. 
GW3965 + Vemurafenib Therapy: i.) control diet; ii.) GW3965 diet (75 mg/kg); iii) 
vemurafenib diet (50 mg/kg); iv) GW3965 (75 mg/kg) + vemurafenib (50 mg/kg) combined 
diet or vemurafenib diet (50 mg/kg) alternated with GW3965 diet (75 mg/kg), as indicated.  
GW3965 + anti-CTLA-4 Ab Therapy: i) control diet + IgG; ii) GW3965 diet (100 mg/kg) + 
IgG; iii) control diet + anti-CTLA-4 Ab; iv) control diet + anti-CTLA-4 Ab + B16F10-GM-
CSF vaccine; v) GW3965 diet (100 mg/kg) + anti-CTLA-4 Ab. IgG Ab or anti-CTLA-4 Ab 
(BioXcell) was administered on day 4 post-injection at a dose of 100 μg/mouse followed by 
two successive 50 μg/mouse doses every 3 days by i.p injection. The antibodies were 
administered in PBS for a total injection volume of 200 μL per mouse.  The B16F10 GM-
CSF vaccine, comprised of 1 × 106 irradiated (16,000 Rads, 1 hour prior to treatment) 
B16F10-GM-CSF cells, was administered at the same time as the antibody treatment by 
subcutaneous injection into the lower back area, as previously described (van Elsas et al., 
1999). B16F10 cells were engineered to overexpress GM-CSF by transfection of 2 μg of 
	   199 
pCMV6-GM-CSF vector (MC208342, OriGene) into B16F10 cells 48 hours prior to 
injection. GM-CSF overexpression was confirmed by ELISA (88-7334-22, Affymetrix 
eBioscience) analyses of conditioned cell media collected 48 hours post-transfection. Typical 
extracellular GM-CSF levels detected were in the range of 20-40 ng of GM-CSF per 1 
million cells. 
Tumor dimensions were measured using digital calipers, and tumor volume was 
calculated as (small diameter)2  × (large diameter)/2. For survival analyses, mice were 
euthanized when total tumor burden exceeded 1500 mm3 in volume. All drug-formulated 
diets were prepared by Research Diets, Inc. 
Genetically Initiated Model of Melanoma Progression 
The Tyr::CreER; B-RafV600E/+; Ptenlox/+ / Tyr::CreER; B-RafV600E/+; Ptenlox/lox  
conditional model of melanoma progression was previously established and characterized by 
Dankort et al. (2009). Briefly, melanoma in these mice was induced at 6 weeks of age by 
intraperitoneally injecting 4-HT (H6278, 70% isomer, Sigma-Aldrich) at a dose of 25 mg/kg. 
The 4-HT stock solution was prepared by dissolving it in 100% EtOH at 50 mg/mL by 
heating at 45°C for 5 min and mixing.  Once dissolved, the stock 4-HT solution was then 
diluted 10-fold in peanut oil, yielding a 5 mg/mL 4-HT working solution that was then 
injected into mice on three consecutive days. After the first 4-HT injection, mice were 
blindedly assigned to receive either a control diet or a diet supplemented with GW3965 (100 
mg/kg). Mice were examined three times a week for the presence and progression of 
melanoma lesions. At day 35, dorsal skin samples were harvested from control-treated and 
GW3965-treated Tyr::CreER; B-RafV600E/+; Ptenlox/lox mice, washed in PBS, fixed in 4% PFA, 
and photographed at 10X. The percentage of pigmented melanoma lesion area out of the total 
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dorsal skin area was quantified using ImageJ. For survival analyses, mice were monitored 
daily for melanoma progression and euthanized according to a standard body condition score, 
taking into account initial signs of moribund state and discomfort associated with the 
progression of melanoma burden. Post-mortem, the lungs, brains, and salivary glands were 
harvested and examined for the presence of macroscopic melanoma lesions.  
Generation of DTIC-Resistant Melanoma Cells 
DTIC-resistant B16F10 mouse melanoma cells were generated by continuously 
culturing the cells in the presence of DTIC (D2390, Sigma-Aldrich). First, the cells were 
treated with 500 μg/mL DTIC for one week. Following this initial DTIC treatment, the 
remaining (~10%) viable cells were allowed to recover for one week, after which 750 μg/mL 
of DTIC was added to the cell media for 5 days. Subsequent to this high-dose treatment, the 
cells were allowed to recover in the presence of low-dose DTIC (100 μg/mL) for one week.  
The cells were then continuously cultured in media containing 200 μg/mL DTIC for two 
months prior to grafting the cells onto mice. DTIC was added to fresh cancer cell media 
every 3 days. For tumor growth experiments, 5 × 104   B16F10 parental and DTIC-resistant 
cells were subcutaneously injected into the lower flank of 7-week-old C57BL/6 mice. 
Following formation of small tumors measuring 5-10 mm3 in volume, the mice were 
randomly assigned to the following treatment groups:  (1) control diet + vehicle, i.p. (citric 
acid, 50 mg/kg); (2) control diet + DTIC i.p. (50 mg/kg); (3) GW3965-supplemented diet 
(100 mg/kg) + vehicle i.p. . DTIC was co-dissolved with citric acid (1:1 by weight) in dH2O 
and administered daily by intraperitoneal injection.  
The DTIC-resistant MeWo human melanoma sub-line was generated following DTIC 
treatment of mice bearing MeWo tumors measuring 600-800 mm3 in volume. After initial 
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tumor shrinkage in response to daily DTIC dosing (50 mg/kg, i.p.), the tumors eventually 
developed DTIC resistance and resumed growth, at which point tumor cells were dissociated, 
propagated in vitro, and the DTIC-resistant MeWo cell line was established. The cells were 
expanded in vitro in the presence of DTIC (200 μg/mL) for one week, after which 5 × 105 
DTIC-resistant MeWo cells were subcutaneously implanted onto 8-week old NOD SCID 
gamma mice.  Following the growth of tumors to 5-10 mm3 in volume, mice were blindedly 
assigned to the following treatment groups: (1) control diet; (2) control diet + DTIC (50 
mg/kg);  (3) GW3965-supplemented diet (100 mg/kg). To determine the effect of DTIC on 
tumor growth by parental unselected MeWo cells, 5 × 105 MeWo cells were subcutaneously 
injected into NOD SCID gamma mice, and the mice were treated with a control vehicle or 
DTIC (50 mg/kg) following the formation of tumors measuring 5-10 mm3 in volume. DTIC 
was administered as described above in cycles consisting of five consecutive daily treatments 
interspersed by two-day off-treatment intervals.  Tumor growth was measured twice a week. 
Generation of Vemurafenib-Resistant Melanoma Cells 
For generation of vemurafenib-resistant primary mouse melanoma YUMM cells, 1 × 
105 cells were subcutaneously injected bilaterally into the lower flank of C57BL/6 mice. 
Following formation of tumors measuring ~10 mm3 in volume, the mice were randomly 
assigned to a control diet or a vemurafenib-supplemented diet (100 mg/kg), prepared by 
Research Diets, Inc. After initial inhibition of tumor growth in response to vemurafenib, 
tumor growth in the presence of the drug eventually resumed, and resistant clones were 
isolated from a subset of vemurafenib-resistant tumors (~400 mm3) harvested at day 52.  The 
resistant sub-lines were propagated in the presence of vemurafenib (2 μM) continuously 
added to the cell media. The A375 vemurafenib-resistant cells were similarly generated 
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following the in vivo vemurafenib treatment of A375 melanoma tumors grafted onto NOD 
SCID gamma mice. Following tumor relapse, melanoma cells were dissociated and expanded 
in vitro as described above. 
 
miRNA Microarray Hybridization 
For identification of miRNAs showing deregulated expression across highly 
metastatic melanoma cell line derivatives, total RNA from multiple independent metastatic 
derivatives and their respective parental MeWo and A375 cell populations was used to enrich 
for small RNAs, which were then labeled and hybridized onto microfluidic custom 
microarray platforms by LC Sciences. The arrays were designed to detect 894 mature 
miRNAs corresponding to the miRNA transcripts listed in the Sanger miRBase Release 13.0. 
Out of all the probes analyzed, those corresponding to 169 miRNAs yielded signal above a 
background threshold across the multiple cell lines tested. The raw signal intensities, 
corresponding to probe hybridization, were median-normalized for each cell line. We used a 
threshold of 2-fold or higher up-regulation of median-normalized expression values in order 
to identify miRNAs commonly induced in multiple metastatic derivatives for two 
independent human melanoma cell lines. 
 
Microarray-Based Target Gene Prediction for miR-199a and miR-1908 
In order to identify potential genes targeted by miR-199a-3p, miR-199a-5p, and miR-
1908, total RNA was extracted from MeWo cell lines with loss- or gain-of-function of each 
miRNA and submitted to the genomics core facility at The Rockefeller University for 
hybridization onto Illumina HT-12 v3 Expression BeadChip microarrays. The raw signal 
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intensities, corresponding to probe hybridization, were then median-normalized for each cell 
line sample. We generated three sets of microarray profile comparisons: (1) MeWo control 
cells relative to MeWo cells over-expressing miR-199a or miR-1908, (2) MeWo-LM2 
control cells relative to MeWo-LM2 cells expressing a short hairpin (miR-Zip) targeting 
miR-199a-3p, miR-199a-5p, or miR-1908, and (3) MeWo parental cells relative to MeWo-
LM2 cells. Based on the median-normalized expression values from these arrays, we used 
the following criteria to arrive at possible target genes common to miR-199a and miR-1908: 
(1) genes downregulated by more than 1.5-fold upon individual overexpression of each miR-
199a and miR-1908, (2) genes upregulated by more than 1.5-fold upon inhibition of either 
both miR-199a-3p and miR-1908 or both miR-199a-5p and miR-1908, and (3) genes 
downregulated by more than 1.5-fold in LM2 cells, which express physiologically higher 
levels of the three miRNAs, relative to MeWo parental cells.  
 
Analysis of miRNA and mRNA Expression in Cell Lines 
Total RNA was extracted from various cell lines using the miRvana kit (AM1560, 
Applied Biosystems). The expression levels of mature miRNAs were quantified by a stem-
loop qRT-PCR method, starting with 100 ng of total RNA and using the TaqMan miRNA 
expression assay (4427975, Life Technologies) and the TaqMan universal master mix 
(4440040, Life Technologies), as per the supplier’s recommendation. RNU44 was used as an 
endogenous control for normalization. For mRNA transcript expression analyses, 600 ng of 
total RNA was reverse transcribed using the cDNA First-Strand Synthesis Kit (18080-051, 
Invitrogen), and roughly 200 ng of the resulting cDNA was then mixed with SYBR® green 
PCR Master Mix (4309155, Applied Biosystems) and the appropriate primers. Each reaction 
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was performed in quadruplicate, and mRNA expression was quantified by performing real-
time PCR amplification using an ABI Prism 7900HT Real-Time PCR System (Applied 
Biosystems).  GAPDH was used as an endogenous control for normalization. For pri-miRNA 
transcript expression analyses, 600 ng of total RNA were converted to cDNA as described 
above and analyzed using the TaqMan pri-miRNA assay (4427013, Life Technologies) and 
the GusB TaqMan gene expression assay (4333767T, Life Technologies), which was used as 
an endogenous control. For experiments testing the effect of LXR agonist treatment on 
melanoma cell ApoE mRNA expression, roughly 7 × 105 melanoma cells were treated with 
DMSO, GW3965, or T0901317 at 1 μM for 48 hours, after which the transcript levels of 
ApoE were analyzed as described above. All primers used for qRT-PCR analyses are listed 
in Appendix B. 
 
Analysis of miRNA Copy Number 
To determine the relative genomic copy number of miR-199a-1, miR-199a-2, and 
miR-1908, genomic DNA was extracted from melanoma parental cells and their metastatic 
derivatives, and the genomic regions spanning each miRNA sequence were amplified and 
quantified by qRT-PCR using two independent primer sets corresponding to each genomic 
miRNA region (See Appendix B). The expression of each miRNA was normalized to let-7c. 
 
Analysis of Nuclear Hormone Receptor Expression in the NCI60 Series 
The heat-map displaying the relative expression of all nuclear hormone receptors in 
the NCI-60 melanoma cell line collection was constructed using the publicly available RNA: 
Affy HG-U133 (A, B) NCI-60 microarray dataset (PMID: 17339364) downloaded from the 
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CellMinerTM Database Version 1.4 (http:// discover.nci.nih.gov/cellminer/loadDownload.do). 
To determine the relative expression of each nuclear hormone receptor, we calculated the 
change in standard deviations (z-score) for the expression value of each receptor relative to 
the average expression value of all genes (>39,000 transcripts) detected in each melanoma 
cell line.  
 
Analysis of LXR and RXR Isoform Expression in Primary Human Melanoma Lines 
Whole-cell total RNA was extracted from primary melanoma cells using the Total 
RNA Purification Kit (17200, Norgen, Thorold, Canada) and 600 ng of total RNA was 
reverse transcribed into cDNA using the cDNA First-Strand Synthesis Kit (18080-051, 
Invitrogen, Carlsbad, CA). The heatmap depicting the relative expression of LXRα, LXRβ, 
RXRα, RXRβ, and RXRγ in primary human melanoma lines was constructed using expression 
levels determined by qRT-PCR amplification using an ABI Prism 7900HT Real-Time PCR 
System (Applied Biosystems) and normalized as previously described (Fu et al., 2005). In 
brief, the PCR efficiency (E) for each primer pair used to specifically amplify each nuclear 
hormone receptor was calculated based on the slope of a standard curve generated from 
known quantities of cDNA, using the following formula:  
E=10-1/slope 
The determined efficiencies for each primer set were then used to convert logarithmic cycle 
times (Ct) raw amplification values into linear units, and the relative expression of each 
receptor was obtained by normalization to an internal positive control (GAPDH) for each 
sample based on the following formula:  
(E-Ct)LXR or RXR isoform / (E-Ct)GAPDH 
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Transcriptomic Analysis of Secreted Gene Products in Melanoma Cells Treated with 
GW3965 
In order to identify secreted factors transcriptionally upregulated by activation of 
LXR signaling in melanoma cells, MeWo cells were treated with DMSO or GW3965 at 1 
μM for 48 hours, after which total RNA was extracted, biotin-labeled using the TargetAmp-
Nano Labeling Kit for Illumina Expression BeadChip (TAN091096, Epicentre), and 
submitted to the genomics core facility at the Rockefeller University for hybridization onto 
Illumina HumanHT-12 V4.0 expression beadchip. The raw signal intensities, corresponding 
to probe hybridization, were quantile-normalized and processed using the lumi package. For 
statistical comparisons, q-values < 0.05 were deemed statistically significant. Out of the 365 
genes that were significantly upregulated in the GW3965 treatment group relative to the 
DMSO group, we identified 41 factors that were previously annotated on the NCBI server as 
extracellular components. 
 
Lentiviral miRNA Inhibition and mRNA Knockdown Studies 
293T cells were seeded in a 10-cm plate and allowed to reach 60% confluency.  Prior 
to transfection, the cell media was replaced with fresh antibiotic-free DMEM media 
supplemented with 10% FBS. 6 µg of vector A, 12 µg of vector K, and 12 µg of the 
appropriate miR-Zip (System Biosciences, Mountain View, CA) or shRNA plasmid construct 
(MSKCC HTS Core Facility or Sigma-Aldrich) were co-transfected using 60 µL of TransIT-
293 transfection reagent (MIR 2700, Mirus Bio LLC).  The cells were incubated at 37°C for 
48 hours, and the virus was harvested by spinning the cell media for 10 minutes at 2000 g 
followed by virus filtration through a 0.45-µm filter. Subsequently, 1 × 105 cancer cells were 
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transduced with 2 mL of the appropriate virus in the presence of 10 µg/mL of polybrene (TR-
1003-G, Millipore) for 6 hours. After 48 hours, 2 µg/mL of puromycin (P8833, Sigma-
Aldrich) was added to the cell media for lentiviral selection. The cells were kept in 
puromycin selection for 72 hours. The miR-Zip or shRNA sequences used for knocking 
down each respective miRNA or mRNA are listed in Appendix C. 
 
Retroviral miRNA and Protein Overexpression Studies 
6 µg of vector VSVG, 12 µg of vector Gag-Pol, and 12 µg of pBabe plasmid 
containing the coding sequences of human ApoE, DNAJA4, or an empty vector or 12 µg of 
miR-Vec containing the precursor sequence of miR-199a, miR-214, miR-1908, or a control 
hairpin were co-transfected into 60%-confluent 293T cells using 60 µL of TransIT-293 
transfection reagent. The cells were incubated at 37°C for 48 hours, after which the virus was 
harvested and transduced into cancer cells in the presence of 10 µg/mL of polybrene for 6 
hours. After 48 hours, 2 µg/mL of puromycin or 10 µg/mL of blasticidin (15205, Sigma-
Aldrich) were added to the cell media for retroviral selection. The cells were kept in 
puromycin selection for 72 hours or in blasticidin selection for 7 days. The cloning primers 
used for overexpression of the coding sequences of ApoE and DNAJA4 are listed in 
Appendix B.  
 
siRNA-Based Gene Knockdown 
To determine whether transient knockdown of CREB regulates miR-199a-3p, miR-
199a-5p, or miR-1908, MeWo-LM2 cells were transferected with siRNAs targeting CREB1 
or a control siRNA at a final siRNA concentration of 100 nM and using lipofectamineTM 
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2000 transfection reagent (11668-09, Invitrogen). The transfection cell media was replaced 
with fresh media 5 hours post-transfection. The levels of the mature and pri-miRNAs were 
quantified 48 hours post-transfection by qRT-PCR. To identify the ApoE receptors on 
melanoma cells and endothelial cells mediating ApoE’s effects, siRNAs targeting LRP1, 
LRP8, VLDLR, LDLR, or a control sequence were transfected into cancer cells or HUVEC 
cells at a final concentration of 100 nM using lipofectamineTM 2000 transfection reagent. 
After 5 hours, the transfection media was replaced with fresh media. The cells were subjected 
to matrigel invasion or endothelial recruitment assays 72-96 hours post-transfection. Cells 
transduced with siRNAs targeting LRP1 or a control sequence in the setting of miR-1908 
inhibition were tail-vein injected into NOD SCID mice for lung colonization assays 72 hours 
post-transfection. Individual targeting siRNAs and control non-targeting siRNAs were 
obtained from Dharmacon (Thermo Fisher Scientific).  
 
LNA-Based miRNA Inhibition 
LNAs complementary to mature miR-199a-3p, miR-199a-5p, miR-1908, or a control 
sequence were transfected at a final concentration of 50 nM into 50-70% confluent cancer 
cells cultured in antibiotics-free media using lipofectamineTM 2000 transfection reagent. After 
8 hours, the transfection media was replaced with fresh media. After 48 hours, the cells were 
intravenously injected into immunocompromised mice for lung colonization assays. 
 
Therapeutic LNA-Based In Vivo Targeting of miRNAs  
To determine whether intravenously administered in vivo optimized LNAs antisense 
to miR-199a-3p, miR-199a-5p, and miR-1908 get delivered into metastatic nodules and 
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inhibit expression of these miRNAs, mice were injected with 4 × 104 MeWo-LM2 cells. 
Following lung metastatic nodule formation, mice were treated with LNA-3 miRNAs (at a 
total dose of 12.5 mg/kg per each treatment) or a control mock PBS treatment three times 
with a three-day interval between each treatment. MeWo-LM2 cells were dissociated from 
lung nodules 24 hours after the last LNA treatment, as described above, and propagated in 
culture for 48 hours prior to RNA extraction using the miRvana total RNA extraction kit. 
Expression levels of miR-199a-3p, miR-199a-5p, and miR-1908 in MeWo-LM2 cells 
dissociated from lung nodules of LNA-3 miRNAs or PBS-treated mice were quantified by 
qRT-PCR using the TaqMan miRNA expression assays and starting with 100 ng of total 
RNA, as described above. RNU44 was used as an endogenous control. To determine whether 
the in vivo administered LNAs also target the mouse homologs of the three miRNAs, 24 
hours after the last LNA treatment, mouse cardiac and liver tissues were harvested, and total 
RNA was extracted. The expression levels of miR-199a-3p, miR-199a-5p, and miR-1908 in 
mouse cardiac and liver tissues were assessed by qRT-PCR using the TaqMan miRNA 
expression assays and starting with 100 ng of total RNA. Mouse U6 snRNA was used as an 
endogenous control for normalization.  
 
Luciferase Reporter Assays 
Validation of Direct miRNA Target Genes 
Heterologous luciferase reporter assays were performed as previously described 
(Tavazoie et al., 2008). In brief, the full-length 3’UTR’s of ApoE and DNAJA4 were cloned 
downstream of a renilla luciferase reporter into the psiCheck2 dual luciferase reporter vector 
(C8021, Promega), while the full-length CDS’s (minus the start codon) of ApoE and 
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DNAJA4 were chimerically fused to the C-terminus of the renilla luciferase reporter in the 
psiCheck2 vector by removing the luciferase stop codon and inserting a 6 amino acid-long 
linker connecting the CDS of luciferase to the CDS of each ApoE or DNAJA4. 4 × 104 
parental MeWo cells, MeWo-LM2 cells, MeWo cells overexpressing miR-199a, miR-1908, 
or a control hairpin, and MeWo-LM2 cells expressing a miR-Zip hairpin targeting miR-199a-
3p, miR-199a-5p, miR-1908, or a control sequence were transfected with 100 ng of the 
respective specific reporter constructs using the TransIT-293 transfection reagent. After 48 
hours, the cells were lysed, and the ratio of renilla to firefly luciferase expression was 
determined using the dual luciferase assay (E1910, Promega). Putative miRNA binding sites 
in each target construct were identified by alignment to the complementary miRNA seed 
sequences (miR-199a-3p: 5’-CAGUAGUC-3’; miR-199a-5p: 5’-CCAGUGUU-3’; miR-
1908: 5’-GGCGGGGA-3’). The miRNA complementary sites on each target construct were 
mutated using the QuickChange Multi Site-Directed Mutagenesis Kit (200514, Agilent 
Technologies). Based on miRNA seed sequence complementarity analysis, the CDS of ApoE 
was mutated by introducing silent mutations at amino acid positions: 45 (GAA to GAG), 46 
(CTG to CTT), 47 (GCA to GCT), 48 (CTG to CTT), 95 (GAA to GAG), 96 (CTG to CTT), 
277 (GCC to GCT), and 278 (CGC to CGA). The CDS of DNAJA4 was mutated by 
introducing silent mutations at amino acid positions: 124 (TGC to TGT), 125 (CCG to CCA), 
and 306 (CAC to CAT). The 3’UTR of ApoE was mutated at nucleotide positions: 83-85 
(GCC to ATA) and 98-100 (CTG to ACA). The 3’UTR of DNAJA4 was mutated at 
nucleotide positions: 576-578 (CTG to ACA), 1096-1098 (CTG to TCT), 1396-1398 (CGC 
to TGT), and 1596-1598 (CTG to TGT).  All cloning and mutagenesis primers used are listed 
in Appendix B. 
	   211 
ApoE Promoter Activity Assay 
The ApoE promoter, consisting of a sequence spanning 980 base pairs upstream and 
93 base pairs downstream of the ApoE gene, was cloned into a pGL3-Basic vector (E1751, 
Promega) upstream of the firefly luciferase gene using NheI and XhoI restriction enzymes.  
Then, multi-enhancer elements 1 (ME.1) or 2 (ME.2) were cloned directly upstream of the 
ApoE promoter using MluI and NheI restriction enzymes.  To assess ApoE promoter- and 
ME.1/ME.2-driven transcriptional activation by LXR agonists, 5 × 104 MeWo cells were 
seeded into a 24-well plate.  The following day, 100 ng of pGL3-ME.1/ME.2-ApoE promoter 
construct and 2 ng of pRL-CMV renilla luciferase construct (E2261, Promega) were co-
transfected into cells in the presence of DMSO, GW3965, or T0901317 at 1 µM, each 
condition in quadruplicates.  To assess transcriptional activation by LXRα or LXRβ, 5 × 104 
MeWo cells expressing a control shRNA or an shRNA targeting LXRα or LXRβ were seeded 
into a 24-well plate.  The following day, 200 ng of pGL3-ME.1/ME.2-ApoE promoter 
construct and 2 ng of pRL-CMV renilla luciferase were co-transfected into cells in the 
presence of DMSO, GW3965, or T0901317 at 1µM, each condition in quadruplicates.  After 
24 hours, cells were lysed, and cell lysates were analyzed for firefly and renilla luciferase 
activity using the Dual Luciferase Assay System (E1960, Promega) and a Bio-Tek Synergy 
NEO Microplate Reader.  Firefly luciferase signal was normalized to renilla luciferase signal, 
and all data are expressed relative to the luciferase activity ratio measured in the DMSO-
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Western Blotting 
Total and phosphorylated CREB levels were assessed in parental MeWo and MeWo-
LM2 cells by lysis of the cells in RIPA buffer (Sigma-Aldrich), SDS-PAGE separation of 
total protein lysates (15 μg), transfer to a PVDF membrane, and blotting with antibodies 
against total CREB (48H2, Cell Signaling), phospho-CREB (87G3, Cell Signaling), or 
GAPDH (G9545, Sigma-Aldrich). 
To determine the effect of ApoE/LRP8 targeting on endothelial VEGFR2 activation, 
HUVEC or primary mouse lung endothelial cells (MLECs) were incubated in the presence of 
recombinant ApoE3 for 1 hour at 2 μg/mL or 5 μg/mL (HUVEC) or 10 μg/mL (MLECs). 
Subsequently, endothelial cells were pulsed with either human VEGF (12 ng/mL) or mouse 
VEGF (30 ng/mL), respectively, for 15 min. After that, cells were lysed in RIPA buffer on 
ice, and protein was extracted. Total protein lysates (20 μg) were separated by SDS-PAGE 
and transferred to a PVDF membrane that was then blotted with antibodies against total 
VEGFR2 (2472, Cell Signaling), phospho-VEGFR2 (2478, Cell Signaling), or GAPDH 
(G9545, Sigma-Aldrich). For analysis of VEGFR2 expression and activation in primary 
melanoma tumors, subcutaneous tumors formed by MeWo cells overexpressing miR-199a or 
miR-1908 or a control were extracted and homogenized on ice in RIPA buffer. The 
expression of total and phopsho-VEGFR2 was assessed as described above. The LRP8 
protein expression levels in MLECs dissociated from LRP8 wild-type, LRP8 heterozygous, 
or LRP8 null mice were analyzed in 40 μg of total protein lysate by SDS-PAGE and blotting 
with an antibody specific for LRP8 (NB100-2216, Novus Biologicals). 
For analysis of ApoE protein expression in stromal tissues upon LXR agonist 
treatment, mouse lung, adipose, and brain tissues were extracted from mice treated with a 
	   213 
control diet or an LXR-agonist supplemented diet (20 mg/kg) for 10 days. Lung and brain 
tissues were homogenized on ice in RIPA buffer (Sigma-Aldrich). Mouse adipose tissue was 
homogenized in TNET buffer (1.5 mM Tris pH 7.5, 150 mM NaCl, 2mM EDTA, 1% triton, 
protease inhibitors). For analysis of ApoE protein expression in human melanoma cells 
treated with DMSO, GW3965, or T0901317 at 1 μM for 72 hours, cells were lysed in RIPA 
buffer. Total protein lysates (2 μg for tissue lysates; 40 μg for melanoma cell lysates) were 
separated by SDS-PAGE, transferred to a PVDF membrane, and blotted with antibodies 
against mouse ApoE (ab20874, Abcam), human ApoE (ab1906, Abcam), and tubulin (2148, 
Cell Signaling).  
 
ApoE ELISA 
Extracellular ApoE levels in serum-free conditioned media collected from melanoma 
cells were quantified using the human ApoE ELISA kit (Innovative Research), following the 
manufacturer’s protocol. Conditioned cancer cell media was prepared by culturing 70%-
80%-confluent cells in 02% FBS media for 24-36 hours. 
 
DNAJA4 Immunoprecipitation and MS-Based Analysis of Interacting Partners 
To identify putative interacting partners of DNAJA4, total protein was extracted from 
melanoma cells overexpressing flag-tagged DNAJA4.2 or DNAJA4.3 or melanoma cells 
expressing an empty control vector. The cells were lysed in a buffer comprised of 50 mM 
Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% triton, and protease/phosphatase inhibitors.  
Flag-tagged DNAJA4.2 and DNAJA4.3 were immunoprecipitated from MeWo parental or 
MeWo-LM2 cells using magnetic beads coated with an anti-flag antibody and rotating at 4°C 
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for four hours. The beads were consecutively washed in wash buffer 1 (50 mM Tris (pH 7.5), 
300 mM NaCl, 1% triton) and wash buffer 2 (50 mM Tris (pH 7.5), 150 mM NaCl) and the 
immunoprecipitated product was eluted using a flag peptide (50 mM Tris (pH 7.5), 150 mM 
NaCl, 10% 3X Flag Peptide). The eluted product was then mixed with 5X sample buffer and 
separated by SDS-PAGE on a 4-12% Bis-Tris Gel. Proteins that ran on the gel were 
coomassie stained, and bands of interest were submitted for mass spectrometry (MS) analysis 
at the Proteomics Core Facility at the Rockefeller University. Identified protein candidates 
were ranked by the number of unique peptides detected by MS. Hits with three or more 
unique peptides present were prioritized. The MS results only list proteins that were detected 
in either the DNAJA4.2 or DNAJA4.3 flag immunoprecipitation product, but not in the 
empty control pull down.  
 
LXRβ ChIP 
To determine a potential interaction of endogenous LXRβ with the ApoE multi-
enhancer element in human melanoma cells, the ChIP-IT® High Sensitivity kit (53040, 
Active Motif) along with an LXRβ antibody previously optimized for ChIP (61177, Active 
Motif) were used. The ChIP experiment was carried out by following the precise 
recommendations of the kit’s manufacturer. In brief, chromatin was extracted from ~5 × 106 
MeWo cells treated with DMSO or GW3965 (1 μM) for 8 hours and cross-linked in 
formaldehyde-based cell fixation solution. Chromatin was sonicated on ice using a micotrip 
system (Branson Sonifier, model SSE-1, Danbury, CT) and the following sonication regime: 
25% amplitude, 30 seconds on and 30 seconds off for a total “on” sonication time of 10 
minutes. Chromatin shearing efficiency was confirmed by running 500 ng of reversely cross-
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linked sheared chromatin on an agarose gel. ChIP reactions were set-up by mixing 18 μg of 
sheared chromatin with anti-LXRβ (10 μL per reaction) or IgG antibody and ChIP buffer, 
containing protease inhibitions. The ChIP reactions were incubated on an end-to-end rotator 
for 16 hours at 4 °C.  The ChIP product was then filtered and bound to a column, eluted, 
reverse cross-linked, protein-digested, and DNA was purified. Purified DNA product was 
analyzed by qRT-PCR. Standard curves for each primer set were generated using dilution 
series from known amounts of input chromatin and used to extrapolate the amount of PCR 
product in each ChIP reaction. Appendix B lists the qRT-PCR primers used to detect a region 
on chromosome 19 containing the ME.2 LXRβ-binding motif (LXRE-pos) and a negative 
control genomic region on chromosome 1 devoid of LXRβ-binding sites (LXRE-neg). 
 
Phenotypic Assays 
In Vitro Cell Proliferation Assay 
To determine the effects of miR-199a or miR-1908 overexpression and combinatorial 
LNA-based miRNA inhibition on cell proliferation, 2.5 × 104 cells were seeded in triplicate 
in, and viable cells were counted after 3 or 5 days. To test the effect of recombinant ApoE on 
in vitro melanoma cell proliferation, 3 × 104 MeWo-LM2 cells were seeded in triplicates and 
incubated in the presence of BSA or recombinant ApoE (100 μg/mL), and viable cells were 
quantified at days 1, 3, and 5 post-treatment. To determine the effects of GW3965, 
T0901317, and bexarotene on in vitro cell proliferation, 2.5 × 104 melanoma cells were 
seeded in triplicate and cultured in the presence of DMSO, GW3965, T0901317, or 
bexarotene at 1 μM each. After 3 or 5 days, the number of viable and dead cells was counted 
using the trypan blue dye (72-57-1, Sigma-Aldrich), which selectively labels dead cells. 
	   216 
Endothelial Adhesion Assay 
1 × 105 HUVEC were seeded in 6-well plates and allowed to form monolayers. 
Cancer cells were serum starved in 0.2% FBS DMEM-based media for 30 minutes and 
pulsed with Cell Tracker Green CMFDA dye (C7025, Invitrogen) for 45 minutes. 2 × 105 
cancer cells, resuspended in 0.5 mL starvation media, were seeded onto each endothelial 
monolayer. The cancer cells were allowed to adhere to the HUVEC monolayers for 30 
minutes at 37°C. The endothelial monolayers were then washed gently with PBS and fixed 
with 4% paraformaldehyde for 15 minutes. Each well was then coated with PBS, and 8 
images were taken for each endothelial monolayer using an inverted Fluorescence 
microscope (Zeiss Axiovert 40 CFL) at 10X magnification. The number of cancer cells 
adhering to HUVEC was quantified using ImageJ. 
Colony Formation Assay 
Fifty MeWo parental cells overexpressing miR-199a, miR-1908, or a control hairpin 
were seeded in quadruplicate into 6-cm plates. After two weeks, the cells were washed with 
PBS, fixed with 6% glutaraldehyde (G5882, Sigma-Aldrich), and stained with 0.5% crystal 
violet (HT90132, Sigma-Aldrich). The number of positive-staining colonies was counted. 
Serum Starvation Assay 
To determine the effects of miR-199a and miR-1908 on melanoma cell serum 
starvation capacity, 1 × 105 MeWo parental cells overexpressing miR-199a, miR-1908, or a 
control hairpin were seeded in quadruplicate and incubated in 0.2% FBS starvation DMEM-
based media for 48 hours, after which the number of viable cells was counted using trypan 
blue. 
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Anoikis Assay 
1 × 106 MeWo cells overexpressing miR-199a, miR-1908, or a control hairpin were 
seeded in low adherent plates containing cell media supplemented with 0.2% methylcellulose 
(M7140, Sigma-Aldrich). Following 48 hours in suspension, the numbers of dead and viable 
cells were counted using trypan blue (T8154, Sigma-Aldrich).  
Matrigel Invasion Assay 
Cancer cells were serum-starved in 0.2% FBS DMEM-based media for 12-16 hours. 
Trans-well invasion chambers (354480, BD Biosciences) were pre-equilibrated prior to 
beginning the assay by adding 0.5 mL of starvation media to the top and bottom chambers. 
After 30 minutes, the media in the top chamber was removed, and 0.5 mL of media 
containing melanoma cells (1 × 105 for the MeWo line; 5 × 104 for the A375, HT-144, SK-
Mel-2, or SK-Mel-334.2 lines), was added into each matrigel-coated trans-well insert and 
incubated at 37°C for 24 hours. For neutralization antibody and/or recombinant protein 
experiments, antibody/recombinant protein was added to each trans-well at the start of the 
assay at the following concentrations: 40 μg/mL anti-ApoE 1D7 (Heart Institute, University 
of Ottawa) or anti-IgG (AB-108-C, R&D Systems) and 3.44 μg/mL recombinant human 
ApoE3 or BSA. For experiments testing the effects of LXR or RXR agonists on cell 
invasion, various melanoma cells were cultured in the presence of DMSO, GW3965, 
T0901317, or bexarotene at 1 μM for 56 hours, after which melanoma cells were switched to 
starvation media (0.2% FBS) for 16 hours in the presence of each drug. Following starvation, 
cells were seeded into matrigel-coated trans-well inserts, and the invasion assay was allowed 
to proceed for 24 hours at 37°C. Upon completion of the assay, matrigel-coated inserts were 
washed with PBS, the cells at the top side of each insert were scraped off, and the inserts 
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were fixed in 4% paraformaldehyde for 15 minutes. The inserts were then cut out and 
mounted onto slides using VectaShield mounting medium containing DAPI (H-1000, Vector 
Laboratories). The basal side of each insert was imaged using an inverted fluorescence 
microscope (Zeiss Axiovert 40 CFL) at 5X magnification, taking three representative images 
for each insert. The number of invaded cells was quantified using ImageJ (NIH).  
Endothelial Recruitment Assay 
5 × 104 melanoma cells were seeded into 24-well plates approximately 24 hours prior 
to the start of the assay. HUVEC were grown to 80% confluency in EGM-2 media 
supplemented with 2% FBS and subsequently serum starved in EGM-2 media supplemented 
with 0.2% FBS for 16 hours. HUVEC were then pulsed with Cell Tracker Red CMTPX dye 
(C34552, Invitrogen) for 45 minutes. Meanwhile, cancer cells were washed with PBS, 0.5 
mL of 0.2% FBS EGM-2 media was added to each well, and a 3.0 μm HTS Fluoroblock 
insert (351151, BD Falcon) was placed into each well. 1 × 105 HUVEC, resuspended in 0.5 
mL of starvation media, were seeded into each trans-well insert, and the recruitment assay 
was allowed to proceed for 16-20 hours at 37°C. For neutralization antibody and/or 
recombinant protein experiments, antibody/recombinant protein was added at the start of the 
assay to each bottom well containing the melanoma cells at the following concentrations: 40 
μg/mL anti-ApoE 1D7 or anti-IgG and 3.44 μg/mL recombinant human ApoE3 or BSA. To 
test the effect of LXR or RXR agonists on endothelial recruitment, melanoma cells were 
treated with DMSO, GW3965, T0901317, or bexarotene at 1 μM for 56 hours, after which 5 
× 104 cells were seeded in a 24-well plate in the presence of each drug and allowed to attach 
for 16 hours prior to starting the endothelial recruitment assay. Upon completion of the assay, 
the inserts were processed and analyzed as described for the matrigel invasion assay above. 
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Endothelial Migration Assay 
Serum-starved HUVEC cells were pulsed with Cell Tracker Red CMTPX dye for 45 
minutes and seeded into HTS Fluoroblock trans-well inserts at a concentration of 1 × 105 
HUVEC in 0.5 mL starvation media per each insert. The assay was allowed to proceed for 
16-18 hours at 37°C, and the inserts were processed and analyzed as described above (See 
Matrigel Invasion Assay). 
ApoE Gradient Migration Assay 
HUVEC transduced with a control siRNA or an siRNA targeting LRP8 were serum-
starved in 0.2% FBS EGM-2 media for 16 hours and labeled with Cell Tracker Red CMTPX 
dye for 45 minutes. Meanwhile, the indicated amounts (1, 2, or 5 μg) of recombinant human 
ApoE3 or BSA were mixed with 250 μL of matrigel and allowed to solidify at the bottom of 
a 24-well plate for 30 min. 250 μL of HUVEC EGM-2 media containing 0.2% FBS was then 
added to each matrigel-coated well, and 3.0 μM HTS Fluoroblock inserts were fitted into 
each well. 1 × 105 HUVEC, resuspended in 0.5 mL of starvation (0.2% FBS) EGM-2 media, 
were seeded into each insert and allowed to migrate along the matrigel gradient for 16-18 
hours at 37°C. Upon completion of the assay, the inserts were mounted on slides and 
analyzed as described above (See Matrigel Invasion Assay). 
In Vivo Matrigel Plug Assay 
10 μg/mL recombinant human ApoE3, 10 μg/mL BSA, or 400 ng/ml VEGF (01-185, 
Millipore) were mixed with matrigel as indicated in Figure 4.9a. 400 μL of matrigel 
containing the indicated recombinant proteins were injected subcutaneously just above the 
lower ventral flank of 6-week old immunocompromised NOD SCID mice. Plugs were 
extracted on day 3 post-injection and fixed in 4% paraformaldehyde for 48 hours. Plugs were 
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then paraffin-embedded and sectioned at 5-μm thick increments. Plug sections were 
immunohistochemically stained using a primary antibody against the mouse endothelial 
antigen MECA-32, detected by peroxidase-conjugated secondary antibody (BA-4000, Vector 
Laboratories), and subsequently visualized by DAB oxidation. To quantify the extent of 
endothelial cell recruitment into each matrigel plug, the number of endothelial cells was 
counted in 4-5 random fields for each plug, and the average number of endothelial cells per 
given plug area was calculated. 
 
Histochemistry 
Macroscopic Lung Nodule Visualization 
Animals were perfused with PBS followed by fixation with 4% paraformaldehyde 
infused via intracardiac and subsequent intratracheal injections. The lungs were sectioned 
out, incubated in 4% paraformaldehyde at 4°C overnight, washed in PBS, 50% EtOH, and 
70% EtOH. Tissues were stored in 70% EtOH and were then embedded in paraffin, and 
sliced into 5-μm thick increments. For gross macroscopic metastatic nodule visualization, 
lung sections were H&E stained. 
Endothelial Cell Content Analysis 
For endothelial content analysis in metastatic nodules formed by human melanoma 
MeWo cells in mice, paraffin-embedded lung sections were double-stained with primary 
antibodies against MECA-32 (Developmental Studies Hybridoma Bank, The University of 
Iowa), which labels mouse endothelial cells, and human vimentin (VP-V684, Vector 
Laboratories), which labels human melanoma cells. Various Alexa Flour dye-conjugated 
secondary antibodies were used to detect primary antibodies. To determine the endothelial 
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density within metastatic nodules, fluorescence was measured using a Zeiss laser scanning 
confocal microscope (LSM 510), and the MECA-32 signal within each metastatic nodule, 
outlined based on co-staining with human vimentin, was quantified in a blinded fashion using 
ImageJ (NIH). For endothelial content analysis in metastatic nodules formed by mouse 
B16F10 mouse melanoma cells in wild type and ApoE genetically null mice, representative 
lung sections were stained for MECA-32, and the MECA-32 signal within each nodule, 
demarcated based on cell pigmentation, was quantified in a blinded fashion. The collective 
endothelial cell area, given as the percentage area covered by endothelial cells relative to the 
total area of each metastatic nodule, was obtained by background subtraction (rolling ball 
radius of 1 pixel) and use of a pre-determined threshold as a cut-off. A metastatic nodule was 
defined as any region of greater than 2000 μm2 total area. For large nodules, minimum of 
four representative images were obtained, and their average blood vessel density was 
calculated. 
Metastatic Nodule Angiogenic Perfusion Analysis 
For analysis of metastatic nodule perfusion, mice were intravenously injected with 2 
mg of biotinylated dextran (10,000 MW, D1956, Invitrogen) resuspended in 0.2 mL of PBS. 
Dextran was allowed to circulate through the mouse vasculature for 10 minutes, after which 
the animals were anesthetized, and lungs were extracted and processed as described above. 
Dextran perfusion within metastatic nodules was detected by performing co-immunostaining 
for biotin and human vimentin. The extent of metastatic nodule perfusion was determined in 
a blinded manner by quantifying the dextran signal within each metastatic nodule using 
ImageJ and the same approach as described for the MECA-32 signal quantification above. 
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Histochemical Analyses of LXR Agonist-Treated Tumors 
Tumors were excised from mice and fixed in 4% paraformaldehyde at 4°C for 48 
hours. Tumors were washed in 50% and 70% EtOH and were subsequently paraffin-
embedded and sectioned into 5-μm thick increments. For endothelial cell content analysis in 
tumors, tumor sections were stained with a primary antibody against the mouse endothelial 
cell marker MECA-32 (Developmental Studies Hybridoma Bank, The University of Iowa) or 
CD31 (DIA-310, Dianova) and counterstained with DAPI nuclear stain. To determine tumor 
cell proliferation and apoptosis, tumor sections were stained with antibodies against the 
proliferative marker Ki-67 (ab15580, Abcam) and the apoptotic marker cleaved caspase-3 
(9661, Cell Signaling), respectively. Various Alexa Flour dye-conjugated secondary 
antibodies were used to detect primary antibodies. Fluorescence was measured using inverted 
fluorescence microscope (Zeiss Axiovert 40 CFL) at 5X magnification for MECA-32 and Ki-
67 staining and 10X magnification for cleaved caspase-3 staining. Endothelial cell content 
density and tumor proliferative cell density were quantified by calculating the average 
percentage of MECA-32 or Ki-67 positively-staining area out of the total tumor area, 
respectively.  Tumor apoptosis rate was measured by counting the number of cleaved 
caspase-3 expressing cells per given tumor area. 
For co-localization analyses of ApoE protein expression within tumor-infiltrating 
macrophages and leukocytes, anesthetized mice were perfused with PBS followed by 4% 
paraformaldehyde via intracardiac injection. The tumors were excised and fixed in 4% 
paraformaldehyde overnight and incubated in a series of sucrose gradients for 
cryopreservation, (4 hours in 15% sucrose in PBS followed by 30% sucrose in PBS overnight 
at 4°C). Fixed tumors were embedded in Tissue-Tek O.C.T cryosectioning compound (4383, 
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Sakura Finetek), and tissue blocks were cut into 10-μm thick sections. For co-localization of 
ApoE with macrophages, formalin fixed and glycine quenched cross sections of tumors were 
double-stained with primary antibodies against ApoE (1:1000, sc-6384, Santa Cruz 
Biotechnology) and F4/80 (1:500, MCA497, Abd Serotec) overnight at 4°C. Co-localization 
of ApoE with leukocytes was performed using an anti-CD45 antibody (1:250, 550539, BD 
Biosciences). For co-localization of ApoE with endothelial cells, fresh-frozen sections (no 
fixation) were stained with an anti-ApoE primary antibody (1:1000, sc-6384, Santa Cruz 
Biotechnology) and an anti-CD31 primary antibody (1:50, 550274, BD Biosciences). 
Various alexa Fluor dye-conjugated secondary antibodies were used to detect primary 
antibodies. Sections were counterstained with DAPI and mounted with ProLong Gold 
antifade reagent (P36930, Invitrogen).  ApoE immunostaining abundance was determined by 
measuring fluorescence using laser scanning confocal microscope (TCS SP5, Leica 
Microsystems). ApoE mean signal intensity was then analyzed using FiJi software (NIH) and 
quantified within F4/80-positive macrophages, CD45-positive leukocytes or CD31-positive 
endothelial cell present in the tumor microenvironment. 
 
Analysis of miRNA Expression in Primary Melanoma Skin Lesions 
All human clinical samples used in this study were obtained, processed, and analyzed 
in accordance with institutional IRB guidelines. Paraffin-embedded cross-sections of primary 
melanoma skin lesions from 71 human patients were obtained from the MSKCC. The 
samples were de-paraffinized by five consecutive xylene washes (5 minutes each). Following 
de-paraffinization, the malignancy-containing region was identified by H&E staining, 
dissected, and total RNA was extracted from it using the RecoverAll Total Nucleic Acid 
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Isolation Kit (AM1975, Applied Biosystems). The expression levels of mature miR-199a-3p, 
miR-199a-5p, and miR-1908 in each sample were quantified in a blinded fashion using the 
Taqman miRNA assay and starting with 10 ng of total RNA. RNU44 was used as an 
endogenous control for normalization. The expression levels of each miRNA were compared 
between primary melanomas with propensity to metastasize and primary melanomas that did 
not metastasize. Using the GraphPad Prism software, Kaplan-Meier curves were generated 
by plotting metastasis-free survival data of patients as a function of the expression levels for 
each miRNA in each patient’s tumor. The aggregate expression of the three miRNAs was 
determined as the sum of the expression values of each individual miRNA. Patients whose 
primary melanomas had miRNA levels greater than the median of the population were 
classified as miRNA positive, while those whose primary tumors had miRNA levels below 
the median were classified as miRNA negative. Metastatic recurrence to such sites as lung, 
brain, bone, soft tissue, skin, and subcutaneous tissues were previously documented and 
allowed for a retrospective analysis of the relationship between the expression levels of the 
identified miRNAs and metastatic recurrence. 
 
Analysis of ApoE and DNAJA4 Protein Levels in Primary Melanoma Skin Lesions 
Human primary melanoma skin samples were resected from melanoma patients at the 
MSKCC, formalin-fixed, embedded in paraffin, and sectioned into 5-μm thick increments. 
To determine ApoE and DNAJA4 protein expression, the samples were first de-paraffinized 
by two consecutive xylene washes (5 minutes each), and rehydrated in a series of ethanol 
washes (100%, 95%, 80%, and 70% EtOH). Antigen retrieval was performed by incubating 
the samples in the presence of proteinase K (5 μg/mL) for 20 minutes at room temperature. 
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To quench endogenous peroxidase activity, the slides were incubated in 3% H2O2 solution. 
The slides were then blocked in three consecutive Avidin, Biotin, and horse serum block 
solutions for 15 min each at room temperature (SP-2001, Vector Laboratories).  ApoE and 
DNAJA4 were detected by staining with the D6E10 anti-ApoE antibody (1:100, ab1908, 
Abcam) or a custom-made antibody against DNAJA4.3 (1:100, Yenzyme) at 4°C overnight. 
The primary antibodies were then recognized by incubating the slides in the presence of a 
peroxidase-conjugated secondary antibodies (PK-4002, Vector Laboratories) and exposed by 
DAB (SK-4105, Vector Laboratories) oxidation reaction. The slides were imaged at 10X 
magnification and analyzed in a double-blinded manner. Expression of each ApoE and 
DNAJA4 was measured by quantifying the percentage area of DAB-positive staining out of 
the total melanoma lesion’s area, determined based on matched H&E-stained sections for 
each sample. Kaplan-Meier curves depicting patients’ metastasis-free and overall survival 
times were generated by plotting each patient’s relapse-free and overall survival data as a 
function of ApoE or DNAJA4 expression in that patient’s primary melanoma lesion. Patients 
whose tumors had ApoE or DNAJA4 levels lower than the median ApoE or DNAJA4 
expression of the population were classified as ApoE or DNAJA4 negative, whereas patients 
whose melanomas expressed ApoE or DNAJA4 above the median were classified as ApoE 
or DNAJA4 positive, respectively.  
 
Analysis of ApoE, DNAJA4, and LXRβ Protein Expression in TMA Melanoma 
Progression Sets 
For analysis of ApoE and DNAJA4 protein expression in the NIH melanoma TMA 
progression set, TMA slides were de-paraffinized by two xylene washes (5 min each), and 
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rehydrated in a series of ethanol washes (100%, 95%, 80%, and 70% EtOH). Antigen 
retrieval was performed by applying a proteinase K solution (5 μg/mL) to tissues for 20 min 
at room temperature. ApoE expression was detected using a primary antibody against ApoE 
(1:100, ab1906, Abcam) or DNAJA4.3 (1:100, custom-made by Yenzyme) at 4°C overnight 
followed by a peroxidase-conjugated secondary antibody (PK-4002, Vector Labs) and 
visualized by DAB (SK-4105, Vector Labs) oxidation.  
To determine the expression of LXRβ in the NIH melanoma TMA and the US 
Biomax melanoma TMA (ME2082b, Rockville, MD) progression sets, TMA slides were de-
paraffinized by three xylene washes (5 min each). For antigen retrieval, slides were placed in 
1X antigen unmasking solution (H3300, Vector labs) and steamed in a pressure cooker for 20 
min. After slides cooled to room temperature, the tissue was permeabilized in 0.1% Triton-X-
100 in PBS for 2 min and blocked in horse serum for 30 min. Samples were stained at 4°C 
overnight with a primary antibody against LXRβ (1:100, AB24361, Abcam) that was then 
detected by an alkaline phosphatase-conjugated secondary antibody (1:250, SC2949, Santa 
Cruz Biotechnology) and visualized by NBT/BCIP (Roche) hydrolysis.  
ApoE, DNAJA4, and LXRβ expression across the different melanoma lesions 
included in the TMA set was quantified in a blinded manner by adopting a scoring system 
reflective of the different levels of protein staining intensity: 0 = no positive cells detectable; 
1 = very few positive cells (< 5%) showing weak light-brown staining; 2 = a few positive 
cells (< 10%) showing weak to medium brown staining; 3 = a few positive cells (< 10%) 
showing medium to dark brown staining; 4 = large number of positive cells (> 10%) showing 
medium to dark brown staining;  5 = large number of positive cells (> 20%)  exhibiting 
medium to dark brown staining. 
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Statistical Analyses 
To determine significance of bioluminescence metastasis measurements, which 
exhibited non-Gaussian distribution, the non-parametric Mann-Whitney t-test was used. To 
statistically assess the prognostic power of the expression of the three miRNAs, ApoE, 
DNAJA4, or their combined expression signatures in predicting metastasis-free survival, the 
Mantel-Cox log-rank test was employed. For survival analyses testing the effect of LXR 
agonist treatment or combination regimens on extending post-tumor mouse survival, survival 
times of control-treated and drug-treated animals were statistically compared using the 
Mantel-Cox log-rank test. To compare cumulative distributions of endothelial cell density 
and dextran perfusion density within metastatic nodules formed by either control melanoma 
cells or cells with knockdown of each miRNA and/or ApoE/DNAJA4, the Kolmogorov-
Smirnov test was utilized. Similarly, the Kolmogorov-Smirnov test was used in comparing 
the ApoE staining cumulative distributions in ApoE co-localization experiments with tumor-
infiltrating leukocytes, macrophages, or endothelial cells in GW3965- or control-treated 
melanoma tumors. All other statistical comparisons were performed using the Student’s t-
tests: one-tailed in cases with an expected direction of the predicted change based on 
previous experimental findings or two-tailed in cases without an a priori expectation. All 
statistical analyses were performed using the GraphPad Prism Software 5.0, except for the 
Kolmogorov-Smirnov test, which was carried out using a web-based analysis tool available 
through the Physics Department at the College of Saint Benedict and Saint John’s University 
(http:/www.physics.csbsju.edu/stats/ KS-test.html). Statistical significance was concluded for 
p < 0.05. The following statistical designations apply to all figures: *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001.  
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